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6 Abstract
ABSTRACT
Background
Type 1 diabetes (T1D) is an autoimmune disease in which the insulin producing beta 
cells of pancreatic islets are gradually destroyed. The clinical presentation of T1D is 
preceded by a prodromal phase characterized by the appearance of diabetes-associated 
autoantibodies in the circulation. Both the timing of the appearance of autoantibodies 
and their quality have been used in the prediction of T1D among first-degree relatives 
(FDR) of diabetic patients. So far, no generally accepted strategies for systematically 
identifying individuals at increased disease risk in the general population have been 
established, although the majority of new cases originate in this part of the population. 
Since the incidence of T1D continues to increase throughout the world and the burden it 
causes is significant, efforts aimed at delaying or preventing the clinical onset of T1D are 
important. Reliable disease prediction is a corner stone both for successful intervention 
trials and for effective and safe preventive therapies in the future.
Aims
This thesis work aimed at assessing the predictive role of diabetes-associated immunologic 
and metabolic risk factors in the general population, and defining risk profiles of these factors 
in comparison with data obtained from studies on family members of affected patients.
Subjects and Methods
Observations of the current studies are reported in original publications I-IV. Study 
subjects in publication I were derived from the Childhood Diabetes in Finland Study 
(DiMe; n=755) and the Cardiovascular Risk in Young Finns Study (LASERI; n=3475). 
The DiMe cohort comprised siblings of children with newly diagnosed T1D, and the 
LASERI cohort randomly selected healthy Finnish children, representing populations 
of the five University Hospital Districts of Finland. Blood samples for autoantibody 
assays were obtained from subjects of both cohorts at the mean age of 10.0 and 10.8 
years, respectively, after which the participants were observed for progression to clinical 
T1D for a median of 15 years. Predictive role of autoantibodies against glutamic acid 
decarboxylase (GADA) and islet antigen 2 (IA-2A) were assessed and compared between 
the two cohorts.
Study subjects (n=7410) for publication II were derived from the ongoing Finnish Type 
1 Diabetes Prediction and Prevention Study (DIPP) in which babies born in Turku, Oulu 
and Tampere University Hospitals are screened for HLA-conferred risk for T1D. Infants 
with diabetes-prone HLA genotypes are enrolled to follow-up study in which various 
diabetes-related risk factors are recorded and samples for autoantibody assays obtained 
on a regular basis.
The role of islet cell antibodies (ICA) alone and in combinations with GADA, IA-2A, 
and autoantibodies against insulin (IAA), were assessed in children participating in 
the DIPP study (“DIPP children”) and the results obtained were compared with those 
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reported from studies on family members of patients with T1D. For publication III, 64 
IAA-positive DIPP children who progressed to overt T1D were matched with 64 healthy 
IAA-positive control children to assess the predictive value of IAA affinity.
DIPP children with persistent positivity for at least two of the diabetes-associated 
autoantibodies were enrolled to a randomized, double-blinded, placebo-controlled 
intervention trial with nasally administrated insulin after reaching the age of 1 year. 
Before starting the intervention treatment, participants underwent oral and intravenous 
glucose tolerance tests (OGTT and IVGTT, respectively). Focus in publication IV was 
on the predictive value of metabolic markers in persistently multipositive DIPP children 
(n=218) with results from at least one OGTT and one IVGTT. 
Results
By combining HLA and autoantibody screening, T1D risks that are similar to those 
reported for autoantibody-positive FDRs of affected children can be observed in children 
and adolescents representing the general population. Predictive sensitivity of GADA, IA-
2A, and their combination is of same magnitude both in siblings of affected children and 
in the general population (68% vs. 50% for GADA; 58% vs. 43% for IA-2A; 48% vs. 36% 
for combined positivity, respectively, P>0.05 for all comparisons). Cumulative disease 
risks of single GADA and IA-2A positivity were higher in siblings of affected children than 
in the general population-based cohort (61% vs. 24%, respectively, P<0.001 for GADA; 
74%; vs. 32%, respectively, P=0.002 for IA-2A), but combined positivity indicated similar 
cumulative risk in both populations (83% vs. 86%, respectively, P=0.89).
Natural progression rate to clinical T1D is high in genetically susceptible children testing 
persistently positive for multiple autoantibodies, including persistent positivity for IAA. 
Measurement of IAA affinity failed in stratifying the disease risk assessment in young 
IAA-positive children with HLA-conferred disease susceptibility. The affinity of IAA 
did not increase during the prediabetic period in the current study subjects.
Young age at seroconversion, increased weight-for-height, decreased early insulin 
response, and increased IAA and IA-2A levels predict T1D in young children with HLA-
conferred disease susceptibility and signs of advanced beta-cell autoimmunity. Insulin 
resistance has a minor impact on progression to T1D after the initiation of the disease 
process in young normal-weight children with HLA-conferred disease susceptibility.
Conclusions
Combined genetic HLA-based screening and regular autoantibody measurements reveal 
similar disease risks in children of the general population as those seen in autoantibody-
positive siblings of children with T1D. Our observations confirmed that the assessment 
of disease risk can be stratified further by studying glucose metabolism of prediabetic 
subjects, and that these prediction strategies result in profiles with highly variable 
disease risks. As these screening efforts are feasible also in practice, the information 
now obtained can be exploited when designing intervention trials aimed at secondary 
prevention of T1D, and for the identification of individuals at increased risk for T1D, as 
soon as the first effective preventive measures for T1D have been established.
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ABBREVIATIONS AND DEFINITIONS
APC   Antigen presenting cell
CD   Cluster of differentation
CI95%  95% confidence intervals
CTL   Cytotoxic T-lymphocytes
CTLA4  Cytotoxic T-lymphocyte-associated antigen 4
DAA   Diabetes-associated autoantibodies
DAISY  Diabetes Autoimmunity Study in the Young
DASP  Diabetes Autoantibodies Standardization Program 
DIABIMMUNE  Project testing the hygiene hypothesis in pathogenesis of type 1 
diabetes
DiMe   Childhood Diabetes in Finland Study
DIPP   Finnish Type 1 Diabetes Prediction and Prevention Study
DPT-1  Diabetes Prevention Trial -Type 1
ENDIT  European Nicotinamide Diabetes Intervention Trial
FDR   First-degree relative
FPIR   First-phase insulin release
GAD   Glutamic acid decarboxylase
GADA  Autoantibodies against the 65 kD isoform of glutamic acid  
 decarboxylase
GDM   Gestational diabetes mellitus
HLA   Human leukocyte antigen
HOMA-IR  Homeostasis model assessment for insulin resistance
HOMA-IR/FPIR  Relative insulin resistance
HR   Hazard ratio
IAA   Insulin autoantibodies
IA-2   Islet antigen 2
IA-2A  Autoantibodies against islet antigen 2
IC50   Half maximal inhibitory concentration
ICA   Islet cell antibodies
IDDM  Insulin-dependent diabetes mellitus
Ig   Immunoglobulin
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INS   Gene coding for insulin
IVGTT  Intravenous glucose tolerance test
JDFU   Juvenile Diabetes Research Foundation Unit
LADA  Latent autoimmune diabetes mellitus in adults
LASERI  Study on Cardiovascular Risk Factors in Young Finns
LR-   Likelihood ratio after negative result
LR+   Likelihood ratio after positive result
MODY  Maturity onset diabetes of the young 
Non-progressors  Study subjects who did not develop clinical T1D during follow-up
NPV   Negative predictive value
OGTT  Oral glucose tolerance test
OR   Odds ratio
PBMC  Peripheral blood mononuclear cells
Persistent multipositivity Positivity for ≥2 diabetes-related autoantibodies in ≥2 consecu-
tive blood samples taken ≥3 months apart
PND   Persistent neonatal diabetes
PPV   Positive predictive values
Prefix “p”  Persistent autoantibody positivity 
Progressors  Study subjects who developed clinical T1D during follow-up
PTPN22  Lymphoid-specific protein tyrosine phosphatase-like protein 
22
PTPs   Protein tyrosine phosphatases
QUICKI  Quantitative Insulin-Sensitivity Check Index
rS   Spearman’s correlation coefficient (Rho)
RU   Relative Units
SLC30A8  Gene coding for zinc transporter 8 (ZnT8)
SLE   Systemic lupus erythematosus
SNP   Single nucleotide polymorphism
SPSS    Statistical Package for the Social Sciences
T1D   Type 1 diabetes
TND   Transient neonatal diabetes
TRIGR  Trial to Reduce IDDM in the Genetically at Risk
WHO   World Health Organization
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INTRODUCTION
Type 1 diabetes (T1D) is caused by immune-mediated destruction of pancreatic beta cells 
that is preceded by a preclinical phase during which diabetes-associated autoantibodies 
appear in the circulation. The timing of appearance and the identity of autoantibodies 
against beta cells have been used in the prediction of T1D among first-degree relatives 
of diabetic patients, but so far no consensus has been reached as to strategies aimed 
at identifying individuals at increased disease risk in the general population, although 
around 90% of new cases with T1D are derived from that population. The work presented 
in this thesis sets out to provide new information on prediction of T1D in the pediatric 
general population for filling some of the gaps in our current knowledge.
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CLASSIFICATION OF DIABETES
Throughout centuries, diabetes was recognized as a deadly ailment in which the patient’s 
flesh and limbs melt into urine that has a sweet taste (Brill 2008), and during the pre-
insulin era the life expectancy of the diabetic patient was short and mortality associated 
with the disease high. During the 19th century several basic concepts of the modern 
medical knowledge became established and the nature of the endocrine and exocrine 
organs characterized. In 1869 a German medical student Paul Langerhans observed 
that the pancreas contains two types of cells: those secreting “the normal pancreatic 
juice” and nests of cells of unknown function. The latter were named later the “islets of 
Langerhans” (Rennie and Fraser 1907), and already in 1908, the first experiments were 
performed to treat glucosuria with injections of pancreatic extracts. Even if these extracts 
were only partially purified and caused severe side effects, in 1922 these experiments 
lead to the identification of insulin by Frederic Banting and his colleagues (Banting et 
al. 1922). Today diabetes is considered as a serious but treatable condition in which 
the diabetic individuals either produce insufficient amounts of insulin or the effect of 
secreted insulin is suboptimal due to insulin resistance or defects in the insulin signaling 
system in the target cells.
After the establishment of insulin therapy, the heterogenic nature of diabetes became 
evident. In the 1950s diabetes was reported to manifest in two major types that differed 
from each other by the need of exogenous insulin: the insulin-dependent diabetes 
(type 1 diabetes, T1D) and the non-insulin-dependent diabetes (type 2 diabetes, T2D) 
(Bornstein and Lawrence 1951). Two decades later, in the 1970s, the association of T1D 
and autoimmunity was discovered and the first diabetes-related autoantibodies, islet cell 
antibodies (ICA), were characterized (Bottazzo et al. 1974, MacCuish et al. 1974). The 
modern concept of diabetes includes also gestational diabetes mellitus (GDM), latent 
autoimmune diabetes of the adulthood (LADA), maturity onset diabetes of the young 
(MODY), transient or persistent neonatal diabetes (TND and PND, respectively), and 
double diabetes or “1.5 diabetes”, which refers to diabetes with clinical characteristics of 
both autoimmune diabetes and insulin resistance-related T2D (World Health Organization 
1999, Gillam et al. 2005).
In addition to the subtypes mentioned above, diabetes is observed in certain diseases and 
polyendocrinopathies, such as Wolfram and Alström syndromes, Immunodysregulation 
Polyendocrinopathy Enteropathy X-linked syndrome (IPEX), and Autoimmune 
Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED). In these syndromes, 
diabetes appears usually during early infancy, except for APECED, where diabetes is often 
diagnosed at adult age, and even though these conditions are rare, together they account 
for up to 5% of cases of diabetes among children (Barrett 2007). From the scientific point 
of view these mutation-based conditions are significant, since they provide possibilities 
to study the basic mechanisms of insulin and glucose metabolism and to correlate the 
clinical diabetes phenotype with its genotype. The deeper understanding of the gene 
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and protein interactions in the pathogenesis of diabetes may enable us to develop new 
therapeutic measures for diabetes in the future.
THE IMMUNE SYSTEM
BARRIER fuNCtION
The first line of defense against intruders into the body is the mechanical, physical, and 
chemical barrier provided by the skin and the mucous membranes. The exposed surfaces 
of the body become colonized soon after birth by protective microbes that participate 
in the immunologic defense by competing with pathogens for space and nutrients, and 
by driving the immune responses of the host towards normal immunotolerance. The 
neonatal period is a critical time in life in terms of the induction of oral tolerance (Faria 
2005). The postnatal maturation of the intestine and the development of the normal 
mucosal barrier function require the establishment of the normal microbial flora and a 
well-timed and dosed stimulus by nutritional antigens (Vaarala 1999, Hänninen 2000). 
Breastfeeding has been shown to enhance the development of immunotolerance, whereas 
certain enteral infections, especially those caused by enteroviruses or rotaviruses, have 
been hypothesized to disturb the mucosal barrier function (Honeyman et al. 2000, 
Salminen et al. 2003). The increased permeability and the transfer of foreign antigens 
through the gut mucosa could in turn lead to sensitization and/or false recognition of 
nutrition-originating antigens.
INNAtE AND ADAPtIVE IMMuNIty
The main challenge of the immune system is to segregate foreign structures from 
normal self-originating ones, and consequently, development and maintenance of this 
self-tolerance is crucial for the efficacy of the immune system. Immunologic responses 
can be divided into innate and adaptive immunity, reflecting the level of complexity 
and the evolution of the immune processes required, or into humoral and cell-mediated 
immunity, indicating the molecular mechanisms by which the immune responses are 
mediated. Innate immune responses are most often simple, efficacious, and of maximal 
intensity, but they are non-specific and non-adaptable, and do not evoke immunologic 
memory. Innate immunity is responsible for the acute antigen encounter, after which 
more specific responses of adaptive immunity take over, and the main role of innate 
immunity is to attenuate harm caused by pathogens and to restrict the spreading of the 
infections. The rapid reactivity of the effector cells of the innate immunity is made 
possible by the receptors that recognize pathogen-associated molecular patterns and are 
readily accessible on the surface of these cells.
Adaptive immunity, seen only in vertebrates having more advanced immunological 
system, allows the specific recognition of the non-self structures via antigen presentation, 
thus enabling identification of each pathogen by its specific antigenic “signature”. 
Antigen recognition results in precisely targeted immune responses and development 
of immunologic memory, by which a later encounter with the same pathogen leads to a 
stronger and more swift and efficacious immune responses (Murphy et al. 2008).
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CELL-MEDIAtED AND HuMORAL IMMuNIty
Cell-mediated immunity refers to immune responses requiring cell-to-cell contacts, 
whereas humoral immune responses are mediated by the components of the liquid sections 
of the living organism, such as antibodies, cytokines or the complement system. Cell 
mediated immunity relies on antigen presenting cells (APCs) that introduce processed 
antigens attached to their surface receptors (HLA Class I and II molecules). The most 
important of APCs are the dendritic cells that are able, together with macrophages and 
B lymphocytes, to activate naïve CD4+ T cells. HLA Class II molecules are expressed 
by all nucleated cells and therefore activated CD8+T cells can be reactivated by all 
nucleated cells. Antibodies, mainly produced by B cells that have turned to plasma cells, 
are gamma globulin proteins (immunoglobulins) that are involved in the neutralization 
of pathogens and toxins, activation of the complement system (the classical activation 
pathway), opsonization (preparing pathogens for elimination), and phagocytosis (Murphy 
et al. 2008). 
SELf-tOLERANCE AND AutOIMMuNIty
Self-tolerance is maintained by active regulatory processes occurring both in locations 
producing new T cells (thymus) and B cells (bone marrow), and in the peripheral 
tissues. The central tolerance mechanisms aim at destroying or inactivating autoreactive 
lymphocytes, and the peripheral mechanisms at regulating the activity of autoreactive 
lymphocytes that have escaped the central negative selection. Although the majority 
of self-reacting T cells is deleted in thymus, continuously a small number of such 
lymphocytes enter the circulation and reach the peripheral tissues. In optimal conditions 
these autoreactive cells are suppressed by regulatory T cells, and thus remain inactive, 
but this self-tolerance can be broken, leading to initiation of an autoimmune process 
(Christen and von Herrath 2004a, Bluestone et al. 2008).
Although the mechanisms by which the autoimmune destruction is initiated and 
driven further have been studied intensively, the full picture of the course of events 
is still missing. It has been suggested that self-originating antigens share molecular 
characteristics (molecular mimicry) with antigens originating from foreign agents, i.e. 
viruses. The false recognition of the self-antigens might trigger the autoimmune process. 
A part of this false antigen recognition might be caused by genetic defects in the coding 
of the autoantigens and/or the antigen presenting molecules, which could result in an 
ineffective presentation of the autoantigens and suboptimal activation of regulatory cell 
responses. The spreading of the destructive process could occur via activation of the 
previously inactive nearby cells by signaling from the affected and dying cells (“by-
stander effect”), which could join the destruction via apoptosis, and thus increase further 
the self-antigen load available (Fujinami et al. 2006).
One theory regarding the etiology of autoimmunity suggests that the disturbed balance 
between the Th1 responses (involved in the direct cell destruction) and Th2 responses 
(resulting in autoantibody production) could explain both allergies (Th2-based 
overactivation) and autoimmunity (Th1-based overactivation) (Christen and von Herrath 
2004b, Sia 2005). According to this hypothesis, promoting the restoration of Th1/Th2 
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balance with immunomodulatory therapy, autoimmunity can be suppressed and normal 
self-tolerance regained. However, after several more or less successful experiments with 
immunomodulatory therapies targeted at modifying the Th1/Th2 balance, and by the 
more profound knowledge on the role of immunoregulatory cells, it seems that the Th1/
Th2 model is not sophisticated enough to explain the complexity of immunotolerance. 
Briefly, today it seems more likely that maintaining normal self-tolerance requires 
adequate levels of normally-structured circulating autoantigens that can activate 
regulatory T cells to suppress the function of self-reacting T cells (Roep 2003).
PATHOGENESIS OF TYPE 1 DIABETES
CELLuLAR AutOIMMuNIty Of tyPE 1 DIABEtES
Although there are several unanswered questions in theories regarding the molecular 
pathogenesis of T1D, the concept that cellular immune responses are responsible for 
the immune-mediated beta-cell destruction has been established. This view is supported 
by the observations that T cells are present in the islets of Langerhans in insulitis, 
immunosuppressive drugs selectively targeting T cells are able to delay the disease 
process, and beta-cell specific autoreactive T cells are present in the circulation of 
patients with newly diagnosed T1D (Roep 2003).
The site, the cause, and the primary autoantigen, if there is such an antigen, of the initial 
activation of the islet-specific autoreactive T cells have remained unidentified (Wong 
2005). The activation of these T cells requires antigen presentation by MHC Class II 
molecules that are not normally expressed on beta cells, but can be induced in vitro 
with the combined stimulation of IFN-γ and TNF-α (Pujol-Borrel et al. 1987). These 
observations suggest that the initiation of the immune response targeting beta cells can 
take place in the islets. Yet, a more likely location for the activation is pancreatic lymph 
nodes, where APCs normally present antigens to naïve T cells.
The strong association between the genes coding for the MHC Class II molecules 
and T1D susceptibility supports the hypothesis that the beta-cell specific autoimmune 
response is antigen-driven. However, it is possible that autoimmunity against beta cells 
could originally represent autoantigen-independent hyperactivation of the immune 
system, triggered by cell damage caused by e.g. viral infection or toxic agents. This initial 
immune response could then disturb normal immune regulation and lead to breakage of 
self-tolerance. The primary autoantigen initiating the autoimmune process in T1D has 
remained unknown, although in the HLA DR4-DQ8-positive form of T1D it has been 
suggested to be either insulin or proinsulin (Eisenbarth 2003, Jasinski and Eisenbarth 
2005, Wong and Wen 2005), while in the HLA DR3-DQ2-positive form of the disease, 
the 65 kD isoform of GAD could be the primary autoantigen, since the appearance of 
autoantibodies against this molecule has been associated with this haplotype (Knip 
2002). The quest of the primary autoantigen still continues.
The next steps in the process leading to beta-cell damage are also partly undefined, but it 
seems that after priming, activated T cells migrate into the islets where they re-encounter 
their beta-cell specific autoantigen, become re-activated and cause inflammation in 
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the islets. The scarcity of suitable material for studies on the morphology of human 
pancreatic islets and the T1D-related changes in islet structure and function emphasize 
the significance of animal studies.
In non-obese diabetic (NOD) mice, inflammation in structures surrounding the islets 
(periinsulitis) (O’Reilly et al. 1991) precedes insulitis characterized by infiltrations of 
CD8+ and CD4+ T cells, macrophages, and B cells in the islets. The involvement of 
the CD4+ and CD8+ T cells in beta-cell destruction seems essential, since genetically 
athymic or perinatally thymectomized NOD mice do not develop autoimmune diabetes 
(Yoon and Jun 2001, Christen and von Herrath 2004a). According to studies with T 
cells that were transferred from diabetic NOD mice to neonatal or irradiated NOD mice, 
CD4+ T cells were able to accelerate independently the progression to diabetes in young 
recipients, but an effective transfer required the simultaneous transfer of CD8+ T cells 
reacting with MHC I molecules (Miller et al. 1988, Roep 2003, Wong and Wen 2005). 
The role of CD4+ cells is believed to be related to successful homing of CD8+ effector 
cells to the islets. The actual mechanisms of beta-cell death are not fully understood, but 
according to the first, recognition-based model, self-reactive cytotoxic T lymphocytes 
(CTLs) recognize autoantigens located on the surface of beta cells and induce cell death 
by secreting soluble death mediators, such as IFN-γ, TNF-α, IL-6, and free radicals. In 
the second, activation-based model, APCs located close to the islets introduce beta-cell 
specific antigens to T cells that become activated and cause apoptosis of the nearby beta 
cells through soluble mediators (Mathis et al. 2001).
The main problem with animal studies is that the results obtained are seldom applicable 
to humans as such, and often the simple phenomena observed in animals appear to be 
more complicated in man. Antigen-specific T-cell responses related to T1D have been 
studied mainly by using human peripheral blood mononuclear cells (PBMCs), and until 
recently, similar responses have been observed both in diabetic patients and healthy 
subjects. However, in a recent study with fresh PBMCs, both the classical proliferative 
T cell assay and an immunoblotting assay could distinguish patients from controls, 
indicating that a reasonable numbers of beta-cell specific autoreactive T cells do circulate 
in peripheral blood (Seyfert-Mangolis et al. 2006). Whether and how these cells reflect 
the autoimmune process in the islets remains still unknown.
Other open questions are related to the immunoregulation and the role of the regulatory T 
cells. It has been suggested that defects in this subpopulation of T cells might contribute 
to the initiation and/or maintenance of self-destructive autoimmune processes in T1D, 
and that, in theory, it could be possible to therapeutically boost immunoregulation by 
altering the functions of these cells (Tree et al. 2006, Roep 2003). It is, however, still too 
early for major clinical implications in this field.
HuMORAL BEtA-CELL AutOIMMuNIty
Immunoglobulins, like many other molecules, are able to permeate the placenta and reach 
the fetal circulation. Therefore, positivity for diabetes-associated autoantibodies during 
the first months of life can originate from the mother. In the case of maternally transferred 
autoantibodies both the maternal blood sample and the cord blood sample of the newborn 
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infant show similar autoantibody patterns, and without endogenous seroconversion (no 
signs of de novo synthesis), autoantibody levels decrease and disappear at the latest by 
the age of 18-24 months (Koczwara et al. 2004, Hämäläinen et al. 2000 and 2002).
In seroconversions occurring during the first years of life, IAA are often the first 
autoantibody reactivity to appear, followed by ICA, GADA and IA-2A, respectively, 
but any of the diabetes-related autoantibodies can be the first one to emerge (Kimpimäki 
et al. 2001a, Kupila et al. 2002, Kukko et al. 2005). The characteristics of autoantibody 
response (number, level, subclass and affinity of autoantibodies, as well as the number 
and types of epitopes) have been used in the prediction of T1D (Elliot and Pilcher 1994, 
Franke et al. 2005). In general, the broader the response (multiple positive DAAs with 
high levels and affinities, and multiple epitopes and subclasses), the higher the disease 
risk.
Affinity of the autoantibodies
Antigens may contain several binding sites and the strength of the binding between 
antigen and its receptor can vary remarkably. In general, strong binding of an antigen 
has been associated with advanced or mature immune responses. Affinity describes the 
binding force of a single antigen binding site and a single antigenic determinant, and is 
expressed as the association constant (k; litres/mole). Instead of representing the actual 
binding force of one actual interaction, it represents the average binding force of several 
similar, simultaneously occurring interactions. When the antigen is polyvariant, i.e. has 
several variable binding sites, the total strength of binding between a polyvariant antigen 
and its antibody is the sum of all the affinity bonds, and this total binding force is called 
avidity (Murphy et al. 2008). Affinity of autoantibodies has been regarded as a marker 
of maturation status of the immune response. Low affinity values have been reported to 
associate with transient and/or single autoantibody positivity and low disease risk (Wabl 
et al. 1999, Westerlund et al. 2005, Mayr et al. 2007, Schlosser et al. 2005a, Achenbach 
et al. 2007).
Epitope specificities, isotypes and subclasses of the autoantibodies 
As the adaptive immune system communicates via T cell receptors, their epitope 
recognition is crucial for the development and loss of self-tolerance. Both intramolecular 
(from one epitope to another within the same autoantigen) and intermolecular (from 
one autoantigen to another) spreading of the autoimmune response is characteristic of 
prediabetic autoimmune response (Mackay and Rowley 2004, Di Lorenzo et al. 2007), 
and the spreading of humoral autoimmune response occurs mainly within a relatively 
short time frame (Hoppu et al. 2004a and b, Schlosser et al. 2005b, Kawasaki et al. 
1998 and 2001). If the humoral autoimmune response has not spread within 12 months 
after the first signs of beta-cell autoimmunity, it rarely does so thereafter (Kupila et al. 
2002).
According to observations in several prospective studies on the natural history of 
T1D, positivity for solitary autoantibody specificity represents mainly harmless non-
progressive beta-cell autoimmunity (Colman et al. 2000, Mrena et al. 2003), whereas 
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the appearance of multiple autoantibodies reflects a progressive prediabetic autoimmune 
process that seldom reverts (Kulmala et al. 1998, Strebelow et al. 1999, Achenbach et 
al. 2004a). Transient positivity for diabetes-associated autoantibodies is a relatively rare 
phenomenon, both among young children with affected family members and in young 
children in the general population having HLA-conferred disease susceptibility (Spencer 
et al. 1984, Kimpimäki et al. 2002). Such positivity is, however, occasionally observed, 
especially among older siblings of affected children, in males, and in those who do not 
carry the high-risk HLA DR3/DR4 genotype (Yu et al. 2000a, Savola et al. 2001).
Various cytokines regulate the repertoire of immunoglobulin isotypes and subclasses, 
but the network of their action is complex and incompletely understood. In general, 
it has been proposed that as the active cytokine profile directs the class swiching of 
autoantibodies, likewise the isotypes of the antibodies present in peripheral blood may 
reflect polarization of immune responses towards either Th1- or Th2-biased responses 
(Mosman and Sad 1996).
AutOANtIBODIES IN tyPE 1 DIABEtES
Islet cell autoantibodies, ICA
Islet cell antibodies (ICA) were characterized in 1974 in diabetic patients with autoimmune 
polyendocrine deficiencies (Bottazzo et al. 1974, MacCuish et al. 1974). ICA are directed 
against cytoplasmic structures and are mainly of IgG (IgG1) class. They recognize 
all cell types in the pancreatic islets. Later studies on the epidemiology of T1D have 
shown that low-level (<20 JDFUs) ICA without other signs of beta-cell autoimmunity 
represent innocent, non-progressive beta-cell autoimmunity that is quite commonly 
detected among healthy relatives of patients with T1D, as well as in the general population 
(Bottazzo et al. 1991, Colman et al. 2002). High levels of ICA, meanwhile, are considered 
to reflect ongoing beta-cell destruction, since the frequency of the individuals with high 
ICA levels decreases sharply during the first years after the diagnosis of T1D, indicating 
that by the destruction of the islets also the target antigens have mainly disappeared. High 
levels of ICA are mainly detected along with other diabetes-predictive autoantibodies, 
resulting in multipositivity that is associated with an increased disease risk and short 
diabetes-free survival time (Bingley et al. 1996 and 1997, Mrena et al. 1999, Krischer 
et al. 2003).
The frequency of autoantibody positivity in patients with newly diagnosed T1D varies 
according to the age at diagnosis and the HLA risk genotypes of the diabetic individuals, 
and in Finland ICA positivity was observed to range from 30% (in individuals 
diagnosed earliest at the age of 20 years and carrying the HLA-DQB1*02/y genotype) 
to approximately 85% (in individuals diagnosed before the age of 15 and carrying the 
HLA-DQB1*0302/x genotype) (y and x represent non-protective alleles; Knip et al. 
2002).
ICA do not represent a single autoantibody reactivity, but various antibodies that react 
with GAD65, IA-2A, and other still unknown antigens (Månsson et al. 2001). Notably, 
ICA may not contain any reactivity related to IAA. These findings have been obtained 
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in experiments using preabsorption of ICA-positive sera with either insulin, GAD65 
or the IA-2 molecule; the latter two block or decrease the subsequent ICA staining by 
sera containing these reactivities. Accordingly, ICA levels correlate relatively strongly 
with the IA-2A levels and more weakly with the GADA levels. The ICA titer can be 
considered to reflect the combined levels of IA-2A and GADA. Since ICA are detected 
with indirect immunofluorescence on sections of human pancreatic tissue from subjects 
with blood group O, the assay is difficult to standardize, is labor intensive, and requires 
access to high-quality human pancreatic tissue.
Autoantibodies against insulin, IAA
Antibodies against insulin detectable before treatment with exogenous insulin were 
discovered in 1983 (Palmer et al. 1983), and soon after that finding antibodies to 
proinsulin (PAA) were characterized (Castaño et al. 1993, Williams et al. 1999). IAA 
appear usually as the first of diabetes-associated autoantibodies, and although the 
IAA levels may fluctuate during the prediabetic phase, most often IAA positivity is of 
high affinity already at the beginning of the disease process, and thus rarely transient 
(Schlosser et al. 2005a, Achenbach et al. 2007).
In general, the prevalence of the IAA positivity has been reported to be 0.9-3.3% in 
the general population, while 40-60% of patients with newly diagnosed T1D are IAA 
positive at the time of diagnosis. IAA levels have been suggested to be predictive of T1D 
and to be highest among individuals with a rapid beta-cell destruction and progression to 
T1D (Yu et al. 2000b, Achenbach et al. 2004a). Genetic susceptibility to T1D, especially 
DR3/DR4 heterozygosity and DR4 homozygosity as well as the INS and PTPN22 gene 
polymorphisms associated with increased disease susceptibility, have a predisposing 
effect on the appearance of IAA positivity and the IAA levels (Walter et al. 2003, 
Hermann et al. 2005 and 2006). As described above, in Finland IAA positivity observed 
at diagnosis of T1D ranged from 20% (in individuals diagnosed earliest at the age of 20 
years and carrying the HLA-DQB1*02/y genotype) to 60% (in individuals diagnosed 
before the age of 15 and carrying other HLA genotypes than those associated with high 
or moderate disease risk) (Knip et al. 2002).
Autoantibodies against glutamic acid decarboxylase, GADA
Glutamic acid decarboxylase (GAD) is an enzyme that catalyzes the formation of the 
γ-aminobutyric acid (GABA, an inhibitory neurotransmitter) from glutamate. GABA 
has been suggested to have a regulatory role in the secretion of insulin, glucagon, and 
somatostatin (Sorenson et al. 1991). The GAD protein has two molecular forms, GAD65 
and GAD67 that differ from each other by molecular weight and repertoire of antigenic 
determinants. Antibodies against GAD (GADA) were first detected in 1982 as antibodies 
against the 64 kD antigen in patients with newly diagnosed T1D, and later also in patients 
with stiff-man syndrome (Baekkeskov et al. 1990, Daw et. al 1996). The 64 kD antigen 
was identified as GAD in 1990.
GADA are more common in postpubertal prediabetics and in patients with LADA, but 
depending on the population observed, 20-90% of newly diagnosed patients with T1D are 
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GADA-positive at the time of diagnosis (Seissler et al. 1993, Hagopian et al. 1995). Many 
initially GADA-positive diabetic patients remain positive for years after their diagnosis. 
This phenomenon has been suggested to occur due to the fact that GAD is expressed also 
outside the islets, thus providing a possible source of an activating autoantigen for GAD-
targeted autoimmune responses (Ronkainen et al. 2004). In Finland GADA positivity 
observed at diagnosis of T1D ranged from 50% (in individuals diagnosed earliest at the 
age of 20 years and carrying the HLA-DQB1*02/y genotype) to approximately 70% (in 
individuals diagnosed before the age of 15 and carrying the HLA-DQB1*02/y genotype) 
(Knip et al. 2002).
Autoantibodies against islet antigen 2, IA-2A
In further studies on the 64 kD islet cell protein, it was shown that trypsin digestion of 
this molecule resulted in several protein fragments (50 kD, 40 kD, and 37 kD molecules) 
with different autoantibody binding profiles. The 40 kD fragment was recognized to 
be the intracellular portion of islet antigen 512, a transmembrane protein belonging to 
the family of protein thyrosine phosphatases (PTPs). This molecule is more commonly 
known nowadays as islet antigen 2, IA-2 (Rabin et al. 1994, Bonifacio et al. 1995a, 
Morgenthaler et al. 1997). Several potential islet-related antigens belonging to the family 
of PTPs have been identified, among them the precursor molecule of the 37 kD fragment, 
IA-2β (phogrin; Kawasaki et al. 1998). Antibodies against IA-2 (IA-2A) recognize the 
cytoplasmic domain of the IA-2 molecule, and no reactivity to extracellular regions of 
the molecule has been observed.
IA-2A appear usually as the last reactivity of the diabetes-related autoantibodies, and are 
thus considered as an indicator of advanced beta-cell autoimmunity, but occasionally the 
appearance of IA-2A has been the first sign of T1D-associated humoral autoimmunity. 
In the majority of these cases the appearance of IA-2A has been followed by wide-
spread beta-cell specific autoimmune responses (Kimpimäki et al. 2002). In Finland 
IA-2A positivity observed at diagnosis of T1D ranged from 20% (in individuals 
diagnosed earliest at the age of 20 years and carrying the HLA-DQB1*02/y genotype) 
to approximately 95% (in individuals diagnosed before the age of 15 and carrying the 
HLA-DQB1*0302/x genotype) (Knip et al. 2002).
Autoantibodies against zinc transporter 8 (Znt8A)
The ZnT8A, i.e. autoantibodies against the cation efflux transporter zinc transporter 8 
(ZnT8) are the latest of the diabetes-associated autoantibodies that seem to gradually 
establish their role in the prediction of T1D. Zinc is a trace mineral that is supposed to 
participate in the formation of the hexamer insulin complexes (insulin storage molecule) 
found in insulin secretory granules. The beta-cell specific ZnT8 protein permits active 
efflux of zinc into the secretory granules (Chimienti et al. 2004).
Both the genetic variation of the gene encoding ZnT8 (SLC30A8) and the autoantibodies 
to ZnT8 have been suggested to have prognostic value in T1D (Wenzlau et al. 2007, 
Achenbach et al. 2009). The binding of the ZnT8A has been shown to correlate with the 
variants of the SLC30A8 gene. Subjects positive for ZnT8A (COOH terminal associated) 
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and homozygous for SLC30A8 SNP rs 13266634 are likely to progress to overt T1D 
more rapidly than subjects being heterozygous for this variant (Achenbach et al. 2009). 
The importance of ZnT8A is in the stratification of T1D risk, since about 60-70% of 
newly diagnosed patients test positive for ZnT8A at the time of diagnosis, and moreover, 
ZnT8A positivity has been observed both in prediabetic subjects and in patients with 
T1D who were previously identified as autoantibody negative or had tested positive only 
for single autoantibody reactivities (Gohlke et al. 2008, Achenbach et al. 2009). The 
combination of the analysis of ZnT8A and SLC30A8 genotyping may contribute to the 
prediction of T1D in the future.
EPIDEMIOLOGY AND ETIOLOGY OF TYPE 1 DIABETES 
INCIDENCE Of tyPE 1 DIABEtES
The incidence of T1D varies conspicuously between different countries. According to 
the WHO DIAMOND report, published in 2006 covering the time period 1990-1999, 
the difference between a high-incidence country like Finland (with an incidence of 
40.9/100,000/year in children under the age of 14) and a low-incidence country such 
as China or Venezuela (with 0.1/100,000/year) was 400-fold (Soltez et al. 2007). The 
incidence of T1D has continuously increased almost everywhere in the world since 
World War II, and at the moment, the most rapid increase is observed in countries with 
rapid socio-economical development, such as Poland, the former Yugoslav Republic of 
Macedonia, Czech Republic, and Israel (Gale 2002, Patterson et al. 2009, Wild et al. 
2004). Part of this increase is, however, associated with the fact that T1D is diagnosed 
nowadays at a younger age than some decades ago, and actually, the incidence of 
T1D in postpubertal subjects has gradually decreased according to some data sources 
(DIAMOND 2006, Patterson et al. 2009).
PREDIABEtIC DISEASE PROCESS
The clinical presentation of T1D is usually preceded by a prediabetic phase associated 
with immune-mediated destruction of beta cells of the islets of Langerhans (Fig. 1). The 
first humoral signs of beta-cell autoimmunity appear often during the first year(s) of 
life, e.g. in the Finnish DIPP Study the youngest children to seroconvert were less than 
3 months old (Kimpimäki et al. 2001a), but seroconversion to positivity for DAAs can 
occur at any age, as is the case with overt T1D. The prediabetic phase is highly variable 
in duration, ranging from months to decades, and especially among young IAA-positive 
children the disease process seems to be rapid and aggressive (Knip 2002).
The first detectable signs of beta-cell autoimmunity are the diabetes-associated 
autoantibodies, four of which, islet cell antibodies (ICA) and autoantibodies against 
insulin (IAA), the 65 kD isoform of the glutamic acid decarboxylase (GADA), and the 
tyrosine phosphatase-related IA-2 molecule (IA-2A) are nowadays used in the prediction 
of the disease risk. In many pediatric populations with genetic predisposition for T1D the 
proportion of the autoantibody positive individuals is higher than the prevalence of T1D 
(e.g. in Finland 4-6% and 1 %, respectively) indicating that even though signs of beta-
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cell autoimmunity are seen, counteracting mechanisms do occur during the prediabetic 
phase and self-tolerance can be regained after the autoimmune process has once been 
initiated (Gardner et al. 1999, Kukko et al. 2005).
Beta-cell
function Triggering events leading to immunodysregulation
and beta-cell destruction
100%
Diabetes-associated autoantibodies:
IAA, ICA, GADA, IA-2A
Loss of FPIR
10-20%
TimeGenetic predisposition with autoimmunity promoting and attenuating factors
Prediabetic beta-cell autoimmunity
T1D
Glucose intolerance
Figure 1. Progression to type 1 diabetes. 
Modified from Eisenbarth 2003.
GENEtIC BACKGROuND Of tyPE 1 DIABEtES
A recent genome-wide association study combined with a meta-analysis of previous 
studies has shown that there are more than 40 genetic polymorphisms conferring 
susceptibility to T1D (Barrett et al. 2009). The majority of the susceptibility genes are 
encoding molecules that are involved in the immune responses. It has been shown that 
HLA region associated with disease risk (IDDM1) explains ∼50% of the genetic disease 
susceptibility (Grant and Hakornason 2009) and all other regions associated with the 
disease susceptibility have a minor impact, a fact that is reflected by the estimated odds 
ratios for disease risk which are >6 for the HLA region and 1.1-2.4 for non-HLA genes. 
Although the impacts of the other single genetic determinants are minor, their combined 
effect may play a role in the initiation of the diabetic autoimmune process, especially 
among those with HLA genotypes associated with lesser disease susceptibility. Their role 
may also become more important in the future, as it seems that proportion of individuals 
with newly diagnosed T1D carrying neutral or protective HLA genotypes is gradually 
increasing (Fourlanos et al. 2008).
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Table 1. HLA-DQB1 genotypes in 560 Finnish children with type 1 diabetes (T1D) and in 10541 
healthy Finnish newborns. OR, odds ratio; PPV, positive predictive value.
HLA-DQB1 
genotype
Children with T1D,
N (%)
Newborn infants,
N (%)
OR PPV*
Risk genotypes:
02/0302 161 (28.8) 303 (2.9) 13.63 7.03
0302 191 (34.1) 1039 (9.9) 4.73 2.55
0302/0603 17 (3.0) 213 (2.0) 1.52 1.12
0301/0302 23 (4.1) 293 (2.8) 1.50 1.10
02 102 (18.2) 1384 (13.1) 1.47 1.04
Subtotal 494 (88.2) 3232 (30.7)
Protective genotypes:
02/0301 9 (1.6) 321 (3.0) 0.52 0.40
302/0602 6 (1.1) 324 (3.1) 0.34 0.26
02/0603 4 (0.7) 273 (2.6) 0.27 0.21
0301 10 (1.8) 1049 (10.0) 0.16 0.14
02/0602  2 (0.4) 406 (3.9) 0.09 0.07
0301/0603 1 (0.2) 198 (1.9) 0.09 0.07
0602 4 (0.7) 1421 (13.5) 0.05 0.04
0602 or 0603 3 (0.5) 1264 (12.0) 0.04 0.03
0301/0602 0 (0.0) 349 (3.3) 0.00 0.00
Subtotal 39 (7.0) 5605 (53.2)
Others: 27 (4.8) 1740 (16.2) 0.26 0.22
total 560 (100) 10541 (100)
* Based on an estimated disease risk of 0.75% in the population studied.
Modified from Ilonen et al. 2002.
HLA genotypes
The observation that autoimmunity-based diseases aggregate in families holds true also 
for T1D, and the highest genetic disease risk is associated with the HLA genotype HLA-
DQB1*02/*0302 (high-risk genotype), followed by HLA-DQB1*0302/x (x≠protective 
allele; moderate risk associated genotypes). The disease risk by the age of 15 years 
associated with the high risk genotype (frequency 3% in the Finnish background 
population) is ∼7%, while the disease risk associated with the moderate risk genotypes 
(carried by 11% of this population) is 2-3% (Ilonen et al. 1996 and Hermann et al. 2004). 
The HLA region (IDDM1) associated with increased genetic susceptibility to T1D is 
located on the short arm of chromosome 6 (6p21, the MHC Class II region).
The dysregulation of the immune system associated with HLA is hypothesized to be 
related to changes in the antigen-binding peptide groove of the MCH Class II molecules, 
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which could have an effect on the binding affinity of the self-originating structures and 
could change the conformation of the antigen-MHC complex (Hermann et al. 2003). 
These changes in turn could make the self-antigen look foreign to T cells that are 
interacting with the HLA molecules, or generate strong immune responses that could 
lead to suppression of the regulatory T cell responses (Caillat-Zucman 2009). Different 
HLA genotypes have been associated with several autoimmune diseases, e.g. HLA-B27 
with spondylarthropathies, and HLA-DR3 and/or HLA-DR4 with T1D, celiac disease, 
Addison’s disease, myasthenia gravis and autoimmune thyroid diseases (De Block et al. 
2001).
Insulin gene (INS -23 HphI) polymorphism
The gene coding for insulin is positioned on the short arm of chromosome 11 (11p15), 
and its role as a genetic determinant of T1D was reported for the first time as early as 
in 1984 (Permutt et al. 1984). The INS gene is associated with a variable number of 
tandem repeats (VNTRs) that can be classified into three groups: Class I containing 
30-60 repeats (high-risk variant), Class II containing 60-120 repeats (slightly protective 
variant), and Class III containing 120-170 repeats (protective variant). The number of 
repeats is associated with the amount of insulin produced in thymus, and thus presented to 
maturating T cells. Higher concentrations of thymic insulin may induce effective negative 
selection of insulin-reactive T cells, and the increased risk for T1D that is associated with 
the homozygous genotype of Class I is attributed to the low concentrations of thymic 
insulin available (Walter et al. 2003). The effect of Class II and III alleles is, however, 
dominant, and only one of these protective alleles is needed to ensure the protective 
effect (Haller et al. 2004, Barrat et al. 2004). 
Protein tyrosine phosphatase-like molecule 22 (PtPN22) gene polymorphism
The gene for the protein tyrosine phosphatase-like molecule 22 (PTPN22), a negative 
regulator of T cell activation, is located on the short arm of chromosome 1 (1p13). 
A single-nucleotide polymorphism (SNP; C1858T; Arg620Trp variant) in this gene 
has been associated with a series of autoimmune diseases, including T1D, systemic 
lupus erythematosus (SLE), rheumatoid arthritis, autoimmune thyreoid diseases, and 
generalized vitiligo (Vang et al. 2007, Gregersen and Olssen 2009). The high-risk and 
moderate-risk variants (TT and CT, respectively) have been reported to participate in the 
regulation of insulin-specific autoimmunity and progression from prediabetes to clinical 
disease, and they associate with an increased risk for developing positivity for IAA and 
additional autoantibodies. The effect of PTPN22 on disease susceptibility seems to be 
more significant in males and in subjects with low-risk HLA genotypes (Hermann et al. 
2006).
Cytotoxic t-lymphocyte antigen 4 (CtLA-4) gene polymorphism
The gene for the cytotoxic T-lymphocyte antigen 4 (CTLA-4) is located on the short 
arm of chromosome 2 (2q33), and polymorphism (SNP +49 A/G) of this gene causes 
changes in the levels of intracellular CTLA-4 and IL-2, which in turn leads to altered 
T-cell proliferation. These changes may contribute to the initiation/progression of beta-
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cell autoimmunity by decreasing the levels of CTLA-4 in CD4+ and CD4+CD25+ cells, 
or decreasing the number of Treg cells. Polymorphism of CTLA-4 has been associated 
with T1D, autoimmune thyroid diseases, celiac disease, and SLE. CTLA4 is expressed 
on the surface of regulatory T cells and activated effector T cells, and its role as the key 
down regulator of the T cell function has been emphasized by the fact that mice lacking 
this gene (CTLA-4 knockout mice) will die young from a severe lymphoproliferative 
disorder resulting from aggressive autoimmunity (Schmidt et al. 2009). However, the 
association with an increased risk of T1D has been modest and not confirmed in all 
studies (Ueda et al. 2003, Hermann et al. 2005). 
Autoimmune regulator gene (AIRE)
The autoimmune regulator gene (AIRE) is located on the short arm of chromosome 
21 (21p22), and loss of function mutations of this gene result in the development of 
a recessively inherited disorder called autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy (APECED or autoimmune polyglandular syndrome type 1, APS-
1), which is characterized by loss of self-tolerance in multiple organs. The protein coded 
by AIRE regulates the expression levels of peripheral self-antigens in the thymus, such 
as insulin, and the prevalence of T1D among APECED patients is relatively high (∼18%) 
(Gylling et al. 2000, Holmdahl 2007). 
GENEtIC VS. ENVIRONMENtAL fACtORS IN EtIOLOGy Of tyPE 1 DIABEtES
Several facts indicate that environmental factors propably play critical roles in the etiology 
of T1D and genetic factors can not explain all phenomena seen in the epidemiology 
of T1D. Some of the most prominent arguments in favor of a crucial contribution of 
environmental determinants are the following:
In most populations with available data the incidence of T1D has increased remarkably 1. 
after World War II, e.g. in Finland from 12/100 000/year in 1953 to 64/100 000/year 
in 2006 among children under the age of 15 years (Harjutsalo et al. 2008). Changes 
in the genetic pool occur slowly over many generations.
There are significant differences in the incidence of T1D between populations with 2. 
highly similar genetic backgrounds but different living conditions, e.g. a six-fold 
gradient between Finland and Russian Karelia (Kondrashova et al. 2007).
The concordance of T1D is around 50% among monozygotic twins (Redondo et al. 3. 
2001, Metcalfe et al. 2001).
Genes predisposing to T1D are relatively common in the general population, e.g. in 4. 
Finland the combined proportion of risk conferring HLA genotypes is approximately 
20% in the general population, and still less than 5% of individuals with such 
genotypes will eventually develop T1D (Ilonen et al. 2002). Even individuals with a 
protective genotype may occasionally develop T1D (Table 1).
The incidence of T1D increases in the offspring when people move from a low-5. 
incidence country to a high-incidence country (Hjern and Söderström 2008).
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As the major burden of T1D lies upon countries with high standard of living, located 
in the northern part of the globe, factors that are related to the climate or the amount of 
sunshine, the socio-economic structure of society, the level of education and the standard 
of hygiene have been implicated to explain the phenomenon. So far none of these factors 
have been shown to have a primary role in the development of T1D, but interestingly, 
even in a low-incidence country like China, climate has been observed to have an effect 
on the disease risk; the incidence of T1D is higher during the winter months and in 
the colder areas of China (Yang et al. 2005). The seasonal variation in the appearance 
of beta-cell autoimmunity and overt T1D, with a peak incidence occurring during the 
winter months in the northern hemisphere, has been observed in many countries, e.g. in 
Hungary (Gyürüs et al. 2002), the northern part of the United Kingdom (Mooney et al. 
2004), and Belgium (Weets et al. 2004).
Also the month of birth has been linked to the disease risk in various parts of the world 
(Lewy et al. 2008, Kahn et al. 2009). These observations suggest that environmental 
factors operating during the prenatal and postnatal development of the child may be 
important in the etiology of T1D. The mechanisms by which various environmental 
factors mediate their actions resulting in the initiation and progression of the prediabetic 
disease process have largely remained unknown. The reason for this confusing picture is 
most likely that each risk factor requires optimal timing and dosing, repeated exposures 
and co-acting determinants to have an effect on the risk of developing T1D.
Microbial etiology
In humans, the well-know connection between the congenital rubella infection and an 
increased prevalence of diabetes in the offspring represents the most solid evidence 
for the involvement of microbial agents in the initiation of the beta-cell destruction 
(Yoon 1985, Gale 2008). Other indirect evidence includes the seasonal variation in the 
appearance of the first diabetes-associated autoantibodies and in the manifestation of 
clinical T1D resembling the variation in the frequency of certain common virus infections 
(Kordonouri et al. 2002, Moltchanova et al. 2009). Furthermore, enterovirus-positive 
staining has been detected in histological sections of islets of patients that have died soon 
after the diagnosis of T1D (Oikarinen et al. 2008).
Theories regarding the mechanisms by which viral infections could lead to the initiation 
of beta-cell autoimmunity and destruction include: 1) molecular mimicry, whereby parts 
of foreign antigens and self-originating molecules might have similar antigenic structures 
leading to cross-reactivity with the self-antigen instead of the pathogenic antigen; 2) 
the hygiene hypothesis, according to which early infections facilitate the development 
of a balanced immune system, and a reduced microbial load during the early years of 
life may increase the risk of autoimmunity; 3) the “bystander effect”, in which beta 
cells undergoing destruction caused by a viral infection could send activation signals 
to initially unaffected nearby cells, which would then join the destructive process and 
worsen the cell damage, exposing further autoantigens to be presented to autoreactive T 
cells (von Herrath 2009).
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Bacterial, fungal, and parasitic exposures provided by environment may also have an 
effect on risk for T1D, most probably mainly by driving immune responses towards Th2-
dominated responses and normal self-tolerance. However, the role of fungal infections is 
less well known and there are indications that fungal toxins might even contribute to the 
risk of diabetes by causing stress to endoplasmic reticulum (Hettiarachchi et al. 2008). 
As the incidence of T1D has increased rapidly since the World War II, we might learn 
important lessons about the role of hygiene and living conditions in the development of 
T1D by studying the longitudinal changes in these factors.
Another approach to study factors associated with the hygiene hypothesis is to study 
societies with similar genetic disease susceptibility background but differing living 
conditions and social standard as well as incidence of T1D. One natural geographic area 
for this kind of studies lies in the north-eastern Europe covering Finland, Estonia and 
North-Western Russian Karelia. Estonia represents a country in which similar social and 
economic changes that Finland went through after WWII have occurred during the last 
decades, and in Russian Karelia there are areas in which the standard of living resembles 
that of Finland in the 1950’s. The genetic pool is relatively similar in these three countries, 
but the incidence of T1D in Finland is nearly three-fold when compared to Estonia and 
six-fold when compared to Russian Karelia (Kondrashova et al. 2007, Teeäär et al. 2009). 
This study design has been utilized in an ongoing study, the DIABIMMUNE project, in 
which the hygiene hypothesis and the mechanisms related to the standard of hygiene that 
could potentially explain changes in immunoregulation are tested in the context of T1D 
and other immune-mediated diseases.
Nutritional factors
General health and the nutritional status of the pregnant woman is directly reflected 
in the well-being of the fetus, and factors that regulate the transplacental transfer of 
nutrients, antigens and antibodies to the fetus could theoretically have an effect on the 
risk of T1D in the offspring. Effects of nutritional prenatal conditions on subsequent risk 
of T1D have been reported in several studies. Only one association has been established: 
inverse correlation between maternal cod liver oil supplementation (containing vitamin 
D, vitamin A, and omega-3 fatty acids) during pregnancy and risk of T1D in the offspring 
(Stene et al. 2004). Studies on the effects of postnatal nutrition have, in contrast, resulted 
in several important findings that might possibly be applied in future trials aimed at 
preventing T1D. These findings are related mainly to the key nutritional elements 
of the first year of life, such as breastfeeding, supplemental feeding, and vitamin D 
supplementation (Åkerblom et al. 2005, Wahlberg et al. 2006, Holmberg et al. 2007, 
Rosenbauer et al. 2008).
The role of early feeding in the initiation of autoimmunity against islet cells has remained 
controversial. According to results from the TRIGR trial studying infants with at least one 
affected family member, the risk of beta-cell specific autoimmunity was lower among 
infants who had received a highly hydrolyzed formula as to compared to infants fed with 
a regular formula (Åkerblom et al. 2005). From the Finnish DIPP study it was reported 
that short duration of exclusive breastfeeding and early introduction of supplementary 
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formula feeding were related to an increased risk of advanced beta-cell autoimmunity 
(Kimpimäki et al. 2001b).
The mechanisms by which breastfeeding might mediate its protective effects against 
T1D comprise protection against infections via protective (IgA class) antibodies secreted 
into breast milk, delayed exposure to foreign dietary antigens, and enhancement of the 
maturation of the gut-associated lymphoid tissue caused by cytokines and growth factors 
present in breast milk (Piirainen et al. 2009). Bovine insulin present e.g. in ordinary 
cow milk-based formula has been shown to induce production of anti-bovine insulin 
antibodies that are cross-reactive with human insulin, thus being a potential inductor 
of immune responses against endogenous insulin in the infant (Tiittanen et al. 2006, 
Vaarala 2006).
In the German BabyDiab study, however, no association was observed between cow’s 
milk exposure and beta-cell autoimmunity, whereas early (age <3 months) introduction 
of cereals was associated with an increased risk of beta-cell autoimmunity, when 
compared to later introduction of cereals (Ziegler et al. 2003). Also an American study 
indicated that early exposure to cereals (before the age of 4 months) was a risk factor for 
subsequent beta-cell autoimmunity, but in that study also late exposure, at the age of 7 
months or later, increased the risk of beta-cell autoimmunity (Norris et al. 2003).
Various vitamins, minerals, and fatty acids such as vitamin D and E, nicotinamide 
(vitamin B3), zinc, and n-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) 
have been suggested to protect against T1D (Elliot and Chase 1991, Knekt et al. 1999, 
Mandrup-Poulsen et al. 1993, Manna et al. 1992, Haglund et al. 1996, Uusitalo et al. 
2008). The active form of vitamin D (1,25-dihydroxyvitamin D) has been shown to 
increase the mRNA levels of interleukin-4 (IL-4) and transforming growth factor and to 
decrease the concentrations of INF-γ and TNF-α mRNAs, thus inducing a deviation in 
the function and activity of T helper cells (Cantorna et al. 2004, Mathieu et al. 2004). 
Vitamin D deficiency has been linked to an increased risk of T1D in epidemiological 
studies, but since this condition is rare in developed countries, the protective effect of 
vitamin D supplementation is difficult to prove in the general population. The optimal 
dosing of vitamin D is also poorly defined, and the doses for supplementation in infancy 
have varied from a daily dose of 200 IU in the USA to 400 IU in Finland to 100,000 IU 
used in a French study (Lamberg-Allardt and Viljakainen 2008).
The promising results obtained from animal studies regarding the protective effect of 
nicotinamide was an impetus for the European Nicotinamide Diabetes Intervention 
Trial (ENDIT) in which 549 first-degree relatives of patients with T1D who were ICA-
positive (≥20 JDFU) were randomized to receive either oral nicotinamide 1.2 g/m2/day 
(ad 3 g/day) or placebo for 5 years. Nicotinamide supplementation did not prevent T1D, 
although it reduced the level of INF-γ in high-risk individuals (Schatz and Bingley 2001, 
Gale et al. 2004, Hyppönen 2004).
In general, reports of associations between nutritional factors and the risk of T1D 
have not been convincing. This is not surprising when taking into account that these 
studies have focused on nutritional factors in common use that may act as predisposing 
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determinants only in genetically susceptible individuals (Atkinson and Gale 2003). So 
far there are some implications that breastfeeding, nicotinamide, zinc, and vitamins C, 
D, and E provide some degree of protection against T1D, while early exposure to cow’s 
milk, obesity, increased linear growth, and N-nitroso compounds may increase the risk 
(Virtanen and Knip 2003, Moltchanova et al. 2004). As any single nutritional factor may 
have only a weak effect, it is challenging to obtain firm evidence for the significance of 
a specific factor in the etiology of T1D.
Early growth and body composition
Studies focusing on growth-related risk factors have resulted in contradictory findings. 
The risk for T1D associated with increased energy intake (and thus with high-energy 
nutrients) has been hypothesized to be due to metabolic disturbances, insulin resistance 
and compensatory increase in the expression of insulin induced by obesity, but already 
high or low birth weight for gestational age have been associated with an increased 
disease risk for T1D. Rapid weight gain in early infancy has been associated with an 
increased risk for T1D in several case-control studies (Hyppönen et al. 2000, Harder 
et al. 2009). Increased relative height has also been linked to an increased risk of T1D 
in some studies, but results from other studies have been contradictory (Wilkin 2001, 
Harder et al. 2009).
INSuLIN: SyNtHESIS, SECREtION AND RESIStANCE
The synthesis of insulin that occurs in the pancreatic beta cells begins with the synthesis 
of the insulin precursor molecules, preproinsulin and proinsulin. After initial synthesis 
proinsulin is cleaved by proteolytic enzymes into three protein chains, A, B, and C. 
The C-peptide is then removed and the A chain is bound to the B chain via disulfide 
bonds to form the active insulin molecule. Since equal amounts of active insulin and 
C-peptide are produced, the measurement of C-peptide can be used to assess the patient’s 
endogenous insulin secretion after the initiation of treatment with exogenous insulin. 
After posttranslational modifications insulin is packed into insulin secretory granules 
located near the plasma membrane of the beta cell and is then ready to be secreted 
(Becker et al. 2001).
The secretion of insulin is triggered by a rise in the blood glucose level that also increases 
the amount of glucose molecules entering the beta cells, which in turn causes the release of 
secretory granule-packed insulin. This initial secretion phase, first phase of insulin release 
(FPIR), begins 1-2 minutes after the initiation of the glucose stimulus and continues for 
10-15 minutes. Intravenous glucose stimulates insulin secretion less efficiently than oral 
glucose administration, because oral nutrients trigger also the mediatory signaling of the 
gastrointestinal tract, resulting in the release of peptides that enhance insulin secretion, 
such as glucose-dependent insulinotropic peptide, cholecystokinin, and glucagon-like 
peptide-1 (Mari et al. 2008).
The second phase of insulin release, which requires synthesis and secretion of newly 
produced insulin molecules, begins when the glucose stimulus continues. FPIR 
promotes peripheral utilization of glucose, suppresses hepatic gluconeogenesis, and 
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limits postprandial glucose elevation. The binding of insulin to its peripheral receptors 
initiates a cascade that leads to translocation of the glucose transporter molecules to 
the plasma membranes of the target cells and increased glucose uptake to these cells. 
Without appropriate insulin stimulus, peripheral cells use other sources than glucose for 
their energy production, which results in the formation of acidic metabolic end-products 
(ketones), and if the insulin deficiency continues, the buffer capacity of the body is 
exceeded at some point, and the state of ketoacidosis is reached (Faideau et al. 2005).
In T1D the loss of beta-cell mass begins months to years before the appearance of 
clinical signs of diabetes, and at the time of diagnosis, 80-90% of the beta cells have 
been destroyed. Frequently, the remaining beta cells are dysfunctional and respond 
poorly to glucose stimulation (Keskinen et al. 2002, Barker et al. 2007). The fading of 
FPIR represent an early sign of a disturbed beta-cell function that appears soon after 
seroconversion, at a time when no other abnormalities in the glucose metabolism can be 
observed (Bingley et al. 1992, Colman et al. 1998, Mrena et al. 2003, Harrison 2001). 
The mechanisms maintaining the balance between beta-cell replication/neogenesis and 
apoptosis/destruction is unknown in humans, but prolonged hyperglycemia and elevated 
levels of free fatty acids have been suggested to be toxic to beta cells (glucotoxicity and 
lipotoxicity) (Maedler et al. 2002, Martin-Gallán et al. 2007).
The programming of insulin resistance, a condition in which a normal amount of 
insulin results in an incomplete insulin response in peripheral tissues, has remained 
poorly defined. It seems that factors appearing already in the prenatal environment may 
predispose to insulin resistance, since individuals born small for gestational age are more 
insulin resistant later in life than those with higher birth weight and normal early weight 
gain (Veening et al. 2002 and 2003).
The sensitivity to insulin follows the pattern of normal distribution, and is significantly 
reduced in early puberty (Conwell et al. 2004). Although body composition plays an 
important role in insulin sensitivity and an increased insulin resistance can be observed in 
pregnancies associated with excessive weight gain and in obese patients with metabolic 
syndrome, it also partly explains the transient hyperglycemias observed in various 
infections and can be seen even in cachectic patients suffering from anorexia nervosa 
(Scheen et al. 1988, Conwell et al. 2004).
In general, in individuals with normal glucose metabolism, beta cells can compensate 
the increase in insulin resistance by enhancing insulin secretion, and this enhancement 
can be observed both in FPIR and in basal insulin secretion. Insulin resistance alter the 
metabolism of various target organs, resulting to reduced glucose uptake and storing of 
local glycogen in the muscle cells, impaired synthesis of glycogen and unnecessary active 
gluconeogenesis in the liver cells, and enhanced hydrolysis of triglycerides leading to an 
increased release of free fatty-acid from the adipose tissues. The increase in the levels 
of circulating glucose and free fatty-acids might explain the reduction of beta-cell mass 
occurring also in advanced T2D in which no immune-mediated islet cell destruction is 
observed (Becker et al. 2001).
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the accelerator hypothesis
Insulin resistance has been hypothesized to link together the two major types of diabetes, 
T1D and T2D. This hypothesis originates from the findings that the incidence rates of 
obesity and T1D are rising simultaneously, and that sometimes it is clinically difficult to 
distinguish between T1D and T2D at the time of diagnosis. According to the accelerator 
hypothesis (Wilkin 2001) there are three factors that accelerate beta-cell destruction: 
obese bodily constitution, insulin resistance, and autoimmune response targeting islet 
cells. The accelerator hypothesis implies that none of the accelerators can lead to 
diabetes in the absence of weight gain, which causes an increase in insulin resistance 
and weakens the control of glucose metabolism. The elevated blood glucose level could 
in turn accelerate apoptosis of the beta cells via glucotoxicity, and the increased beta-
cell immunogenicity would further accelerate apoptosis and lead to an intense immune 
response in a subset of genetically predisposed individuals. “Only tempo distinguishes 
type 1 from type 2” (Wilkin 2001). The accelerator hypothesis has been tested in young 
patients with newly diagnosed T1D and the findings have been controversial. Some 
recent studies have reported no connections between body composition, indicated by 
relative weight, and progression to T1D (Dabalea et al. 2006, O’Connell et al. 2007).
Assessment of insulin resistance
Several methods for assessing beta-cell function and insulin resistance have been reported. 
The “gold standard” has been the hyperinsulinemic euglycemic clamp technique in 
which insulin is infused intravenously in increasing concentrations (rate 10-120 mU/m2/
minute) and the amount of infused glucose (20% solution) needed to maintain euglycemia 
(blood glucose 5.0-5.5 mmol/l) is measured. The higher the amount of glucose needed 
to prevent hypoglycemia, the higher the insulin sensitivity of the subject. This technique 
requires, however, complicated methodology and frequent sampling, and is also time-
consuming, and therefore more simplified methods have been developed.
Two methods based on the fasting values of glucose and insulin, the Homeostasis Model 
Assessment for Insulin Resistance (HOMA-IR = [Glucosefasting] x [Insulinfasting] / 22.5 ) 
and the Quantitative Insulin-Sensitivity Check Index (QUICKI = 1/ {log[Insulinfasting] + 
[Glucosefasting]}), have been demonstrated to provide insulin resistance/sensitivity values 
that correlate well with the values obtained from the clamp method (Matthews et. al 1985, 
Katz et al. 2000) and also have a good intercorrelation (Radziuk 2000). By combining 
the fasting data with a short intravenous glucose tolerance test in which glucose (0.5 g/
kg, 20% solution) is intravenously infused within 3 minutes ± 15 seconds and venous 
blood samples for glucose and insulin assessments are taken 1, 3, 5, and 10 minutes after 
the infusion, both the assessment of insulin resistance and FPIR can be simultaneously 
obtained.
Regarding pediatric population, the major hindrance for utilizing the data gathered from 
IVGTTs has been the absence of reference values obtained from non-obese, healthy 
children and adolescents. Lately, the reported thresholds for insulin resistance (HOMA-
IR) in adolescents have ranged from 3.2 to 4.4 (Lee et. al 2006).
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PREDICTION AND PREVENTION OF TYPE 1 DIABETES
PREDICtION Of tyPE 1 DIABEtES
By 2004, when the current work was initiated, the predictive characteristics of the 
susceptibility genes, diabetes-related autoantibodies, and FPIR had been established in 
the FDR population (Tables 1, 2, and 3; Bonifacio et al. 1995a, Greenbaum et al. 1999, 
Mrena et al. 1999, Bingley et al. 2001), while the knowledge of the role of these markers 
in the general population had been scarce but accumulating.
Table 2. Data on the four major diabetes-associated autoantibodies available by 2003.
Antigen Detection Relevance to prediction Examples of 
references
Islet cells Indirect 
immunofluorescence 
on sections of human 
pancreas
High ICA level associated with 
increased risk of diabetes
Disease risk associated with 
intracellular staining pattern
10, 22, 23, 30, 33, 
34, 35, 38, 76, 80, 
125, 137, 153, 
169, 186, 208, 246
Insulin Radiobinding assay 
using specific mono-
iodinated insulin
IAA first to appear in prediabetes in 
children
Distinct epitopes might identify 
diabetes-related from non-progressive 
IAA
30, 44, 80, 84, 
144, 194, 211, 
259, 274, 275, 294
GAD65 Radiobinding assay 
using radiolabelled 
human recombinant 
GAD65
Prevalence of GADA increase with age 
and is higher in females
Middle and carboxy-terminal regions 
are the major antigenic regions
Epitope recognition conformational
Predicts the future need for exogenous 
insulin in type 2 diabetic subjects
2, 10, 11, 19, 27, 
41, 54, 64, 86, 
128, 132, 207, 
227, 228, 247, 
250, 252
IA-2
(40-kD)
Radiobinding assay 
using radiolabelled 
recombinant IA-2
IA-2A positivity in multipositive 
relatives predict rapid progression to 
type 1 diabetes
Intracellular domain the main 
immunodominant region
Epitope recognition conformational
Shared antigens between IA-2 and IA-
2β (37-kD)
27, 35, 36, 48, 56, 
151, 155, 158, 
162, 190, 195, 
198, 202, 211, 
218, 231, 268, 
283, 292
Modified from Franke et al. 2005.
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Table 3. Prevalence of the four major diabetes-associated autoantibodies in the general population 
and in first-degree relatives of patients with type 1 diabetes. 
Autoantibodies Prevalence (%),
general population
Prevalence (%),
first-degree relatives
Examples of 
references
ICA 0.59-5.3 1-12
25, 33, 34, 50, 57, 63, 
78, 91, 121, 125, 137, 
143, 146, 149, 196, 
210, 217, 221, 243, 
257, 278, 286
IAA 1.07-3.9 1.4-6.9
22, 25, 27, 50, 79, 80, 
91, 121, 124, 143, 
146, 196, 210, 226, 
257, 262, 286
GADA  0.4-2.97 5-13
2, 11, 18, 19, 27, 35, 
79, 86, 91, 121, 146, 
149, 196, 243, 262, 
286
IA-2A 0.1-2.4 1.5-5.3
19,  25, 74, 79, 121, 
146, 149, 196, 198, 
202, 210, 217, 243, 
262, 286
Modified from Franke et al. 2005.
The focus of the prediction of T1D has been on the unaffected family members of patients 
with T1D, since their identification is relatively easy due to the regular medical follow-
up visits needed for the index case, and because the disease risk is approximately 3- to 
5-fold when compared to individuals of the general population. However, most (∼90%) 
patients with newly diagnosed T1D have no affected family members, and targeting only 
FDRs of affected patients will result in the identification of the minority of individuals 
with an increased risk for T1D.
The Bayes' theorem claims that predictive markers have lower positive predictive value 
in the general population than in a selected group of individuals among whom the 
prevalence of the outcome measures is higher, i.e. FDRs of patients with T1D (Díaz et 
al. 2003). Accordingly, single predictive factors provide rarely enough information on 
the disease risk for subjects in the general population, but the combination of several risk 
factors may lead to similar disease risk estimates that are observed for family members 
of affected patients.
Today the basis of prediction of T1D in the general population lies on the identification 
of subjects carrying genetic T1D susceptibility and regular autoantibody monitoring of 
the genetically T1D-prone individuals. According to observations in the FDR population, 
the next step in the stratification of the disease risk is to assess the metabolic status 
of those individuals that develop signs of beta-cell autoimmunity during the follow-
up. By combining immunologic and metabolic markers, the assessment of the disease 
risk in susceptible individuals in the general population can reach the level required for 
the recruitment of subjects for trials aimed at disease prevention. The ultimate purpose 
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of prediction of T1D is not only to clarify the natural history of T1D, but to develop 
effective measures aimed at preventing beta-cell destruction caused by the immune-
mediated response targeting the beta cell.
PREVENtION StRAtEGIES
The accumulated knowledge of the immunoregulatory mechanisms involved in the 
development of T1D has paved the way for the development of immunomodulatory means 
of preventing T1D and although no break-through has been seen yet, several potentially 
successful intervention trials are ongoing. Prevention schemes can be classified into four 
different stages according to the diabetic disease process (Fig. 2): primary prevention 
targeting genetically susceptible individuals without any signs of beta-cell autoimmunity; 
secondary prevention during prediabetic beta-cell autoimmunity; tertiary prevention at 
the time of the diagnosis of T1D; late prevention of disease-related complications and 
attempted restoration of the lost functions in an established disease.
MEANS
Beta-cell
Function (%)
Nutrition
Microbial environment
Molecules enhancing regulatory immune responses
Immunosuppression
Beta-cell transplants 
Modified stem cells
100
PREVENTION OF TYPE 1 DIABETES
AIMS
PHASE
Time
Promoting 
immunotolerance
Intercepting autoimmunity
Delaying beta-cell destruction
Preventing complications
Maintaining normal functions
Genetic suspectibility      Beta-cell autoimmunity                Type 1 diabetes
10-20
Primary                            Secondary                                   Tertiary        Late
Intensity of immunomodulation
Figure 2. Time line for prevention of type 1 diabetes.
An example of primary prevention is the Trial to Reduce IDDM in the Genetically at 
Risk (TRIGR), in which genetically susceptible infants with affected family members are 
weaned to either a normal cow’s milk-based formula or to a highly hydrolyzed formula 
containing fragmented milk proteins instead of intact, more immunogenic ones (Åkerblom 
et al. 2005). The latest ongoing secondary prevention trials include a study with oral 
insulin given to prediabetic individuals with high IAA levels (DPT-1), and another study 
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in which humanized FcR non-binding anti-CD3 monoclonal antibody will be given to 
prediabetic subjects (Schatz and Bingley 2001, Bisikirska and Herold 2004, Skyler et al. 
2005). Tertiary prevention trials aimed at preserving the beta-cell mass and its remaining 
function, and if possible, promoting its recovery, are performed on patients with newly 
diagnosed T1D, and as these patients already have established T1D, more effective, 
but potentially more harmful immunomodulatory treatments might be used. The latest 
ongoing tertiary prevention trials include studies with parenterally administrated GAD 
(Diamyd®), CTLA-4 Ig (Abatacept®), anti-CD20 (Rituximab®), a rabbit polyclonal 
anti-thymocyte globulin (Thymoglobulin, Thymo®), and IL-2 (Proleukin®) combined 
with rapamycin (Rapamune®). The majority of these intervention studies are organized 
within the TrialNet network (http://www.diabetestrialnet.org; Skyler 2008).
ETHICAL CONSIDERATIONS
An important fact supporting the establishment of a population-based screening program 
is that the clinical status of newly diagnosed T1D patients has been shown to be better 
among those who have partaken in prospective follow-up before diagnosis (Barker et 
al. 2004, Hekkala et al. 2007). However, each step of the screening program aimed at 
the identification of individuals with an increased disease risk may potentially cause 
psychological discomfort and ethically challenging situations. Even the decision to take 
part in genetic screening may cause anxiety, especially since the testing occurs often 
during puerperium, when the mothers of the newborn infants are highly sensitive to any 
concerns regarding their offspring. The role of the personnel informing the families and 
individuals about the screening procedures is critical and good communication skills are 
essential.
The psychological effects of the screening programs have been studied in parallel with 
ongoing programs. According to these studies, the participating families are in general 
coping well with the mental pressure caused by the study procedures (Roth 2001, 
Ludvigsson et al. 2001, Simonen et al. 2006). According to a Finnish study on families 
participating in the DIPP study, more than 90% of the parents were content with the 
knowledge regarding the disease risk, even though 55% of the mothers and 37% of 
fathers of the high-risk newborn infants had experienced modest anxiety when they 
had received the results of the genetic screening. In families experiencing increased 
discomfort, anxiety was usually connected with other stressful life events, and the coping 
mechanisms in the family were emotion-focused or based on avoiding behavior (Simonen 
et al. 2006). However, while planning a screening program, it is important to pre-arrange 
a strategy to identify individuals and families with anxiety and to provide them with 
more intensive counseling, if needed. Adaptation to the fact of being at increased genetic 
disease risk, and if applicable, to the prediabetic disease process and to overt T1D may 
become easier, if problematic issues are discussed during the follow-up period.
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AIMS OF THE CURRENT STUDY
To evaluate the value of DAA and metabolic determinants as prognostic factors in the 
prediction of T1D in children with and without family history of T1D we have:
1) Compared the predictive values of GADA and IA-2A and their combination between 
FDR of patients with newly diagnosed T1D and a comparable cohort of general population 
over a 15-year follow-up period.
2) Assessed the predictive characteristics of diabetes-associated autoantibodies in a 
general population-derived cohort of children with HLA-conferred susceptibility to 
T1D.
3) Assessed whether children who progress rapidly to T1D are characterized by a higher 
prediabetic IAA affinity than IAA-positive subjects remaining unaffected or progressing 
more slowly to T1D, and whether IAA affinity increases when the time of diagnosis 
approaches.
4) Assessed the role of the first-phase insulin release and insulin resistance as predictors 
of T1D in children with HLA-conferred disease susceptibility and signs of advanced 
beta-cell autoimmunity recruited from the general population.
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RESEARCH DESIGN AND METHODS
STUDY SUBJECTS
PuBLICAtION I
In this observational study, signs of beta-cell autoimmunity and T1D were assessed in two 
cohorts of healthy Finnish children and adolescents. The first cohort was derived from 
the Childhood Diabetes in Finland (DiMe) study, in which 755 non-diabetic siblings of 
children with newly diagnosed T1D were recruited at the time of diagnosis of the index 
child (Table 4, Tuomilehto et al. 1992). The second cohort comprised 3-18 year-old 
individuals (n=3475) from the general population that were randomly selected from the 
Finnish National Registry to take part in the Cardiovascular Risk Factors in Young Finns 
(LASERI) study (Table 4, Åkerblom et al. 1999). The comparisons between the two 
population cohorts were based on autoantibody measurements in single blood samples 
obtained as soon as possible after the identification of the index case in the sibling cohort, 
and at the first visit to the study center in the general population cohort.
Table 4. Study subjects in Publication I. Time-related variables are medians (range). 
DiME (n=755) LASERI (n=3475)
Population cohorts Siblings of children with newly diagnosed T1D 
Random selection; 3-18 year-
old individuals from the general 
population
Geographical  
coverage
All Finnish hospitals taking care of 
children with newly diagnosed T1D
Five university hospital referral 
areas in Finland
Recruitment During 1986-1989 In 1980
Follow-up for the 
current report December 31, 2002 June 30, 1995
Progression to T1D, 
n (%) 51 (6.8%) 15 (0.4%)
Age at diagnosis of 
T1D, years 14.1 (1.5-28.4) 16.8 (5.5-32.8)
Follow-up for non-
progressors, years 14.8 (13.7-16.3) 14.9 (14.8-15.1)
Timing of the blood 
samples
The first sample obtained after the 
diagnosis of the index child The first sample obtained
Age at sampling, years 10.0 (1.3-19.9) 10.8 (2.7-18.9)
PuBLICAtION II
the finnish Diabetes Prediction and Prevention (DIPP) study
In the Finnish Diabetes Prediction and Prevention (DIPP) study, children from the 
general population with genetic predisposition for T1D are observed from birth for 
38 Research Design and Methods
signs of beta-cell autoimmunity and clinical T1D. The DIPP study was launched in 
1994 in Turku, in 1995 in Oulu and in 1997 in Tampere (Kimpimäki et al. 2002). The 
majority (>90%) of the 11 000 babies annually born in these centers participate in 
the cord blood screening to assess HLA-conferred susceptibility to T1D, and infants 
carrying the high risk genotype (HLA DQB1*02/0302) or the moderate risk genotypes 
(HLA DQB1*0302/x; x≠*02, *0301, *0602, or *0603) are invited to a prospective 
follow-up study. Publication II contains data on a subcohort of DIPP children (n=7410) 
who had participated in the follow-up at least until the age of 1 year by August 31, 2004, 
or had developed T1D by that time (Table 5; Publication II, Online Supplement Fig. 
1). Data on diabetes-associated autoantibodies and progression to T1D was collected 
until December 31, 2008.
Table 5. Study subjects in Publications II-IV. Time-related variables are medians (range).
Publication II Publication III Publication IV
DIPP cohort (n=7410) DIPP subcohort (n=128) DIPP subcohort (n=218)
Population 
cohorts
Children with HLA-
conferred susceptibility 
to T1D derived from the 
general population
IAA-positive DIPP 
children:
64 progressors and
64 matched unaffected 
children
Persistently multipositive 
DIPP children;
Undergone at least one 
IVGTT by December 
31, 2005
Geographical  
coverage
Turku, Oulu, and 
Tamperea
* Same as Publication II *
Recruitment Ongoing. Based on cord 
blood samplesb 
* *
Follow-up for 
the current 
work
Until December 31, 
2008
* *
Timing of the 
blood samples
Every 3-12 months since 
birth
* *
Data assessed 
in the current 
thesis work
All autoantibody 
samples available by 
December 31, 2008
First and last prediabetic/
early diabetic IAA-
positive samples 
from progressors and 
comparable samples 
from non-progressors
Autoantibody samples 
available by December 
31, 2008; weight and 
height (from birth to 
IVGTT); metabolic data 
from the first IVGTT
Progression to 
T1D, n (%)
180 (2.4%) 64 (50%) 117 (53.7%)
Age at diagnosis 
of  T1D, years
5.0 (0.9−12.5) 3.9 (0.9−8.8) 5.3 (2.1–12.5)
Follow-up for 
non-progressors, 
years
9.3 (5.4−14.2) 7.6 (3.5−11.7) 10.2 (4.9–14.2)
aUniversity referral areas in Finland; bRecruitment started in Turku (1994), followed by Oulu 
(1995) and Tampere (1997)
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In the DIPP study, the information regarding the family history of T1D is generated with 
structured questionnaires completed by the parents soon after the birth of each index 
child. In the Oulu and Tampere study centers, clinical follow-up visits are scheduled to 
take place at the age of 3, 6, 12, 18, and 24 months, and after that annually, while in Turku 
the schedule for the basic visits is once in every 3 months until the age of 2 years, and 
thereafter with an interval of 6 months. Follow-up visits are arranged in all centers every 
3 months for children who develop signs of beta-cell autoimmunity (seroconversion 
to ICA positivity; See chapter Autoantibodies). Infants with transplacentally acquired 
maternal antibodies are regarded as seronegative as long as no de novo synthesis of 
diabetes-related autoantibodies is observed. In this report autoantibody positivity was 
considered to be persistent (prefix “p”) if at least two sequential samples (taken at least 
3 months apart) and the last sample available were positive for the same autoantibodies. 
The last prediabetic and/or the first diabetic samples (obtained within 7 days after the 
diagnosis) were taken into account when defining the persistence of the autoantibody 
status.
Intervention trial with Nasally Administrated Insulin
Subjects with persistent positivity for at least two of the four autoantibodies measured 
(ICA, IAA, GADA, and IA-2A) were eligible for an intervention trial with intranasally 
administrated insulin. Before starting the treatment, eligible children underwent oral 
(OGTT) and intravenous glucose tolerance tests (IVGTT) to exclude subclinical 
diabetes and to assess their glucose metabolism. The aim in the intervention was to 
delay the clinical manifestation of T1D, but unfortunately, as the treatment group codes 
were opened in November 2007, the results showed that this type of intervention did 
not have any effect on the progression rate to T1D (Näntö-Salonen et al. 2008). For 
participation in the intervention trial and its effects, see: Publication II, Supplementary 
Table1; Publication III, Tables 2-3; Table 15.
PuBLICAtION III
Pilot studies 1-2 for Publication III
The method of measuring IAA affinity was optimized in two pilot studies on 57 samples 
from the Finnish Pediatric Diabetes Register before starting the analyses for Publication 
III (Table 6, Mäkinen et al. 2008). In the first part of the pilot study, samples obtained 
from diabetic patients (n=17) and from unaffected family members (n=14) of patients 
with T1D were studied, while in the second part samples obtained from unaffected parents 
(n=24) and siblings (n=17) of patients with newly diagnosed T1D were analyzed. In 
addition, some samples from siblings who were unaffected at initial sampling, but later 
progressed to T1D (n=7) were studied.
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Table 6. Study subjects in the pilot studies for Publication III. Time-related variables are medians 
(range).
Pilot study 1 Pilot study 2
Source The Finnish Pediatric Diabetes Register (n=57)
Selected 
subjects
Patients with parenteral insulin 
treatment for T1D (n=17)
Unaffected family members of 
patients with T1D (n=14)
Unaffected parents (n=24) and 
siblings (n=17) of patients with T1D
Initially healthy siblings that later 
progressed to T1D (n=7)
Geographical  
coverage
All Finnish hospitals treating new 
patients with T1D * Same as in Pilot Study 1
Recruitment
At the time of the diagnosis of the 
index case in the family; sample 
collection started in 2002
*
Blood samples 
in focus
The first samples taken at the 
diagnosis of the index child *
Progression to 
T1D, n (%) 7 (14.6%) *
Age at 
sampling, years 27.3 (1.4−58.6)
By December 31, 2006, 118 children (1.6%) from the original DIPP subcohort (described 
above) had developed clinical T1D (Table 5). Repeated positivity for IAA was observed in 
82 (69.5%) of these progressors in preclinical phase. Based on the availability of samples 
for the assessment of IAA affinity, 64 IAA-positive progressors and 64 non-diabetic IAA-
positive control children from the original DIPP cohort (non-progressors) were included 
in the study. The non-progressors were matched with the progressors for HLA genotype, 
gender, age at the appearance of IAA positivity (±12 months), place of birth, and the 
availability of subsequent IAA-positive samples. Regarding gender, HLA genotype, and 
age at the appearance of IAA positivity, the proportion of completely matched pairs was 
92%. For detailed data on the study subjects, see Publication III, Tables 1-3.
PuBLICAtION IV
As described above, DIPP children older than 1 year of age with persistent positivity for 
multiple autoantibodies and a non-diabetic OGTT were eligible for an intervention trial 
with intranasally administrated insulin, and before starting the intervention treatment these 
children underwent an IVGTT (Publication IV, Table 2 and Fig. 1). The study cohort in this 
work comprised 218 DIPP children with results from at least one IVGTT by December 31, 
2005, and 179 (82.1%) of these children participated in the intervention trial.
METHODS
GENEtIC SCREENING
The HLA-DQB1-associated risk genotypes (HLA DQB1*02/0302 and HLA 
DQB1*0302/x; x≠*02, *0301, *0602, or *0603) were screened in cord blood samples 
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by time-resolved triple-label hybridization with allele-specific probes (Sjöroos et al. 
1995). Insulin gene (INS; -23 HphI variant) polymorphism was assessed with a PCR-
based method and lanthanide-labeled oligonucleotide hybridization, and the PTPN22 
C1858T polymorphism with a homogenous genotyping method and a minisequencing 
assay (Haller et al. 2004, Hermann et al. 2006).
AutOANtIBODy ASSAyS
Blood samples obtained from the two cohorts, DiMe and LASERI, were analyzed for 
GADA and IA-2A between the years 2002 and 2004 to ensure comparable antibody 
analyzing methods. According to the DIPP Study protocol, the measurement of ICA 
is used as the first step of autoantibody screening, and if a child seroconverts to ICA 
positivity or develops diabetes, also the other three autoantibodies, IAA, GADA, and 
IA-2A, are analyzed in all samples available from that individual. A subset of DIPP-
children (n=1006) was directly screened for all the above mentioned autoantibodies.
Serum samples for autoantibody determinations were stored at −70ºC prior to analysis. 
ICA were measured by indirect immunofluorescence on sections of human pancreas 
(cut-off level for positivity 2.5 Juvenile Diabetes Foundation Units, JDFU; Bottazzo et 
al. 1974), and IAA, GADA, and IA-2A with specific radiobinding assays as described 
previously (Williams et al. 1997, Savola et al. 1998 a and b). Cut-off values for IAA 
(3.48 Relative Units, RU), GADA (5.36 RU; 14.13 WHO Units/ml), and IA-2A (0.43 
RU; 1.91 WHO Units/ml) positivity were based on the 99th percentile levels observed 
in Finnish non-diabetic pediatric population (n=370). All ICA-positive samples and 
samples with IAA, GADA and/or IA-2A levels between the 97th and 99.5th percentiles 
were reanalyzed to confirm the antibody status.
The laboratories that performed the autoantibody measurements have participated in 
the international Diabetes Autoantibody Standardization Program (DASP) workshops. 
According to the workshop results in 2003, the disease sensitivity and specificity of the 
GADA assay were 82% and 98%, while the corresponding characteristics for the IA-
2A assay were 64% and 100%, respectively. In 2005 the disease sensitivity of the IAA, 
GADA, and IA-2A assays were 58%, 82%, and 72%, respectively, while corresponding 
specificities were 98%, 96%, and 100%. Disease sensitivity and specificity of the ICA 
assay were 100% and 98%, respectively (Greenbaum et al. 1992a, Bingley et al. 2003, 
Törn et al. 2008).
ASSAy fOR MEASuREMENt Of IAA AffINIty
Insulin autoantibody affinity was assessed with a competitive homologous radiobinding 
assay with human recombinant insulin (Amersham, GE Healthcare, Buckinghamshire, 
UK; mono-125I labeled at TyrA14 with activity 2000 Ci/mmol and concentration 0.148 
nmol/l) after competition with eight increasing concentrations (ranging from 4.0x10-13 to 
5.9x10-5 mol/l) of unlabeled human recombinant insulin (Roche Diagnostics, Mannheim, 
Germany). The assay protocol was a modification of that described earlier (Achenbach 
et al. 2004b). The total volume of the samples (measured in duplicates) was 55 μl/well. 
The amount of bound labeled insulin was measured with a liquid scintillation detector 
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(1450 MicroBeta Trilux; Perkin Elmer Life Sciences, Turku, Finland) after precipitation 
of immune complexes, and the results were given as counts per minute (cpm). GraphPad 
Prism 5.0 for Windows (GraphPad Software, San Diego, CA, USA) was used to calculate 
the values for the half maximal inhibitory concentration (IC50) and dissociation constant 
(Kd), and the reciprocal of the Kd value (l/mol) was used to represent the IAA affinity. 
The coefficient of variation of the assay was 12.3%. Further details regarding the assay; 
see Publication III (Materials and Methods section).
ORAL AND INtRAVENOuS GLuCOSE tOLERANCE tEStS
Oral glucose tolerance tests were performed by giving perorally (p.o.) 1.75 g glucose/
kilogram body weight (Glucodyne® 227.3 mg/ml solution, maximal dose 75 g) after 
taking the baseline (0 min.) venous sample for glucose measurement. Another sample 
for testing the plasma glucose level was taken 2 h after the administration of glucose, and 
the results were interpreted according to the WHO criteria (Table 7).
Table 7. Diagnostic criteria for diabetes mellitus and other types of hyperglycemia.
Glucose concentration, mmol/l (mg/dl)
Whole blood Plasma
Venous Capillary Venous
Diabetes mellitus
Fasting or
2h after glucose challenge
≥ 6.1 (≥ 110)
≥ 10.0 (≥ 180)
≥ 6.1 (≥ 110)
≥ 11.1 (≥ 200)
≥ 7.0 (≥ 126)
≥ 11.1 (≥ 200)
Impaired glucose tolerance
Fasting, if measured, and
2h after glucose challenge
< 6.1 (<110)
≥ 6.7 (≥ 120)
< 6.1 (< 110)
≥ 7.8 (≥ 140)
< 7.0 (< 126)
≥ 7.8 (≥ 140)
Impaired fasting glycemia
Fasting, and if measured
2h after glucose challenge
≥ 5.6 < 6.1
(≥ 100 < 110)
< 6.7 (< 120)
≥ 5.6 < 6.1
(≥ 100 < 110)
< 7.8 (< 140)
≥ 6.1 < 7.0
(≥ 110 < 126)
< 7.8 (< 140)
Modified from World Health Organization 1999.
The standardized ICARUS protocol (Bingley et al. 1992) was used for performing 
the IVGTTs: After overnight fasting, baseline samples for the glucose and insulin 
measurements were taken and 0.5 g glucose/kg body weight was infused intravenously 
(20% solution) in 3 minutes ± 15 seconds. The maximal dose of glucose was 35 g. 
Venous blood samples for glucose and insulin assessments were taken 1, 3, 5, and 10 
minutes after the infusion. Glucose concentrations were measured in plasma samples 
with an enzymatic method, and serum intact insulin concentrations with an enzyme-
linked two-site immunoassay (Beach and Turner 1958, Yalow and Berson 1960). Cross-
reactivity with proinsulin was not tested. Insulin concentrations in serum samples 
obtained in Oulu and Tampere were analyzed in the Research Laboratory, Department 
of Pediatrics, University of Oulu, while the samples obtained in Turku were assayed in 
the laboratory of Turku University Hospital (Dako Cytomation, Ely, United Kingdom).
The concentrations analyzed in Turku were converted to values comparable to those 
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analyzed in Oulu according to a regression equation (R2=0.94) based on a comparison of 
100 samples between Oulu and Turku.
The sum of the insulin concentrations in post infusion samples at 1 and 3 minutes was 
defined as the first-phase insulin response (FPIR), and the homeostasis model assessment 
of insulin resistance index (HOMA-IR) was calculated by multiplying the fasting glucose 
value (mmol/l) by the fasting insulin value (mU/l), and by dividing the result by 22.5.
GrOWtH-rElAtED DAtA
The weight (kg) and height (cm) of the children participating in the DIPP study were 
measured at the clinical follow-up visits. The original values obtained were compared 
to the Finnish standardized growth charts (Sorva et al. 1984) and converted into relative 
height (a standard deviation score value, SDS) and relative weight (weight-for-height 
percentage, %).
DAtA ANALySIS
The SPSS program versions 11.0 to 16.0 (SPSS, Chicago, IL, USA) were used for the 
statistical analyses. The confidence intervals were given at 95% (CI95%) and statistical 
significance was set at P<0.05 (two-tailed), except in the case of multiple simultaneous 
analyses, where the Bonferroni correction was used, when applicable. Various parametric 
and non-parametric methods were used, the details of which are respectively described 
in the original publications.
CASE ASCERtAINMENt
In publication I, cases were ascertained from the Central Drug Registry of the National 
Social Insurance Institute (Karvonen et al. 1999). For DIPP-related studies, cases were 
ascertained from the patient records of the three University Hospitals participating in the 
DIPP study and from the Finnish National Pediatric Diabetes Register (Mäkinen et al. 
2008).
EtHICAL ISSuES
The study protocols of the DiMe, LASERI, and DIPP studies have been approved by 
the local ethics committees, and written informed consents were obtained from the 
guardians of the participants before the commencement of the study procedures. In the 
DIPP study, results from HLA genotyping and autoantibody analyses were provided 
to the participating families together with medical consultation services, if needed. 
DIPP children who had developed persistent positivity for at least two of the diabetes-
associated autoantibodies and had reached the age of 1 year were offered the possibility 
to participate in a double-blinded, randomized, placebo-controlled intervention trial with 
nasally administrated insulin. Regarding these children, written informed consents were 
obtained separately prior genetic analysis, and before initiating the follow-up period or 
intervention study.
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RESULTS
Children who progress to t1D seroconvert at a young age
Comparable data on the initial seroconversion were unavailable for the DiME and DIPP 
cohorts, but according to data from the DIPP cohort, seroconversion occurring at a 
young age was a strong risk factor for T1D in children with an increased genetic disease 
risk. The current DIPP cohort comprised 7410 children that were observed for signs 
of beta-cell autoimmunity and progression to T1D for a median follow-up time of 9.2 
years (range 0.9-14.2 years; Publication II, Supplementary Table 1). The median age at 
diagnosis of the 180 progressors (2.4%; 93 males) was 5.0 years (range 0.9-12.5 years), 
and the median follow-up time for the unaffected subjects 9.3 years (range 5.4-14.2 
years). The age at seroconversion of unaffected ICA-positive subjects was 4.2 years (0.2-
13.7 years), whereas the age of progressors was 1.5 years (0.3-9.6 years, P<0.001).
Children with the high-risk HLA genotype and/or positive family history of T1D 
seroconverted more frequently and were younger at seroconversion than DIPP children 
carrying moderate-risk genotypes and having no affected FDRs (Tables 8-9). High-
risk genotype, positive family history for T1D and male gender were also associated 
with multipositivity appearing already at the time of initial seroconversion (Table 10). 
Correlations between seroconversion and HLA genotype and seroconversion and family 
history with T1D remained significant even after controlling for the other baseline factor 
(HLA genotype or family history of T1D, respectively; adjusted rS= –0.07 and 0.05, 
Table 8. Comparison between DIPP children carrying the high-risk HLA genotype and the 
genotypes associated with moderate disease risk.
High risk Moderate risk
N (%)
Total
Gender, males
T1D affected family members at the birth of the child
ICA-based seroconversion
Seroconversion sample IAA-positive a
Seroconversion sample multipositive a
Positivity for ≥2 DAAs a
Persistent autoantibody positivity a
Persistently positive for ≥2 DAAs a
Participation in the intervention study
Progression to T1D
1575 (21.3)
829 (52.6)
53 (3.4)
325 (20.6)
83 (25.5)
64 (19.7)
141 (43.4)
194 (59.7)
109 (33.5)
82 (25.2)
80 (5.1)
5835 (78.7)
3068 (52.6)
124 (2.1)*
848 (14.5)†
155 (18.3)‡
97 (11.4)†
250 (29.5)†
478 (56.4)†
174 (20.5)†
137 (16.2)†
100 (1.7)†
Years, median (range)
Age at diagnosis
Age at seroconversion
Age at maximal DAA status
Delay from seroconversion to maximal DAA status
Delay from seroconversion to diagnosis of T1D
5.1 (1.0–12.0)
3.5 (0.3–13.3)
4.2 (0.5–13.3)
0 (0–9.0)
2.8 (0.1–9.0)
4.9 (0.9–12.5)
4.0 (0.2–13.7)§
5.0 (0.5–13.7)||
0 (0–11.0)*
2.8 (0.0–10.9)
aAmong ICA-positive subjects; *P=0.004, †P<0.001, ‡P=0.006, §P=0.03, || P=0.04.
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Table 9. Comparison between DIPP children with and without first degree relatives with type 1 
diabetes at birth of the child.
FDRs No family history of T1D
N (%)
Total
Gender, males
HLA-DQB1*02/*0302, high risk genotype
ICA-based seroconversion
Seroconversion sample IAA-positive a
Seroconversion sample multipositive a
Positivity for ≥2 DAAs a
Persistent autoantibody positivity a
Persistently positive for ≥2 DAAs a
Participation in the intervention study
Progression to T1D
177 (2.4)
83 (46.9)
53 (29.9)
49 (27.7)
23 (46.9)
16 (32.7)
38 (21.5)
40 (22.6)
31 (17.5)
26 (14.7)
24 (13.6)
7233 (97.6)
3814 (52.7)
1522 (21.0)*
1124 (15.5)†
215 (19.1)†
145 (12.9)†
353 (4.9)†
632 (8.7)†
252 (3.5)†
193 (2.7)†
156 (2.2)†
Years, median (range)
Age at diagnosis
Age at seroconversion
Age at maximal DAA status
Delay from seroconversion to maximal DAA status
Delay from seroconversion to diagnosis of T1D
4.8 (0.9–11.4)
3.0 (0.3–10.5)
4.0 (0.5–12.5)
0.5 (0–8.7)
2.8 (0.3–8.6)
5.1 (1.0–12.5)
4.0 (0.2–13.7)‡
4.9 (0.5–13.7)
0 (0–11.0)†
2.8 (0.0–10.9)
aAmong ICA-positive subjects; *P=0.004, †P<0.001, ‡P=0.02.
Table 10. The effects of gender on seroconversion and type 1 diabetes-related disease process in 
the DIPP study cohort (N=7410).
Males Females
N (%)
Total
High risk genotype (HLA-DQB1*02/*0302)
T1D affected family members at the birth of the child
ICA-based seroconversion
Seroconversion sample IAA-positive a
Seroconversion sample multipositive a
Positivity for ≥2 DAAs a
Persistent autoantibody positivity a
Persistently positive for ≥2 DAAs a
Participation in the intervention study
Progression to T1D
3897 (52.6)
829 (52.6)
83 (2.1)
621 (15.9)
148 (3.8)
98 (15.8)
235 (6.0)
380 (9.8)
169 (4.3)
130 (3.3)
93 (2.4)
3513 (47.4)
746 (47.4)
94 (2.7)
552 (15.7)
90 (2.6)*
63 (11.4)†
156 (4.4)‡
292 (8.3)†
114 (3.2)§
89 (2.5)||
87 (2.5)
Years, median (range)
Age at diagnosis
Age at seroconversion
Age at maximal DAA status
Delay from seroconversion to maximal DAA status
Delay from seroconversion to diagnosis of T1D
4.9 (0.9–12.5)
4.0 (0.5–13.7)
4.9 (0.5–13.7)
0 (0–10.0)
2.8 (0.1–10.9)
5.3 (1.0–12.0)
4.0 (0.2–13.2)
4.8 (0.5–13.5)
0 (0–11.0)§
2.9 (0.0–9.0)
aAmong ICA-positive subjects; *P=0.001, †P=0.03, ‡P=0.002,§P=0.01, || P=0.04.
46 Results
respectively; P<0.001 for both), indicating that these two factors have an independent 
effect on the risk of seroconversion. Gender did not correlate with ICA-based 
seroconversion as such, but male gender was related to indicators of more advanced 
beta-cell autoimmunity, especially persistent positivity for multiple diabetes-associated 
autoantibodies (unpublished data).
The child’s age at seroconversion predicted development of T1D. According to the 
analyses of diabetes survival, DIPP children who seroconverted before the age of 2 years 
had the highest cumulative disease risk (36.9%, CI95% 28.5-45.3%; Publication II, Fig. 
1A), and the odds ratio (OR) for T1D was 5.0 (CI95% 3.5-7.1) when younger seroconverted 
subjects (age <2 years) were compared to those who had seroconverted after the age of 
2 years. Subjects seroconverting before the age of 2 years were more often positive for 
multiple autoantibodies already at the time of the first positive sample than subjects 
who seroconverted later (18.3% vs. 12.1%, P=0.006), but the correlation between age 
at seroconversion and T1D remained significant after controlling for multipositivity 
(adjusted rS= –0.12, P<0.001; unpublished data, Table 11).
DIPP children with the high-risk HLA genotype were younger at seroconversion than 
those with moderate-risk HLA genotypes. Similarly those with a family member affected 
by T1D were younger at seroconversion than those with a negative family history (Tables 
8-9). However, young age at seroconversion correlated with the risk for T1D even after 
adjusting for the association between HLA genotype and FDR status (adjusted rS= –0.28, 
P<0.001; unpublished data).
Table 11. Positivity for insulin autoantibodies (IAA) or for multiple autoantibodies at first ICA-
positive sampling in relation to age at seroconversion among 1173 ICA-positive DIPP children. 
ICA, islet cell antibodies.
N (%) Age at ICA-based seroconversion (years)*
0-1.99 2-3.99 4-5.99 ≥6
Seroconversion sample
IAA-positive 238 (20.3) 132 (41.4) 64 (23.4) 27 (11.9) 15 (4.2)
Seroconversion sample
multipositive 161 (13.7) 58 (18.2) 52 (19.0) 30 (13.2) 21 (5.9)
*P≤0.001 in all comparisons between two consecutive groups
Age at seroconversion does not correlate with the pace of the prediabetic disease 
process
The initial hypothesis was that children who seroconvert at a young age will also 
progress to overt T1D more rapidly than their peers, but in the current DIPP study 
cohort and over the present observation period this was not the case (Fig. 3). The median 
delay from seroconversion to diagnosis was 2.8 years (0.02-10.9 years) in ICA-positive 
children who developed T1D, and the delay did not correlate with the seroconversion 
age (rS=0.005, P=0.95; unpublished data). However, children who had seroconverted 
after the age of 6 years had a slightly faster disease progression than children with 
seroconversion during their third or fourth year of life. The difference in the progression 
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rate was most prominent during the first 2.5 years after the seroconversion, but on other 
hand the number of progressors was low in the eldest cohort, which most likely skews 
the results of this analysis.
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Figure 3. Effect of age at seroconversion on the delay from seroconversion to diagnosis of type 
1 diabetes in DIPP children positive for at least ICA. P=0.04 between the second youngest and 
the oldest group of children.
the maximal effects of baseline factors (gender, HLA genotype, and family history of 
t1D) are seen in the initiation of the prediabetic disease process
The effects of the two main baseline factors, i.e. HLA genotype and family history of 
T1D, were apparent in the whole DIPP study cohort, especially for factors related to the 
beginning of the prediabetic disease process. In this study cohort of young children the 
gender-related differences in the autoantibody values were minor, and although markedly 
high GADA levels associated with the female gender, the mean GADA level was higher in 
males, both at initial seroconversion and during the follow-up (Table 12). The correlations 
between T1D and the levels of ICA, IAA, GADA, and IA-2A remained all significant after 
adjusting for HLA genotype, gender, and family history of T1D (unpublished data: rS=0.29 
for ICA, rS=0.46 for IAA, rS=0.22 for GADA, and rS=0.33 for IA-2A; P<0.001 for all).
In DIPP children with advanced beta-cell autoimmunity, HLA genotype and FDR 
status played a minor role in terms of disease development, and statistically significant 
differences were observed only for GADA that appeared to be higher in children with 
the high-risk HLA genotype (Table 12). Higher GADA levels associated also with the 
female gender in these children.
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Rapid progression to t1D is associated with high levels of diabetes-associated 
autoantibodies
In the whole DIPP cohort, the initial ICA level was a predictor of T1D already at relatively 
low ICA titers (Publication II, Fig. 1B). In the analyses of diabetes-free survival, the 
5-year progression rate for subjects with an initial ICA titer <10 JDFU was 5.7%, while 
the corresponding values for those with moderate (ICA 10-19 JDFU) and high ICA (≥20 
JDFU) levels were 31.8% and 61.2%, respectively (P<0.001 in all comparisons). The 
median ICA level was higher in the progressors already in the first ICA-positive samples 
(15 JDFU vs. 5 JDFU in non-progressors, P<0.001; Publication II). During the follow-
up, the difference in ICA levels between progressors and non-progressors increased, 
reaching maximal median titers of 168 JDFUs in progressors and 5 JDFU in non-
progressors (P<0.001). The 5-year cumulative disease risk assessed, starting from the 
time point at which the maximal ICA level was reached, was 2.3% (CI95% 0.3-4.3%) for 
children with low ICA level, while the comparable values for those with moderate and 
high ICA titers were 11.7% (CI95% 2.9-20.5%) and 76.5% (CI95% 61.4-91.6%; P<0.001 
between all groups), respectively.
Although higher ICA titers correlated with higher numbers of detectable autoantibodies 
at sampling (rS=0.68, P<0.001), the association between ICA level and T1D remained 
significant after adjusting for the number of positive autoantibodies (rS=0.10, P<0.001; 
unpublished data). Comparable categorized assessments of the diabetes-free survival 
regarding the three other autoantibodies were not done, mainly because of the ICA-
based screening strategy used in the DIPP study, but the levels of all these autoantibodies 
were higher in progressors both at the seroconversion based on ICA and at the time of 
appearance of maximal autoantibody positivity in the whole DIPP cohort (Table 13). 
The levels of ICA, IAA, and GADA were higher in the persistently multipositive DIPP 
children at all observation time points (Publication IV, Table 2).
Table 13. Levels of diabetes-associated autoantibodies in 1173 ICA-positive DIPP children at ICA-
based seroconversion and at the time of the maximal combination of positive autoantibodies. 
Levels of DAAs Non-diabetic subjects Progressors
Median RU (range)
At ICA-based seroconversion
ICA 5 (3–640) 15 (4–668)
IAA 0.3 (0–146.1) 9.9 (0–167.8)
GADA 0.1 (0–1154.5) 15.4 (0.1–316.7)
IA-2A 0.1 (0–247.3) 0.3 (0.1–221.7)
At maximal combination of positive DAAs
ICA 5 (2–1280) 35 (4–1742)
IAA 0.3 (0–146.1) 12.0 (0–213.1)
GADA 0.2 (0–1154.5) 26.2 (0–1009.4)
IA-2A 0.1 (0–247.3) 8.1 (0.1–221.7)
For all comparisons between non-diabetic subjects and progressors P<0.001.
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Positivity for IAA and/or multipositivity are two early markers associated with high 
risk for t1D
In addition to the ICA titer, IAA positivity (n=238/1173 ICA-positive children, 20.3%), 
and positivity for multiple autoantibodies (n=161, 13.7%) were associated with increased 
disease risk. The progression rate in ICA-positive DIPP children with IAA positivity 
present at the time of seroconversion for ICA was 76.6% (CI95% 56.7%-96.4%), while 
it was 11.2% (CI95% 6.8%-15.6%) in children being IAA-negative at that time point 
(P<0.001; unpublished data). Similarly, the progression rate of initially multipositive 
children was 71.6% (CI95% 59.7%-83.5%), whereas the rate was 20.6% (CI95% 10.6%-
30.6%) in children initially positive for a single autoantibody (P<0.001; Fig. 4A and 
B; unpublished data). The correlation between initial IAA positivity and multipositivity 
was high (adjusted rS=0.48, P<0.001), and the correlations between T1D and each of 
these factors remained significant after controlling for the other factor (adjusted rS=0.36 
for IAA and rS=0.30 for multipositivity, P<0.001 for both; unpublished data).
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Figure 4. Progression to type 1 diabetes in 1173 ICA-positive DIPP children in relation to IAA 
positivity (A) and multipositivity (B) at seroconversion. P<0.001 for both.
Positivity for IAA at seroconversion was most common in DIPP children who had 
seroconverted under the age of 2 years, and the frequency of this phenomenon differed 
significantly between all groups categorized according to age at seroconversion 
(Table 11). On the other hand, the frequency of multipositivity appearing already at 
seroconversion was similar in all age groups except the oldest one, where multipositivity 
was rare (Table 11).
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Persistence of positivity stratifies the t1D-associated risk of the diabetes-associated 
autoantibodies
Persistence of autoantibody positivity stratifies further the disease risk related to 
diabetes-associated autoantibodies. In the current DIPP cohort, the progression rate of 
children with transient ICA positivity was 1.6% (CI95% 0-3.8%), whereas in children 
persistently positive for at least ICA the cumulative disease risk was 48.6% (CI95% 35.2-
62.1%; P<0.001; Fig. 5A). Persistent IAA positivity seemed to identify DIPP children 
with a high disease risk and rapid progression to T1D and differentiate the children from 
those with a lower disease risk and slower progression rate (Fig. 5B). The disease risk 
associated with persistent IAA positivity was 86.6% (CI95% 77.1%-96.1%), while the risk 
was 34.1% (CI95% 15.6%-52.5%) in ICA-positive subjects who lacked pIAA positivity 
(unpublished data).
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Figure 5. Progression to type 1 diabetes in ICA-positive DIPP children (A; n=1173) in relation to 
persistent ICA-based autoantibody positivity, and in persistently ICA-positive DIPP children (B; 
n=672) in relation to persistent IAA positivity. P<0.001 for both.
IAA affinity is high both in progressors and non-progressors among young IAA-positive 
DIPP children
As transient IAA positivity has been reported repeatedly to occur in young children, we 
assessed whether IAA affinity could be used to clarify the role of IAA positivity in the 
prediction of T1D (Publication III). IAA affinity was high in young IAA-positive DIPP 
children already at the appearance of IAA positivity, and the affinity level was similar in 
both progressors and children remaining unaffected or progressing to T1D at a slow pace 
(Publication III, Fig. 1−2). The affinity value remained at similar level in both groups 
of IAA-positive children, and no maturation of the immune response to insulin was 
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observed. IAA affinity was higher in multipositive samples, but the number of detectable 
autoantibodies did not correlate with IAA affinity (rS=0.05, P=0.45; Publication III, Fig. 
2A).
The predictive role of high vs. low antibody affinity in IAA-positive children (16 
progressors among 29 children) was studied by choosing the median affinity value 
observed in the whole cohort (5.0x109 l/mol) as a cut-off value for binary categorization, 
and then analyzing the progression to multipositivity in children initially positive for IAA 
only (Publication III, Fig. 2A). The proportion of children progressing to multipositivity 
was similar in both groups regardless of IAA affinity. The same cut-off value was used 
when all participating IAA-positive children (n=128) were categorized by their initial 
IAA affinity values in order to analyze their progression to T1D. No differences were 
observed between the groups, and the finding remained the same even if lower cut-
off values (<1.0x109 l/mol or <3.0x109 l/mol) were applied. Thus, the analysis of IAA 
affinity did not facilitate the assessment of the disease risk of young IAA-positive DIPP 
children.
The two groups of IAA-positive children were matched for the main background factors 
(gender, HLA genotype, geographic area, age at appearance of IAA, and availability of 
comparable IAA-positive samples). It became apparent that these groups had highly 
similar profiles for non-HLA gene polymorphisms and similar rates of participation in 
the intervention trial with intranasal insulin (Publication III, Table 2). INS variants or 
treatment with intranasal insulin appeared to have no effect on IAA level or affinity, 
and the change in IAA level observed in children in the insulin treatment group did not 
differ from that seen in children that did not participate in the intervention trial (P=0.45; 
Publication III, Table 3).
The protective PTPN22 CC variant was associated with slightly but significantly 
lower IAA levels than those observed in children carrying the high risk-associated TT 
variant (P=0.04). Increased IAA levels (Publication III, Fig. 1A) and the higher number 
of positive autoantibodies were the only findings differentiating young IAA-positive 
progressors from their more slowly progressing or non-progressing peers. At the first 
sampling, the levels of IAA were similar in both groups (medians 13.6 RU vs. 12.4 RU, 
P=0.23; Publication III, Fig. 1A), whereas at the second sampling the IAA level observed 
in progressors was higher than that seen in slowly progressing or non-progressing 
children (medians 20.1 RU vs. 11.1 RU, P=0.001). IAA levels did not correlate with the 
IAA affinity (rS=0.11; P=0.08) or with the number of positive autoantibodies (rs=0.09; 
P=0.19), although the frequency of multipositivity was higher in progressors at the 
initial seroconversion (59% vs. 38%; P=0.01), at the time of the first and the second 
IAA-positive samples (89% vs. 65%, P=0.001 and 98% vs. 82%, P=0.003), and at the 
end of the follow-up (98% vs. 83%, P=0.002; partly unpublished data).
Categorization of study subjects by their maximal autoantibody status leads to 
identification of profiles with highly variable disease risks
According to previous studies on unaffected family members of patients with T1D, the 
5-year disease risk is approximately 50% among FDRs testing positive for multiple 
 Results 53
diabetes-associated autoantibodies (Skyler et al. 2005). During the analyses for Publication 
II it became evident that the proportions of children progressing to T1D and the delay 
from the initial seroconversion to overt disease are highly variable in multipositive 
DIPP children. The correlation between disease progression and the number of positive 
autoantibodies at the time of ICA-based seroconversion was strong (rS=0.65, P<0.001) 
in the whole cohort, but in the subjects who developed persistent multipositivity during 
the follow-up, the strength of the correlation between T1D and the maximal number 
of simultaneously positive autoantibodies was markedly lower (rS=0.14), although the 
correlation was still significant (P=0.02, unpublished data).
To analyze the predictive role of ICA-based autoantibody combinations further, we 
categorized ICA-positive subjects by their maximal autoantibody status. To assess 
simultaneously the impact of the background factors, the risk estimates were calculated 
first for the whole cohort and follow-up time, and then for 5-year follow-up, family 
history of T1D, and for the HLA risk genotypes, separately (Table 14; partly unpublished 
data). Regarding sensitivity, the highest values of the ICA-based combinations were 
observed for positivity for all four autoantibodies (48%-58%), and in all, positivity for 
at least ICA was associated with a sensitivity ranging from 80% to 88% (Table 14). The 
sensitivity values for persistent triple and quadruple positivity were similar and differed 
only slightly from the values observed for persistent double positivity.
Disease specificity of all multipositive ICA-based combinations were high (98%-100%), 
and the highest of these values were associated with the combination of persistent ICA 
and IAA positivity (Table 14). The highest positive predictive values (PPVs; range 
82%-100%) were observed for the combination of persistently positive ICA and IAA 
in all other subanalyses except for the high risk genotype, in which the combination 
with the highest PPV (100%) included also persistent IA-2A positivity (Table 14). 
Negative predictive values (NPVs) were high for all ICA-based combinations, and 
the highest ones (97%-99%) were seen for positivity for all four autoantibodies (Table 
14).
Regarding the whole follow-up, the highest cumulative disease risk (100%) was 
associated with the combination of persistently positive ICA and IAA. This antibody 
combination represented also a risk marker for rapid prediabetic progression, since 
the cumulative disease risk was 82% already for the 5-year follow-up period. Among 
the double positive combinations, the combined ICA and GADA positivity resulted in 
low progression rates (0%-8%), thus lowering also the overall risk estimates of double 
positivity. In the current DIPP cohort, there were 15 progressors who were seronegative 
during the prediabetic follow-up time. Twelve of these 15 (80%) subjects did not attend 
the follow-up visits as scheduled by the DIPP study protocol, and the median delay from 
the last visit to diagnosis was 3.8 years (range 1.9-6.2 years). All the prediabetically 
seronegative progressors who had an autoantibody sample available at diagnosis 
were seropositive at that time, and all but one had developed positivity for multiple 
autoantibodies. Measurement of the ZnT8A might have revealed beta-cell autoimmunity 
in those three DIPP children who tested seronegative only some months before their 
diagnosis, but unfortunately that data was unavailable.
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To summarize the effects and to assess the proportional hazards of the baseline 
factors (gender, HLA genotype, and family history with T1D), age at seroconversion, 
and autoantibody data at ICA-based seroconversion (ICA, IAA, GADA, and IA-2A 
positivity and levels, and the number of positive autoantibodies) in the whole DIPP study 
cohort, a Cox regression analysis was performed. According to this analysis, the highest 
hazard ratio (HR) was associated with IAA positivity in the first ICA-positive sample 
(HR=3.1, CI95% 1.7-5.8; P<0.001), followed by the number of positive autoantibodies 
at seroconversion (HR=1.9, CI95% 1.5-2.4; P<0.001), positive family history for T1D 
(HR=1.8, CI95% 1.1-3.0; P=0.02), high-risk HLA genotype (HR=1.6, CI95% 1.2-2.3; 
P=0.003), IAA level in the first ICA-positive sample (HR=1.010, CI95% 1.003-1.017; 
P=0.003), and ICA level in the first ICA-positive sample (HR=1.004, CI95% 1.002-1.006; 
P<0.001; Unpublished data).
Predictive values of ICA-based autoantibody combinations are markedly similar in 
comparable age groups of children recruited from the general population and among 
family members of patients with t1D
Pairwise comparison of results of the subanalyses (whole follow-up time vs. 5-year 
follow-up, positive vs. negative family history of T1D, and high-risk vs. moderate-
risk HLA genotypes; Table 14) showed that the maximal differences in the estimates 
of sensitivity, specificity, and NPV obtained from the subgroups varied from 9% to 
12%, while the maximal differences regarding the estimates of PPV and cumulative risk 
were markedly higher, 49% and 63%, respectively. In general, higher sensitivity and 
cumulative disease risk values were associated with high-risk HLA genotype, positive 
family history with T1D and longer follow-up period, while the opposite was true for 
specificity and NPV. The variation observed for PPV was high, but to generalize, higher 
PPV was associated with shorter follow-up time, high-risk genotype and positive family 
history for T1D (partly unpublished data).
The predictive role of GADA and IA-2A positivity was assessed in a direct comparison 
between two cohorts of Finnish children of comparable ages (Publication I). According 
to the findings of that study, both GADA, IA-2A, and combined positivity resulted in 
statistically similar sensitivity values in the comparisons between siblings of affected 
children and children originating from the general population (68% vs. 50% for GADA; 
58% vs. 43% for IA-2A; 48% vs. 36% for combined positivity, respectively, P>0.05 for all 
comparisons). Cumulative disease risks of single GADA and IA-2A positivity were higher 
in siblings of affected children than in the general population-based cohort (61% vs. 24%, 
respectively, [P<0.001] for GADA and 74%; vs. 32%, respectively [P=0.002] for IA-2A), 
but combined positivity indicated similar cumulative risk in both populations (83% vs. 
86%, respectively; P=0.89).
Metabolic factors can stratify the risk of progression to t1D in children with persistent 
multipositivity
The current DIPP study cohort comprised 218 persistently multipositive children 
(129 males, 59.2%) who had undergone at least one IVGTT by December 31, 2005 
(Publication IV, Table 1). One-hundred and seventeen (53.7%) of these children had 
60 Results
developed T1D by the end of 2008 (progressors) at a median age of 5.3 years (range 
2.1-12.5 years). The delay from the initial ICA-based seroconversion to diagnosis varied 
from 0.5 to 10.7 years. The median follow-up time for children who remained non-
diabetic (non-progressors) was 10.2 years (range 4.9-14.2 years). The baseline factors 
(gender, HLA genotype, INS and PTPN22 gene polymorphisms, and family history of 
T1D) for progressors and non-progressors were similar, but regarding the pace of the 
prediabetic disease process, progressors differed from non-progressors by being younger 
at seroconversion and at the appearance of autoantibody multipositivity, and accordingly 
being also younger at the IVGTT (Publication IV).
In the fasting state, the differences between progressors and non-progressors were minor, 
although both plasma glucose and serum insulin concentrations were slightly lower in 
the progressors (Publication IV, Table 3). After the intravenous glucose infusion, the 
maximal glucose concentrations were higher and insulin concentrations were lower in the 
progressors than in the non-progressors. The maximal insulin release is normally reached 
by the 1-minute sampling after the glucose infusion has been given, and this was also the 
case in the majority of both progressors (97 out of 117; 82.9%) and non-progressors (90 
out of 101; 89.1%). However, the timing of the peak insulin level differed between the 
progressors and the non-progressors: 17 progressors (14.5%) and only 4 non-progressors 
(4.0%, P<0.001) showed a delayed rise in their insulin levels (peak level reached 5−10 
minutes after the glucose infusion), and nine of these 17 progressors (53%) reached their 
peak insulin level at the 10-minute sampling.
Progressors have lower first-phase insulin release and relative insulin sensitivity than 
non-progressors soon after the first signs of beta-cell autoimmunity have appeared
The first phase insulin release (FPIR) was lower in the progressors than in the non-
progressors (Publication IV, Fig. 3A), and although the younger age of the progressors 
explained some of the difference in the FPIR values (rS=0.44, P<0.001), the correlation 
between the decreased FPIR and T1D remained significant after adjusting for age 
(P<0.001). FPIR correlated also with the delay from the first IVGTT to diagnosis 
of T1D (rS=0.28; P=0.003) in progressors. FPIR correlated with insulin resistance 
(HOMA-IR) in both groups (age-adjusted rS=0.24, P=0.01 for progressors and 
rS=0.29, P=0.004 for non-progressors), and with relative weight (weight-for height) 
in progressors (rS=0.29; P=0.002), but no correlations were observed between relative 
height and FPIR.
Insulin resitance was low in both groups, indicating that the persistently multipositive 
subjects have normal insulin sensitivity in general. HOMA-IR was, however, higher in 
non-progressors than in progressors (Publication IV, Fig. 3B and Table 3). HOMA-IR 
correlated with age (rS=0.41) and weight-for-height at the IVGTT (rS=0.24), and maximal 
glucose (rS=0.26) and insulin concentrations (rS=0.36; P<0.001 for all correlations). An 
inverse correlation was observed between ICA level at the IVGTT and HOMA-IR (rS= 
–0.20, P=0.003). The relative insulin resistance (HOMA-IR/FPIR) that was higher in 
progressors correlated positively with ICA, IAA, and IA-2A levels at IVGTT (rS=0.22, 
0.25, and 0.17; P<0.01), and with fasting glucose, fasting insulin, and maximal glucose 
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level (rS=0.24, 0.34, and 0.28, respectively), and inversely with the maximal insulin level 
(rS= –0.66; P<0.001 for all latter correlations).
Changes in relative weight during the prediabetic disease process are minor
Linear growth and weight gain were observed in persistently multipositive DIPP children 
in the current study. Data on weight and height were available for 197 children (90.4%) 
for the time preceding the ICA-based seroconversion and for 203 children (93.1%) at and 
after the seroconversion (Publication IV, Fig. 2A and Table 3). Future progressors had 
higher relative weight than non-progressors 12 months before the seroconversion, and 
the correlation between relative weight and T1D remained significant after correction for 
age at the time of measurement (age-adjusted rS=0.19, P=0.03).
Although minor differences were seen in relative weight prior to seroconversion in 
both groups, statistically significant differences were observed only in non-progressors 
and when only subjects who had comparable measurements both before and at 
seroconversion as well as at the IVGTT (n=187, 85.8%) were included in the analyses. 
Their relative weight had decreased from the median of 99.2% before seroconversion to 
98.5% at seroconversion (P=0.03). There were no changes in the relative weight either 
in the progressors or in the non-progressors when comparing weights at the time of 
seroconversion and IVGTT (P=0.58 for non-progressors and P=0.94 for progressors). 
Eight of the 12 children who were overweight (weight-for-height >120%) at their first 
IVGTT progressed to T1D, as did all four children who were obese (weight-for-height 
>140%) at the IVGTT. Three of the obese children had been overweight or obese already 
12 months before seroconversion.
Progression to t1D is highly variable even in children with persistent multipositivity
The initial presumption was that persistently multipositive DIPP children would represent 
a subgroup of children with an estimated 5-year disease risk of approximately 50% and 
accordingly, would form a uniform study cohort. However, as the delay from the ICA-
based seroconversion to diagnosis of T1D varied markedly in the progressors (range 
0.5-10.7 years) and the delay from the ICA-based multipositivity to diagnosis of T1D 
failed to correlate with the age at which this autoantibody status was reached (rS=0.16, 
P=0.09; Fig. 6), we aimed to assess further factors that could explain this variation in the 
pace of the prediabetic disease process.
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Figure 6. Time interval from ICA-based persistent multipositivity to diagnosis of type 1 
diabetes (T1D) in relation to age at which persistent multipositivity was recognized in 218 DIPP 
children.
The age at diagnosis correlated inversely with relative insulin resistance (rS= –0.19; 
P=0.04) and maximal IAA level before IVGTT (rS= –0.46; P<0.001), and directly with 
the age at seroconversion and IVGTT (rS=0.56 and 0.67, P<0.001 for both), as well as 
with glucose and insulin levels (fasting values rS=0.20 and 0.24; peak values rS=0.21 
and 0.49, respectively; P≤0.02), and with FPIR (rS=0.46; P<0.001), and HOMA-IR 
(rS=0.31; P=0.01). Those children who did not participate in the intervention trial were 
slightly older at seroconversion than their peers, but otherwise no other significant 
differences were observed between the intervention groups or between those with and 
without intervention treatment (Table 15; partly unpublished data). No correlations 
were observed between age at diagnosis and any of the genetic factors studied (HLA, 
INS and PTPN22 variants), growth-related factors (weight-for-height preceding and 
at seroconversion or at IVGTT), intervention treatment, or levels of autoantibodies 
except IA-2A (unpublished data). The only correlation between age at diagnosis and 
autoantibodies was seen for the maximal IA-2A level during the observation period 
(rS=0.35; P<0.001; unpublished data).
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Table15. Persistently multipositive DIPP children (n=283) according to participation in the 
intervention trial.
Nasal insulin Placebo Did not par-ticipate
N (%)
Total
Gender, males
HLA-DQB1*02/*0302, high risk genotype
T1D affected family members at birth
Seroconversion sample IAA-positive
Seroconversion sample multipositive
Progression to T1D
91 (32.2)
58 (63.7)
36 (39.6)
13 (14.3)
57 (62.6)
44 (48.4)
49 (53.8)
97 (34.3)
56 (57.7)
35 (36.1)
10 (10.3)
65 (67.0)
42 (43.3)
56 (57.7)
95 (33.6)
55 (57.9)
38 (40.0)
8 (8.4)
52 (54.7)
43 (45.3)
40 (42.1)
Years, median (range)
Age at diagnosis
Age at seroconversion
Age at maximal DAA status
Delay from seroconversion to maximal DAA
Delay from seroconversion to diagnosis of T1D
4.8 (1.0–12.2)
1.8 (0.3–10.1)
3.0 (0.5–10.5)
0.6 (0–7.2)
2.7 (0.5–10.9)
5.5 (2.1–12.5)
1.6 (0.5–9.6)
2.7 (1.0–10.3)
0.6 (0–7.4)
3.3 (0.5–9.0)
4.8 (1.0–11.6)
3.0 (0.5–10.6)*
4.8 (1.0–12.5)†
0.8 (0–10.0)
2.6 (0.1–7.6)
*P=0.004, †P=0.003.
When all the factors that could potentially predict T1D in these persistently multipositive 
DIPP children were analyzed with the Cox regression analysis, a reduced hazard ratio 
(HR) was associated with increasing age at IVGTT (HR=0.78, CI95% 0.68-0.91), and 
increasing FPIR (HR=0.98, CI95% 0.97-0.99), while higher relative weight at IVGTT 
(HR=1.04, CI95% 1.02-1.06), higher IAA level at IVGTT (HR=1.01, CI95% 1.01-1.02), 
and higher IA-2A level at IVGTT (HR=1.01, CI95% 1.00-1.01) indicated increased risk 
of progression to T1D (Publication IV).
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SUMMARY OF FINDINGS
The findings of the current work can be summarized as follows:
1. Sensitivity of GADA, IA-2A and their combination is of same magnitude both in 
siblings of T1D-affected children and in the general population.
2. GADA and IA-2A are both associated with a higher cumulative disease risk in 
siblings of T1D-affected children than in the general population, whereas combined 
GADA and IA-2A positivity indicates a similarly high cumulative disease risk in 
both groups.
3. The combination of HLA and autoantibody screening detects comparable T1D 
risk levels in the general pediatric population and autoantibody-positive FDRs of 
affected children.
4. The natural progression rate to clinical T1D is extremely high in young genetically 
susceptible children testing persistently positive for multiple autoantibodies, 
including persistent positivity for IAA.
5. IAA affinity does not facilitate the risk assessment for future T1D in young IAA-
positive children with HLA-associated disease susceptibility.
6. IAA seem to represent a mature humoral immune response to insulin already when 
antibodies appear in young children with HLA-defined predisposition to T1D, and 
no further maturation is observed during the preclinical disease process.
7. Young age, increased weight-for-height, decreased early insulin response, and 
increased IAA and IA-2A levels predict T1D in young children with HLA-
conferred disease susceptibility and advanced beta-cell autoimmunity.
8. Insulin resistance have minor impact on the progression to T1D after the initiation 
of the disease process in young normal-weight children with HLA-associated 
disease predisposition.
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DISCUSSION
During the current studies it came evident that many of the predictive factors for T1D 
that are commonly used in the context of first-degree relatives of patients with newly 
diagnosed T1D are relevant also in the general population-based cohort of young 
individuals with HLA-associated disease susceptibility. These studies offered conceptual 
tools for future screening efforts by stratifying the role of risk factors associated with 
initiation of the prediabetic disease process, as well as those present during advanced 
beta-cell autoimmunity.
An approach based on screening newborn infants for HLA risk genotypes and combined 
with regular clinical and autoantibody follow-up of individuals carrying increased genetic 
risk for T1D is a feasible and effective way to identify future patients with T1D in the 
general population. It has been estimated that by this strategy maximally 75% of future 
patients developing clinical T1D can be identified (Kupila et al. 2001). According to the 
current studies, autoantibody profiles with highly variable disease risks can be identified 
by defining categories of autoantibody combinations and by including metabolic factors 
as variables to the risk evaluation. Individuals with extremely high disease risk can be 
identified by such a strategy.
Strengths and limitations of the current studies
The strengths and limitations of the current studies are related to the study designs of the 
research projects they are based on, i.e. the DiMe, LASERI, and DIPP studies, and to the 
demographic and cultural characteristics of Finland, i.e. the relatively small population 
size (around 5.3 million at the end of 2008; Statistics Finland, Demographic statistics; 
www.stat.fi) and the possibility, provided by the Finnish Pediatric Diabetes Register, 
to track down and obtain autoantibody samples at the time of the diagnosis from the 
majority of progressors who have dropped-out from prediabetic follow-up (Mäkinen et 
al. 2008). The advantages of the current study populations include the extensive series 
of children studied, which facilitates the recognition of even the less prevalent risk 
factors. From the high T1D incidence in the pediatric population of Finland follows 
that the disease endpoint is reached in comparatively high numbers of children within 
a limited time frame, which decreases the risk of skewing the results of analyses by 
time-dependent confounding factors. It has also been shown that population-based 
screening of genetic susceptibility for T1D, combined with the possibility to participate 
in a secondary prevention trial in case signs of initiation of the disease process appear, is 
well accepted in Finland. Families with children carrying increased genetic disease risk 
also adhere well to frequent follow-up visits, even if these visits include regular blood 
sampling.
The main limitations of these large population based studies are related to the 
heterogeneous screening approaches used in the three different study cohorts, DiMe, 
LASERI, and DIPP, and these differences guided also the selection of the current analyses 
that could be performed in and between these cohorts. Especially, the possibilities of 
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comparing factors associated with seroconversion to autoantibody positivity (timing and 
the effects of the risk genotypes) between DiMe and LASERI cohorts were limited, 
because the original study approach was focused on the markers representing advanced 
autoimmunity (GADA and IA-2A), and comparable background data was not available 
for both cohorts. Regarding the comparisons between the DiMe and LASERI study 
cohorts there was also an issue of time scale, as the recruitment of the cohorts was not 
exactly identical, although within an acceptable time frame.
In the DIPP study cohort the effects of the baseline factors (i.e. gender, family history 
of T1D, HLA genotype, and INS and PTPN22 gene variants) on seroconversion and 
progression to T1D could be assessed, but fully only in subsets of the whole DIPP cohort. 
Detailed data on the seroconversion and the four diabetes-associated autoantibodies 
ICA, IAA, GADA and IA-2A were available for the DIPP cohort, but the strategy of 
using ICA as a marker of beta-cell autoimmunity limited the assessment of diabetes-
related autoimmunity, as subjects testing positive exclusively for autoantibodies other 
than ICA were omitted while studying the seroconverted subjects. In addition, the use of 
ICA for primary screening delayed the identification of seroconversion to autoantibody 
positivity in subjects who seroconverted first to positivity for other autoantibodies than 
ICA. The delay between the initial seroconversion and the appearance of ICA-positivity 
was several years in a few cases. This phenomenon was of minor importance in regard 
to risk assessment, since considering increased disease risk, the spreading of the beta-
cell specific autoimmune response is essential, and among individuals with extended 
delay between the initial seroconversion and ICA-positivity there were mainly subjects 
with transient and/or single autoantibody positivity. However, in sporadic individuals, 
in whom the first immune activation against beta cells had not been sufficient to lead 
to progressive autoimmunity, the second activation, characterized by the appearance of 
ICA, represented the initiation of the destructive disease process.
The sensitivity of the current ICA-based screening program to identify future patients 
with T1D would have increased from 86% to 97%, if the analysis of IAA had been 
added to the initial screening. This would have been important especially for young 
seroconverted children, in whom 23-41% of the first seropositive samples, even those 
preceding ICA positivity, were IAA positive. When compared to ICA screening, the 
combination of ICA and IAA might considerably reduce the number of progressors who 
test negative for all autoantibodies during their prediabetic process. However, in the 
current analyses, the main reason for prediabetic seronegativity was dropping out from 
the follow-up program and only rarely the absence of seroconversion.
In the present series, there were only three progressors who had presented with apparent 
T1D, but had been negative for all four autoantibodies studied 4-8 months before their 
diagnosis. Two of these three progressors were positive for at least ICA and IAA at 
diagnosis, while unfortunately, no autoantibody sample was available from the time of 
diagnosis from the third child. The remaining 12 of the 15 preclinically seronegative 
progressors had discontinued participating in regular follow-up visits, and among these 
subjects the shortest time interval from the last visit to diagnosis was 1.9 years. This 
observation suggests that in screening programs based on monitoring diabetes-associated 
autoantibodies in prepubertal children, 2 years should be the maximal sampling interval. 
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The role of ZnT8A in the identification of otherwise seronegative prediabetic subjects is 
under investigation at the moment and remains to be defined.
Predictive characteristics of autoantibodies in the three study cohorts
Comparisons of the disease risk estimates between cohorts originating from the general 
population and from first-degree relatives of patients with T1D were performed for 
GADA and IA-2A in the context of the DiMe and LASERI studies, but the series of 
DIPP children having affected family members at birth was not large enough for reliable 
comparisons between DIPP children with and without FDRs. However, according to the 
observations in the DIPP cohort, the predictive values of the ICA-based autoantibody 
combinations are essentially similar to those reported in studies on FDRs (Bingley 
et al. 1994, Kulmala et al. 1998, Krisher et al. 2003). The predictive characteristics 
of GADA and IA-2A were highly similar between initially unaffected siblings in the 
DiMe study and participants in the LASERI study, who represented the Finnish general 
population. During the 15-year observation period >80% of the double positive subjects 
developed T1D in both study cohorts, and the disease sensitivities of single GADA or 
IA-2A positivity and the combination of these autoantibodies were similar in siblings of 
affected patients and in the general population.
The cumulative disease risk associated with double positivity was also similar in both 
DiMe and LASERI cohorts, while a higher cumulative disease risk was observed in 
siblings for single GADA and IA-2A positivity. According to previous studies, the majority 
of progressors develop multipositivity months to years before disease presentation, 
and if choosing the combination of GADA and IA-2A for autoantibody screening, all 
multipositive German and American schoolchildren could be identified (LaGasse et 
al. 2002, Schlosser et al. 2002). However, GADA, and especially IA-2A, represent a 
marker of advanced autoimmunity, and the delay from the initial seroconversion to the 
appearance of GADA and/or IA-2A may take several months (Kimpimäki et al. 2002). 
This fact indicates that GADA and IA-2A can only play a minor role in the first step of 
autoantibody screening in young children, among whom the disease process is often 
rapid. As one of our targets for the future is to provide effective and safe preventive 
treatment for prediabetic individuals already at early stages of the disease process, the 
aim of the autoantibody screening is to reliably identify the future progressors as early 
as possible after the initiation of the autoimmune process.
Predictive factors for t1D among DIPP children
We used the Cox regression analysis to assess the role of risk factors related to early 
beta-cell specific autoimmunity that may be potentially present when a child is testing 
positive for ICA for the first time. Based on the whole DIPP cohort, early IAA positivity, 
high number of positive autoantibodies at seroconversion, a positive family history for 
T1D, and high IAA and ICA levels were independent predictors of T1D (Fig. 6). As the 
Cox regression method is relatively sensitive in relation to differences in the baseline 
factors included in the analysis, various potential predictive models were assessed, but 
during the analyses the above mentioned factors remained as independent, but relatively 
weak predictors of T1D.
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The role of early and persistent IAA positivity was, however, highly significant in the 
current DIPP study cohort. As this observation became apparent during the analyses, the 
role of IAA affinity as a potentially stratifying factor for the disease risk was assessed 
in IAA-positive DIPP children. As results supporting the usefulness of the analysis of 
IAA affinity in risk assessment had been reported earlier for older family members of 
diabetic patients and non-diabetic schoolchildren (Achenbach et al. 2004b, Schlosser et 
al. 2005a), our presumption was that a high IAA affinity would differentiate young IAA-
positive children progressing rapidly to overt T1D from IAA-positive subjects remaining 
unaffected or progressing at a slower pace to T1D. At the same time we aimed at finding 
out whether humoral immune response against insulin, the potential primary autoantigen 
in the disease process leading to T1D, maturates during the prediabetic disease process, 
or whether the response is mature soon after its initiation. Our findings showed that IAA 
affinity was high in the majority of the study subjects, and that high IAA affinity did 
not differentiate rapid progressors from their slowly or non-progressing peers, and that 
the immune response against insulin is mature already at the beginning of the disease 
process in young IAA-positive children with HLA-conferred disease susceptibility.
These findings, and the fact that although the progressors and non-progressors were 
not matched for their non-HLA genotypes initially, they resembled each other also in 
these respects, and that during the selection of the non-progressors some of the children 
originally identified as non-progressors did develop T1D before the analyses were 
performed, raised the question whether the groups were basically too similar for the 
detection of any differences. Not surprisingly, the only significant observation in terms of 
IAA and non-HLA polymorphisms in this study cohort was that the protective PTPN22 
genotype (TT) seems to be associated with a slightly lower IAA level when compared 
to the high-risk associated gene variant. We could, however, confirm the findings of 
previous studies showing that the correlation between IAA levels and affinity is poor, 
and that high-affinity antibodies are present also in samples with remarkably low IAA 
levels (Schlosser et al. 2005a). From the point of view of T1D prediction, we observed 
that an increasing IAA level, which was strongly related to positivity for multiple 
autoantibodies, was a marker of increased disease risk in the time frame covered.
Positivity for multiple autoantibodies remained a significant predictor of T1D also 
among our study subjects, and this observation was in concordance with findings from 
previous studies assessing the role of diabetes-associated autoantibodies in family 
members of affected patients and in schoolchildren (Bingley et al. 1994, Hummel et 
al. 2004a). For example, in the DiMe study the siblings who tested positive for at least 
three autoantibodies (4.6 %) had a 5-year cumulative disease risk of 57%, while the 
corresponding risk estimate for triple positive DIPP children (n=263, 3.5%) was 51% 
in the present series. The frequency of multipositivity is, however, higher in FDRs 
than in the background population, and to find similar numbers of individuals at high 
risk for progression to T1D (>50% over 5 years), i.e. triple positive subjects, one third 
more children should be screened from the background population. The screening effort 
would be still worth it, since these children represent the majority of individuals at risk 
for T1D, and without preventive measures covering also individuals at risk in the general 
population, only a proportion of future cases can be prevented.
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Given that the progression rate is extremely high among young persistently multipositive 
children testing positive for IAA, these children might represent a subgroup of prediabetic 
children for whom even more intensive immunomodulatory treatment, aimed at delaying 
or preventing overt disease, might be justified in the future. Regarding preventive 
interventions, the two major challenges for persistently ICA and IAA positive children 
may, however, be the young age and remarkably rapid progression to overt disease, 
e.g. for DIPP children having such an autoantibody profile, the median delay from the 
maximal autoantibody status to diagnosis was 0.4 years and the median age at diagnosis 
only 2.6 years.
The levels of all four autoantibodies studied were significantly higher in progressors 
already at seroconversion and the differences became even more distinct by the time 
when the children had reached their maximal autoantibody status (Table 10). The effect 
of the third independent predictor of T1D in the Cox regression analysis, i.e. a positive 
family history for T1D, on the autoantibody levels was significant in relation to all 
four autoantibodies, but it was even more prominent regarding ICA and IAA (Table 
9). Interestingly, in children with advanced beta-cell autoimmunity, baseline factors 
(genotypes, FDR status and gender) seemed to play a marginal role in explaining the 
differences observed in the autoantibody levels. Our findings confirmed, however, the 
previous observations that higher GADA levels associate with female gender (Sabbah et 
al. 1999, Lindholm et al. 2004) and that the protective INS polymorphisms are associated 
with lower IAA levels (Haller et al. 2004, Barratt et al. 2004).
In the whole DIPP cohort the disease risk associated with single ICA positivity of low 
level (<10 JDFU) did not differ significantly from that observed for autoantibody-
negative children (0.3% vs. 0.5%, respectively; P=0.70). Increased risk for T1D that 
was observed for ICA as a risk marker was associated with ICA≥20 JDFU and with 
simultaneous positivity for other autoantibodies. The two latter findings have also been 
observed among family members of diabetic patients (Bonifacio et al. 1990, Bingley 
et al. 1996), and in fact the clear correlation between multipositivity and ICA level, 
and the differing HRs associated with these markers (1.9 [CI95%1.5-2.4] vs. 1.004 
[CI95%1.002-1.006]), suggest that multipositivity as a risk factor is more important than 
the ICA titer.
Predictive factors in DIPP children with advanced beta-cell autoimmunity
During the assessment of the disease risk associated with different combinations of 
positive autoantibodies, it became clear that even among children with signs of advanced 
beta-cell autoimmunity, i.e. persistent multipositivity, the disease risk and the pace of the 
prediabetic disease progression is highly variable. Previous studies on family members 
of diabetic patients and in ICA-positive children have shown that markers related to 
glucose metabolism could be used in the stratification of the disease risk (Bingley et 
al. 1996, Gungor et al. 2004, Mrena et al. 2006, Barker et al. 2007), and we assumed 
that differences in these factors could at least in part explain the variation observed 
among persistently multipositive DIPP children. These children were also eligible for the 
randomized, double-blinded, and placebo-controlled intervention trial with intranasally 
administrated insulin. To study the baseline metabolic status of children before starting 
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the intervention trial and to assess the prognostic value of the metabolic factors among 
these children, IVGTTs were performed in all voluntary, persistently multipositive DIPP 
children as soon as possible after the antibody status had been confirmed.
The current observations confirmed that in prediabetic FDRs of patients with T1D, 
reduced FPIR was associated with increased disease risk also in persistently multipositive 
DIPP children (Bingley et al. 1996, Mrena et al. 2006, Xu et al. 2007). In general, 
among progressors, reduced FPIR identified children with rapid progression to overt 
T1D, whereas children with higher FPIR values experienced a longer subclinical phase 
and were older when diagnosed with T1D. The individual variation in FPIR values was 
substantial, and both progressors with remarkably high FPIR levels and non-progressors 
with low FPIR values were observed.
When assessing the serum insulin concentrations after the glucose infusion, we noticed 
that progressors reached the maximal insulin level later than non-progressors, and 
on the average, they could secrete nearly normal amounts of insulin. This functional 
abnormality was characteristic of progressors, and in the current study cohort, there 
was only one non-progressor (male with the moderate risk associated HLA genotype) 
that reached his peak insulin level after the 1-minute sampling. Although FPIR in this 
boy was <10 mU/l, he has remained non-diabetic for more than 10 years after the first 
IVGTT. In this case it seems more likely that the low FPIR observed mainly was due to 
a functional disturbance rather than extensive beta-cell destruction, but studies in mice 
have shown that considerable beta-cell recovery can occur after the initiation of the 
prediabetic process (Zorina et al. 2003).
In the Cox regression analysis, indicators that weakly but independently predicted T1D 
included young age, increased relative weight, reduced FPIR, and elevated IAA and 
IA-2A levels. Although in this statistical model insulin resistance and relative insulin 
resistance failed to predict T1D, both were related to significant predictors of T1D; 
insulin resistance to weight-for-height and relative insulin resistance to FPIR. These 
observations support the findings of the ENDIT study and the British study on identical 
twins in which HOMA-IR predicted T1D in subjects with reduced FPIR (Hawa et al. 
2005, Bingley et al. 2008). Similar findings were reported also in the DiMe and DPT-
1 studies in which both HOMA-IR and FPIR/HOMA-IR were significantly associated 
with progression to T1D (Mrena et al. 2006, Xu et al. 2007). These findings indicate that 
while insulin resistance by itself can cause only mild disturbances in glucose metabolism 
in young normal weight individuals with malfunctional insulin release, decreased insulin 
sensitivity may promote progression towards T1D. The role of the obesity-related insulin 
resistance for the risk of T1D seemed marginal in the current study, and in fact, the 
average insulin resistance indexes were lower in progressors than in non-progressors. 
However, among the two progressors and five non-progressors who had elevated HOMA-
IR values, progressors were obese and had higher relative insulin resistance indexes than 
non-progressors. Except for these two cases, no clinically significant long-term changes 
in the growth-related factors were observed.
When analyzing factors that predispose Finnish children to T1D, we observed that in 
subjects with HLA-conferred disease risk and signs of advanced beta-cell autoimmunity 
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the baseline factors, such as gender, genetic risk factors, and family history of T1D 
played minor roles in the prediction of T1D after the initiation of the diabetic disease 
process. This phenomenon might be caused by the selection of subjects with similar 
genetic background, but it may also indicate that these baseline factors contribute mainly 
to the initiation of the disease process and become less significant as the autoimmunity-
mediated beta-cell destruction proceeds.
Prediction and prevention of type 1 diabetes: Practical and ethical issues
Screening programs aimed at identifying individuals at an increased risk for T1D have 
affected already the life of more than 100 000 Finnish families, and internationally 
manifolds. During the years of extensive diabetes-related studies the general knowledge 
of T1D has increased, which has in turn changed the clinical profile of newly diagnosed 
cases of T1D (Barker et al. 2004, Hekkala et al. 2007). Today the proportion of patients 
with severe, life-threatening ketoacidosis at diagnosis is smaller, and in the follow-up 
programs even asymptomatic but diabetic subjects with no metabolic derangements can 
be identified. A good metabolic balance at the beginning of the disease may preserve 
some of the endogenous insulin secretion, which in turn is associated with better 
glycemic control and decreased risk of microvascular complications in the years to come. 
A metabolically balanced beginning of the illness may also provide a good starting point 
for learning the basics of insulin therapy, but on the other hand, may sometimes give a 
slightly skewed conception of the seriousness of this disease, which still remains the 
most common of the chronic, severe, potentially life-threatening illnesses of childhood 
and adolescence.
Diabetes, like any other chronic illness, is associated with burdens of various types 
(Aanstoot et al. 2007). For example, in the USA the productivity loss associated with 
T1D were estimated to equal about a one third reduction in earnings (Ng et al. 2001), and 
in Finland the total costs of medication for individuals with diabetes were assessed to be 
3.5 times higher than those for the non-diabetic control subjects (Reunanen et al. 2000). 
For comparison, the estimated costs for a genetically targeted 10-year prediction program 
in Finland were estimated to be 245 US Dollars, less than 200 Euros per child (Hahl et 
al. 1998), while the costs for T1D prevention program for 2 years were estimated to be 
around 1500 Euros per child (Hahl et al. 2003). However, as to date no safe and effective 
prevention measures have been developed, the ultimate costs of a feasible prediction and 
prevention program remain merely speculative.
Monetary factors play a substantial role when medical care and population-based 
prevention strategies are considered, but one should also take into account the 
psychological effects related to both prevention programs and to the disease itself. 
According to studies on the psychological impact of genetic and autoantibody screening 
on the participating families, the knowledge of increased genetic disease susceptibility 
appears to induce mild anxiety in most parents (Lernmark et al. 2004, Simonen et al. 
2006), but on an average, autoantibody testing reduces the anxiety levels of the families, 
at least in those families who already have affected members (Hummel et al. 2004b). 
Anxiety and discomfort caused by the prediction programs appear relatively insignificant 
when compared to the burden caused by T1D: the possibility of developing severe 
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hypo-/hyperglycemias and long-term complications, efforts needed for reaching optimal 
metabolic balance, potential employment and career problems, etc. (Hahl et al. 2002, 
Wasserman and Trifonova 2006).
When considering various aspects of predictive programs aimed at identifying individuals 
at risk for T1D one has to keep in mind the main goal of all these efforts: finding means 
to prevent T1D, or at least to delay its clinical presentation. Altogether, both earlier 
experiences from prospective follow-up studies and the work presented in the current 
thesis show that it is possible and feasible to genetically screen newborn infants from the 
general population for HLA risk genotypes, to arrange follow-up for children with HLA-
conferred diabetes susceptibility, and to identify individuals who develop progressive 
beta-cell autoimmunity. As soon as safe and effective preventive measures are available, 
population-based prevention programs may become relevant in high-incidence countries, 
such as Finland.
 Conclusions 73
CONCLUSIONS
The rapidly accumulating knowledge of the natural history of T1D has paved the way for 
identifying the majority of future patients with T1D. By combining genetic, immunological 
and metabolic data, prediction of T1D will reach the efficacy and reliability required for 
clinical use. The work presented in this thesis aimed at assessing the immunological and 
metabolic factors associated with an increased risk for T1D in affected families and in 
the general population. The results show that, in a population-based cohort of children 
carrying HLA-conferred disease susceptibility, prospective screening of diabetes-
associated autoantibodies results in the identification of individuals at high risk for T1D, 
and that the estimation of disease risk can be stratified by assessing metabolic markers 
including circulating glucose and insulin concentration in prediabetic individuals. The 
risk estimates associated with positivity for multiple autoantibodies for children recruited 
from the general population, carrying HLA-conferred disease susceptibility, are similar 
to those observed in family members of patients with T1D. Accurate prediction of T1D is 
a prerequisite for secondary prevention of this disease. Identifying the right individuals 
for the right treatment at the right time may in the end save time, money, and resources, 
as well as alleviate the burden caused by T1D.
74 Acknowledgements
ACKNOWLEDGEMENTS
Even though no words can express my gratitude, I will try.
I highly value the intelligence, knowledge, and wisdom of my supervisor, Professor 
Mikael Knip. I appreciate his valuable advice, flexibility, positive attitude, and the 
stimulating challenges he provided me. Your eyes saw much more than mine can ever 
see.
With gratitude I regard my co-authors and collaborators, Professors Olli Simell, Jorma 
Ilonen, Suvi Virtanen, and Antti Reunanen; Doctors Riitta Veijola, Robert Hermann, 
Päivi Keskinen, Taina Härkönen, Tuula Simell, and Paula Vähäsalo; Researchers Anne 
Hekkala, Satu Simell, Jyrki Lähde, and Riikka-Tiina Salonsaari. My special thanks go 
to Emeritus Professor Hans Åkerblom, who provided me an example of an esteemed 
scientist with far-reaching visions, academic backbone, and admirable productivity.
I thank my research-oriented peers, Cecilia Janèr, Kristiina Luopajärvi, Sonja Strang-
Karlsson, Janne Nieminen, Mia Westerlund-Ormio, Emma Marschan, Otto Helve, 
Sanna Hoppu, Kari Ranta, Kirsti Näntö-Salonen, and Vilhelmiina Parikka, and the rest 
of our research team, Samppa Ryhänen, Kirsi Salonen, Anna Mäkinen, and Susanna 
Rosenback, for their enthusiasm and extraordinary love for science.
My sincere gratitude is dedicated to Erja Karjalainen, Matti Koski, and Jari Hakalax 
for their patience and creativity, and their knowledge on practical issues and data 
management. I thank Professor Seppo Sarna and Researcher Janne Pitkäniemi for 
teaching biostatistics in a way which invites novices to the path of understanding.
DIPP children and their families, and the personnels of the DIPP, TRIGR, and 
DIABIMMUNE studies and that of the Research Laboratory of the Hospital for Children 
and Adolescents are warmly acknowledged for their efforts. In particular, Iiris Ollila is 
thanked for her skillful technical assistance.
With appreciation I remember the time spent at the Pediatric Departments of the Länsi-
Uusimaa and Jorvi Hospitals, and I thank the senior pediatricians and the personnels of 
these institutions for introducing me to the beauty of pediatrics.
Acknowledgement is dedicated to sponsors (the National Institutes of Health, the 
Academy of Finland, the European Union Biomed 2, the Social Insurance Institution 
of Finland, the National Board of Health, the Foundation for Pediatric Research in 
Finland, the Medical Research Council, the Juvenile Diabetes Research Foundation, the 
Red Heart Operation Fund, the Association of Finnish Life Insurance Companies, the 
Sigrid Jusélius Foundation, the Juho Vainio Foundation, the Yrjö Jahnsson Foundation, 
the Novo Nordisk Foundation, the Liv and Hälsa Foundation, and the Tampere, Oulu, 
Turku, and Helsinki University Hospitals) that provided monetary support for the DiMe, 
LASERI, and DIPP studies of these projects. In addition, I sincerely thank the National 
Graduate School of Clinical Investigation, Finska Läkaresällskapet, Folkhälsan, and 
 Acknowledgements 75
the Graduate School for the Clinics of Pediatrics and Gynecology of the University of 
Helsinki for providing research grants for the current work.
I thank my parents-in-law, Kirsti and Veli Siljander, for providing constancy in the 
midst of a life full of changes; brothers and sister-in-law for enjoyable moments while 
sharing the mysteries of parenthood; friends, especially the families of Broberg, Ylönen, 
Ojanperä, Ranssi-Matikainen, Ross-Sirola, Purves, Schoenfeld, and Pulkkinen for humor 
and love, and for showing me the light when the path was getting darker.
Emeritus Professor Timo Nevalainen and Lector Eine Nevalainen, my highly esteemed 
parents, deserve my deep gratitude. Their life and example have encouraged and supported 
me throughout my life. They have sown the seeds for the harvest I am now reaping. 
They are acknowledged also for proofreading of the thesis. I warmly thank my brother 
and sister, Kari Nevalainen and Tarja Arukan, for their support and for challenging me 
always one step further.
I thank you, my dear sons, Riku, Rasmus, and Robert Siljander, for your patience under 
the years of this work. To have the privilege of being your mother has filled my heart 
with joy and happiness. With pride I have followed your steps and seen you to grow up 
to meet your challenges with creative solutions. The future is yours.
Love of my life, Esa Siljander, one lifetime seems a short period to share with you. I am 
afraid my words will never reach a tone sincere enough to express my gratitude. From 
my heart I thank you for your love, compassion, and consoling words, and bringing me 
revival when I expected it least. You reminded me of what life is all about, and I rejoice 
when I know that I will share it with you.
from the beginning to the end: “Soli Deo Gloria!”
76 References
REFERENCES
Aanstoot HJ, Anderson BJ, Daneman D, Danne 1. 
T, Donaghue K, Kaufman F, Réa RR, Uchigata Y. 
The global burden of youth diabetes: perspectives 
and potential. Pediatr Diabetes 2007;Suppl 8:1-44
Aanstoot HJ, Sigurdsson E, Jaffe M, Shi Y, 2. 
Christgau S, Grobbee D, Bruining GJ, Molenaar 
JL, Hofman A, Baekkeskov S. Value of antibodies 
to GAD65 combined with islet cell cytoplasmic 
antibodies for predicting IDDM in a childhood 
population. Diabetologia 1994;37:917-924
Achenbach P, Koczwara K, Knopff A, Naserke 3. 
H, Ziegler AG, Bonifacio E. Mature high-affinity 
immune responses to (pro)insulin anticipate the 
autoimmune cascade that leads to type 1 diabetes. 
J Clin Invest 2004b;114:589-597
Achenbach P, Lampasona V, Landherr U, Koczwara 4. 
K, Krause S, Grallert H, Winkler C, Pflüger M, 
Illig T, Bonifacio E, Ziegler AG. Autoantibodies to 
zinc transporter 8 and SLC30A8 genotype stratify 
type 1 diabetes risk. Diabetologia 2009;52:1881-
1888
Achenbach P, Schlosser M, Williams AJ, Yu L, 5. 
Mueller PW, Bingley PJ, Bonifacio E. Combined 
testing of antibody titer and affinity improves 
insulin autoantibody measurement: Diabetes 
Antibody Standardization Program. Clin Immunol 
2007;122:85-90
Achenbach P, Warncke K, Reiter J, Naserke HE, 6. 
Williams AJ, Bingley PJ, Bonifacio E, Ziegler AG 
Stratification of type 1 diabetes risk on the basis 
of islet autoantibody characteristics. Diabetes 
2004a;53:384-392
Åkerblom HK, Viikari J, Raitakari OT, Uhari 7. 
M. Cardiovascular Risk in Young Finns Study: 
general outline and recent developments. Ann Med 
1999;31, Suppl 1:45-54
Åkerblom HK, Virtanen SM, Ilonen J, Savilahti E, 8. 
Vaarala O, Reunanen A, Teramo K, Hämäläinen 
AM, Paronen J, Riikjärv MA, Ormisson A, 
Ludvigsson J, Dosch HM, Hakulinen T, Knip 
M; National TRIGR Study Groups. Dietary 
manipulation of beta cell autoimmunity in infants 
at increased risk of type 1 diabetes: a pilot study. 
Diabetologia 2005;48:829-837
Atkinson M, Gale EAM. Infant diets and type 1 9. 
diabetes: too early, too late, or just too complicated? 
JAMA 2003;290:1771-1772
Atkinson MA, Kaufman DL, Newman D, Tobin AJ, 10. 
Maclaren NK. Islet cell cytoplasmic autoantibody 
reactivity to glutamate decarboxylase in insulin-
dependent diabetes. J Clin Invest 1993;91:350-
356
Baekkeskov S, Aanstoot HJ, Christgau S, Reetz 11. 
A, Solimena M, Cascalho M, Folli F, Richter-
Olesen H, De Camilli P. Identification of the 64 
K autoantigen in insulin-dependent diabetes as 
the GABA-synthesizing enzyme glutamic acid 
decarboxylase. Nature 1990;347:151-156
Banting FG, Best CH, Collip JB, Campbell WR, 12. 
Fletcher AA. Pancreatic extracts in the treatment 
of diabetes mellitus: preliminary report. (CMAJ 
1922;12:141-146) CMAJ 1991;145:1281-1286
Barker JM, Goehrig SH, Barriga K, Hoffman M, 13. 
Slover R, Eisenbarth GS, Norris JM, Klingensmith 
GJ, Rewers M. Clinical characteristics of 
children diagnosed with type 1 diabetes through 
intensive screening and follow-up. Diabetes Care 
2004;27:1399-1404
Barker JM, McFann K, Harrison LC, Fourlanos S, 14. 
Krischer J, Cuthbertson D, Chase HP, Eisenbarth 
GS; DPT-1 Study Group. Pre-type 1 diabetes 
dysmetabolism: Maximal sensitivity achieved 
with both oral and intravenous glucose tolerance 
testing. J Pediatr 2007;150:31-36
Barratt BJ, Payne F, Lowe CE, Hermann R, Healy 15. 
BC, Harold D, Concannon P, Gharani N, McCarthy 
MI, Olavesen MG, McCormack R, Guja C, 
Ionescu-Tîrgovişte C, Undlien DE, Rønningen KS, 
Gillespie KM, Tuomilehto-Wolf E, Tuomilehto J, 
Bennett ST, Clayton DG, Cordell HJ, Todd JA. 
Remapping the insulin gene/IDDM2 locus in type 
1 diabetes. Diabetes 2004;53:1884-1889
Barrett JC, Clayton DG, Concannon P, Akolkar B, 16. 
Cooper JD, Erlich HA, Julier C, Morahan G, Nerup 
J, Nierras C, Plagnol V, Pociot F, Schuilenburg H, 
Smyth DJ, Stevens H, Todd JA, Walker NM, Rich 
SS; The Type 1 Diabetes Genetics Consortium. 
Genome-wide association study and meta-analysis 
find that over 40 loci affect risk of type 1 diabetes. 
Nat Genet 2009;41: 703-707
Barrett TG. Differential diagnosis of type 1 17. 
diabetes: which genetic syndromes need to be 
considered? Pediatr Diabetes 2007;Suppl 6:15-23
Batstra MR, Petersen JS, Bruining GJ, Grobbee 18. 
DE, de Man SA, Molenaar JL, Dyrberg T, 
 References 77
Aanstoot HJ. Low prevalence of GAD and IA2 
antibodies in schoolchildren from a village in the 
southwestern section of the Netherlands. Hum 
Immunol 2001;62:1106-1110
Batstra MR, van Driel A, Petersen JS, van 19. 
Donselaar CA, van Tol MJ, Bruining GJ, 
Grobbee DE, Dyrberg T, Aanstoot HJ. Glutamic 
acid decarboxylase antibodies in screening for 
autoimmune diabetes: influence of comorbidity, 
age, and sex on specificity and threshold values. 
Clin Chem 1999;45:2269-2272
Beach EF, Turner JJ. An enzymatic method for 20. 
glucose determination in body fluids. Clin Chem 
1958;4:462-475
Becker KL, Bilezikian JP, Bremner WJ, Hung 21. 
W, Kahn CR, Loriaux DL, Nylén ES, Rebar 
RW, Robertson GL, Snider RH Jr. Principles 
and Practice of Endocrinology & Metabolism, 
3rd edition. Lippincott Williams & Wilkins, 
Philadelphia, USA, 2001, pp. 1-2512
Bergua M, Sole J, Marion G, Perez MC, 22. 
Recasens A, Fernàndez J, Casamitjana R, 
Gomis R. Prevalence of islet cell antibodies, 
insulin antibodies and hyperglycaemia in 2291 
schoolchildren. Diabetologia 1987;30:724-726
Bingley PJ for the ICARUS Group: Interactions 23. 
of age, islet cell antibodies, insulin autoantibodies 
and first phase insulin response in predicting risk 
of progression to IDDM in relatives: the ICARUS 
dataset. Diabetes 1996;45:1720-1728
Bingley PJ, Bonifacio E, Mueller PW. Diabetes 24. 
Antibody Standardization Program: first assay 
proficiency evaluation. Diabetes 2003;52:1128-
1136
Bingley PJ, Bonifacio E, Williams AJ, Genovese 25. 
S, Bottazzo GF, Gale EA. Prediction of IDDM 
in the general population: strategies based on 
combinations of autoantibody markers. Diabetes 
1997;46:1701-1710
Bingley PJ, Bonifacio E, Ziegler AG, Schatz 26. 
DA, Atkinson MA, Eisenbarth GS; Immunology 
of Diabetes Society. Proposed guidelines on 
screening for risk of type 1 diabetes. Diabetes Care 
2001;24:398
Bingley PJ, Christie MR, Bonifacio E, Bonfanti 27. 
R, Shattock M, Fonte MT, Bottazzo GF, Gale EA. 
Combined analysis of autoantibodies improves 
prediction of IDDM in islet cell antibody-positive 
relatives. Diabetes 1994;43:1304-1310
Bingley PJ, Colman P, Eisenbarth GS, Jackson 28. 
RA, McCulloch DK, Riley WJ, Gale EA. 
Standardization of IVGTT to predict IDDM. 
Diabetes Care 1992;15:1313-1316
Bingley PJ, Mahon JL, Gale EA; European 29. 
Nicotinamide Diabetes Intervention Trial Group. 
Insulin resistance and progression to type 1 
diabetes in the European Nicotinamide Diabetes 
Intervention Trial (ENDIT). Diabetes Care 
2008;31:146-150
Bingley PJ. Interactions of age, islet cell 30. 
antibodies, insulin autoantibodies, and first-phase 
insulin response in predicting risk of progression 
to IDDM in ICA+ relatives: the ICARUS data set. 
Islet Cell Antibody Register Users Study. Diabetes 
1996;45:1720-1728
Bisikirska BC, Herold KC. Use of anti-CD3 31. 
monoclonal antibody to induce immune regulation 
in type 1 diabetes. Ann N Y Acad Sci 2004;1037:1-
9
Bluestone JA, Tang Q, Sedwick CE. T regulatory 32. 
cells in autoimmune diabetes: past challenges, 
future prospects. J Clin Immunol. 2008;28:677-
684
Boehm BO, Manfras B, Seissler J, Schöffling 33. 
K, Glück M, Holzberger G, Seidl S, Kühnl P, 
Trucco M, Scherbaum WA. Epidemiology and 
immunogenetic background of islet cell antibody - 
positive nondiabetic schoolchildren. Ulm-Frankfurt 
population study. Diabetes 1991;40:1435-1439
Bonifacio E, Bingley PJ, Shattock M, Dean BM, 34. 
Dunger D, Gale EA, Bottazzo GF: Quantification 
of islet-cell antibodies and prediction of insulin-
dependent diabetes. Lancet 1990;335:147-149
Bonifacio E, Genovese S, Braghi S, Bazzigaluppi 35. 
E, Lampasona Y, Bingley P, Rogge L, Pastore 
M, Bognetti E, Bottazzo G, Gale E, Bosi E. Islet 
autoantibody markers in IDDM: risk assessment 
strategies yielding high sensitivity. Diabetologia 
1995;38:816-822
Bonifacio E, Lampasona V, Genovese S, Ferrari 36. 
M, Bosi E. Identification of protein tyrosine 
phosphatase-like IA2 (islet cell antigen 512) as 
the insulin-dependent diabetes-related 37/40 K 
autoantigen and a target of islet-cell antibodies. J 
Immunol 1995;155:5419-5426
Bornstein J, Lawrence RD. Two types of diabetes 37. 
mellitus, with and without available plasma insulin. 
Br Med J 1951;1:732
Bottazzo GF, Florin-Christensen A, Doniach 38. 
D: Islet cell antibodies in diabetes mellitus with 
autoimmune polyendocrine deficiencies. Lancet 
1974;2:1279-1283
78 References
Bottazzo GF, Genovese S, Bosi E, Dean BM, 39. 
Christie MR, Bonifacio E. Novel considerations 
on the antibody/autoantigen system in type I 
(insulin-dependent) diabetes mellitus. Ann Med 
1991;23:453-461
Brill MT. Diabetes. Twenty-First Century Books, 40. 
Lerner Publishing Group, Minneapolis, US, 2008, 
pp. 1-118
Butler MH, Solimena M, Dirkx R, Hayday A, De 41. 
Camilli PJr. Identification of a dominant epitope of 
glutamic acid decarboxylase (GAD-65) recognized 
by autoantibodies in stiffman syndrome. J Exp 
Med 1993;178:2097-2106
Caillat-Zucman S. Molecular mechanisms of HLA 42. 
association with autoimmune diseases. Tissue 
Antigens 2009;73:1-8
Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin 43. 
D status, 1,25-dihydroxyvitamin D3, and the 
immune system. Am J Clin Nutr. 2004;80,Suppl 
6:1717S-1720S
Castaño L, Ziegler AG, Ziegler R, Shoelson 44. 
S, Eisenbarth GS. Characterization of insulin 
autoantibodies in relatives of patients with type I 
diabetes. Diabetes 1993;42:1202-1209
Chimienti F, Devergnas S, Favier A, Seve M. 45. 
Identification and cloning of a beta-cell-specific 
zinc transporter, ZnT-8, localized into insulin 
secretory granules. Diabetes 2004;53:2330-2337
Christen U, von Herrath MG. Initiation of 46. 
autoimmunity. Curr Opin Immunol 2004a;16:759-
767
Christen U, von Herrath MG. Manipulating 47. 
the type 1 vs. type 2 balance in type 1 diabetes. 
Immunol Res 2004b;30:309-325
Christie MR, Genovese S, Cassidy D, Bosi 48. 
E, Brown TJ, Lai M, Bonifacio E, Bottazzo 
GF. Antibodies to islet 37 k antigen, but not to 
glutamate decarboxylase, discriminate rapid 
progression to IDDM in endocrine autoimmunity. 
Diabetes 1994;43:1254-1259
Colman PG, McNair P, King J, Caudwell J, 49. 
Jankulovski C, Tait BD, Honeyman MC, Harrison 
LC. Screening for preclinical type 1 diabetes in 
a discrete population with an apparent increased 
disease incidence. Pediatr Diabetes 2000;1:193-
198
Colman PG, McNair P, Margetts H, Schmidli 50. 
RS, Werther GA, Alford FP, Ward GM, Tait BD, 
Honeyman MC, Harrison LC. The Melbourne 
Pre-Diabetes Study: prediction of type 1 diabetes 
mellitus using antibody and metabolic testing. 
Med J Aust 1998;169:81-84
Colman PG, McNair PD, Gellert S, Kewming 51. 
K, Schmidli RS, Steele CE, Harrison LC. 
Development of autoantibodies to islet antigens 
during childhood: implications for preclinical type 
1 diabetes screening. Pediatr Diabetes 2002;3:144-
148
Conwell LS, Trost SG, Brown WJ, Batch JA. 52. 
Indexes of insulin resistance and secretion in 
obese children and adolescents: a validation study. 
Diabetes Care 2004;27:314-319
Dabelea D, D’Agostino RB Jr, Mayer-Davis EJ, 53. 
Pettitt DJ, Imperatore G, Dolan LM, Pihoker C, 
Hillier TA, Marcovina SM, Linder B, Ruggiero 
AM, Hamman RF; SEARCH for Diabetes in Youth 
Study Group. Testing the accelerator hypothesis: 
body size, beta-cell function, and age at onset of 
type 1 (autoimmune) diabetes. Diabetes Care 
2006;29:290-294
Daw K, Ujihara N, Atkinson M, Powers AC. 54. 
Glutamic acid decarboxylase autoantibodies in 
stiff-man syndrome and insulin-dependent diabetes 
mellitus exhibit similarities and differences in 
epitope recognition. J Immunol 1996;156:818-
825
De Block CE, De Leeuw IH, Vertommen JJ, 55. 
Rooman RP, Du Caju MV, Van Campenhout 
CM, Weyler JJ, Winnock F, Van Autreve J, Gorus 
FK. The Belgian Diabetes Registry. Beta-cell, 
thyroid, gastric, adrenal and coeliac autoimmunity 
and HLA-DQ types in type 1 diabetes. Clin Exp 
Immunol 2001;126:236-241
Decochez K, De Leeuw IH, Keymeulen B, Mathieu 56. 
C, Rottiers R, Weets I, Vandemeulebroucke E, 
Truyen I, Kaufman L, Schuit FC, Pipeleers DG, 
Gorus FK. The Belgian Diabetes Registry. IA-2 
autoantibodies predict impending type I diabetes 
in siblings of patients. Diabetologia 2002;45:1658-
1666
Deschamps I, Boitard C, Hors J, Busson M, 57. 
Marcelli-Barge A, Mogenet A, Robert JJ. Life 
table analysis of the risk of type 1 (insulin-
dependent) diabetes mellitus in siblings according 
to islet cell antibodies and HLA markers. An 8-year 
prospective study. Diabetologia 1992;35:951-957
Di Lorenzo TP, Peakman M, Roep BO. Translational 58. 
mini-review series on type 1 diabetes: Systematic 
analysis of T cell epitopes in autoimmune diabetes. 
Clin Exp Immunol 2007;148:1-16
 References 79
DIAMOND Project Group. Incidence and trends 59. 
of childhood Type 1 diabetes worldwide 1990-
1999. Diabet Med 2006;23:857-866
Díaz N, Méndez MA, Pérez-Bravo F, Carrasco 60. 
E, Santos JL. Incidence rate of type 1 diabetes 
in Santiago (Chile) by HLA-DQA1 and DQB1 
genotypes. Eur J Epidemiol 2003;18:787-792
Eisenbarth GS. Insulin autoimmunity: 61. 
immunogenetics/immunopathogenesis of type 1A 
diabetes. Ann N Y Acad Sci 2003;1005:109-118
Elliott RB, Chase HP. Prevention or delay of type 62. 
1 (insulin-dependent) diabetes mellitus in children 
using nicotinamide. Diabetologia 1991;34:362-
365
Elliott RB, Pilcher CC. A universal model of 63. 
antibody prediction (MAP) of type 1 diabetes in 
children. J Autoimmun 1994;7:881-888
Ellis TM, Atkinson MA. The clinical significance 64. 
of an autoimmune response against glutamic acid 
decarboxylase. Nat Med 1996;2:148-153
Faideau B, Larger E, Lepault F, Carel JC, Boitard C. 65. 
Role of beta-cells in type 1 diabetes pathogenesis. 
Diabetes 2005;54, Suppl 2:S87-96
Faria AM, Weiner HL. Oral tolerance. Immunol 66. 
Rev 2005;206:232-259
Fourlanos S, Varney MD, Tait BD, Morahan G, 67. 
Honeyman MC, Colman PG, Harrison LC. The 
rising incidence of type 1 diabetes is accounted for 
by cases with lower-risk human leukocyte antigen 
genotypes. Diabetes Care 2008;31:1546-1549
Franke B, Galloway TS, Wilkin TJ. Developments 68. 
in the prediction of type 1 diabetes mellitus, 
with special reference to insulin autoantibodies. 
Diabetes Metab Res Rev 2005;21:395-415
Fujinami RS, von Herrath MG, Christen U, Whitton 69. 
JL. Molecular mimicry, bystander activation, 
or viral persistence: infections and autoimmune 
disease. Clin Microbiol Rev 2006;19:80-94
Gale EA, Bingley PJ, Emmett CL, Collier T; 70. 
European Nicotinamide Diabetes Intervention 
Trial (ENDIT) Group. European Nicotinamide 
Diabetes Intervention Trial (ENDIT): a randomised 
controlled trial of intervention before the onset of 
type 1 diabetes. Lancet 2004;363:925-931
Gale EA. Congenital rubella: citation virus or 71. 
viral cause of type 1 diabetes? Diabetologia 
2008;51:1559-1566
Gale EA. The rise of childhood type 1 diabetes in 72. 
the 20th century. Diabetes 2002;51:3353-3361
Gardner SG, Gale EA, Williams AJ, Gillespie 73. 
KM, Lawrence KE, Bottazzo GF, Bingley PJ. 
Progression to diabetes in relatives with islet 
autoantibodies. Is it inevitable? Diabetes Care 
1999;22:2049-2054
Gianani R, Rabin DU, Verge CF, Yu L, Babu 74. 
SR, Pietropaolo M, Eisenbarth GS. ICA512 
autoantibody radioassay. Diabetes 1995;44:1340-
1344
Gilliam LK, Brooks-Worrell BM, Palmer JP, 75. 
Greenbaum CJ, Pihoker C. Autoimmunity and 
clinical course in children with type 1, type 2, and 
type 1.5 diabetes. J Autoimmun 2005;25:244-250
Gleichmann H, Bottazzo GF, Gries FA. 76. 
Cytoplasmic islet cell autoantibodies: prevalence 
and pathognomic significance. Adv Exp Med Biol 
1988;246:71-77
Gohlke H, Ferrari U, Koczwara K, Bonifacio E, Illig 77. 
T, Ziegler AG. SLC30A8 (ZnT8) Polymorphism is 
Associated with Young Age at Type 1 Diabetes 
Onset. Rev Diabet Stud 2008;5:25-27
Gorsuch AN, Spencer KM, Lister J, McNally JM, 78. 
Dean BM, Bottazzo GF, Cudworth AG. Evidence 
for a long prediabetic period in type I (insulin-
dependent) diabetes mellitus. Lancet 1981;2:1363-
1365
Gorus FK, Goubert P, Semakula C, Vandewalle CL, 79. 
De Schepper J, Scheen A, Christie MR, Pipeleers 
DG. IA-2-autoantibodies complement GAD65-
autoantibodies in new-onset IDDM patients and 
help predict impending diabetes in their siblings. 
The Belgian Diabetes Registry. Diabetologia 
1997;40:95-99
Gorus FK, Vandewalle CL, Dorchy H, Van 80. 
Crombrugge P, Schuit FC, Pipeleers DG. 
Influence of age on the associations among insulin 
autoantibodies, islet cell antibodies, and HLA 
DAQ1*0301-DQB1*0302 in siblings of patients 
with type 1 (insulin-dependent) diabetes mellitus. 
The Belgian Diabetes Registry. J Clin Endocrinol 
Metab 1994;78:1172-1178
Grant SF, Hakonarson H. Genome-wide 81. 
association studies in type 1 diabetes. Curr Diab 
Rep 2009;9:157-163
Greenbaum CJ, Palmer JP, Nagataki S, Yamaguchi 82. 
Y, Molenaar JL, Van Beers WA, MacLaren NK, 
Lernmark A. Improved specificity of ICA assays 
in the Fourth International Immunology of 
80 References
Diabetes Serum Exchange Workshop. Diabetes 
1992;41:1570-1574
Greenbaum CJ, Sears KL, Kahn SE, Palmer 83. 
JP. Relationship of beta-cell function and 
autoantibodies to progression and nonprogression 
of subclinical type 1 diabetes: follow-up of the 
Seattle Family Study. Diabetes 1999;48:170-175
Greenbaum CJ, Wilkin TJ, Palmer JP. Fifth 84. 
International Serum Exchange Workshop for 
Insulin Autoantibody (IAA) Standardization. 
The Immunology and Diabetes Workshops and 
participating laboratories. Diabetologia 1992;35: 
798-800
Gregersen PK, Olsson LM. Recent advances in 85. 
the genetics of autoimmune disease. Annu Rev 
Immunol 2009;27:363-391
Grubin CE, Daniels T, Toivola B, Landin-Olsson 86. 
M, Hagopian WA, Li L, Karlsen AE, Boel E, 
Michelsen B, Lernmark A. A novel radioligand 
binding assay to determine diagnostic accuracy 
of isoformspecific glutamic acid decarboxylase 
antibodies in childhood IDDM. Diabetologia 
1994;37:344-350
Gungor N, Saad R, Janosky J, Arslanian S. 87. 
Validation of surrogate estimates of insulin 
sensitivity and insulin secretion in children and 
adolescents. J Pediatr 2004;114:47-55
Gylling M, Tuomi T, Björses P, Kontiainen S, 88. 
Partanen J, Christie MR, Knip M, Perheentupa 
J, Miettinen A. Beta-cell autoantibodies, human 
leukocyte antigen II alleles, and type 1 diabetes 
in autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy. J Clin Endocrinol Metab 
2000;85:4434-4440
Gyürüs E, Green A, Patterson CC, Soltész G; 89. 
Hungarian Childhood Diabetes Epidemiology 
Study Group. Dynamic changes in the trends in 
incidence of type 1 diabetes in children in Hungary 
(1978-98). Pediatr Diabetes 2002;3:194-199
Haglund B, Ryckenberg K, Selinus O, Dahlquist 90. 
G.Evidence of a relationship between childhood-
onset type I diabetes and low groundwater 
concentration of zinc. Diabetes Care 1996;19:873-
875
Hagopian WA, Sanjeevi CB, Kockum I, Landin-91. 
Olsson M, Karlsen AE, Sundkvist G, Dahlquist G, 
Palmer J, Lernmark A. Glutamate decarboxylase-, 
insulin-, and islet cell-antibodies and HLA typing to 
detect diabetes in a general population-based study 
of Swedish children. J Clin Invest 1995;95:1505-
1511
Hahl J, Hämäläinen H, Sintonen H, Simell T, Arinen 92. 
S, Simell O. Health-related quality of life in type 
1 diabetes without or with symptoms of long-term 
complications. Qual Life Res 2002;11:427-436
Hahl J, Simell T, Ilonen J, Knip M, Simell O. Costs 93. 
of predicting IDDM. Diabetologia 1998;41:79-85
Hahl J, Simell T, Kupila A, Keskinen P, Knip 94. 
M, Ilonen J, Simell O. A simulation model for 
estimating direct costs of type 1 diabetes prevention. 
Pharmacoeconomics 2003;21:295-303
Haller K, Kisand K, Nemvalts V, Laine A-P, Ilonen 95. 
J, Uibo R. Type 1 diabetes is insulin -2221 MspI 
and CTLA-4 +49 A/G polymorphism dependent. 
Eur J Clin Invest 2004;34:543-548
Hämäläinen AM, Ilonen J, Simell O, Savola K, 96. 
Kulmala P, Kupila A, Simell T, Erkkola R, Koskela 
P, Knip M. Prevalence and fate of type 1 diabetes-
associated autoantibodies in cord blood samples 
from newborn infants of non-diabetic mothers. 
Diabetes Metab Res Rev 2002;18:57-63
Hämäläinen AM, Ronkainen MS, Åkerblom HK, 97. 
Knip M. Postnatal elimination of transplacentally 
acquired disease-associated antibodies in infants 
born to families with type 1 diabetes. The Finnish 
TRIGR Study Group. Trial to Reduce IDDM in 
the Genetically at Risk. J Clin Endocrinol Metab 
2000;85:4249-4253
Hänninen A. Prevention of autoimmune type 98. 
1 diabetes via mucosal tolerance: is mucosal 
autoantigen administration as safe and effective as 
it should be? Scand J Immunol 2000;52:217-225
Harder T, Roepke K, Diller N, Stechling Y, 99. 
Dudenhausen JW, Plagemann A. Birth weight, 
early weight gain, and subsequent risk of type 1 
diabetes: systematic review and meta-analysis. Am 
J Epidemiol 2009;169:1428-1436
Harjutsalo V, Sjöberg L, Tuomilehto J. Time trends 100. 
in the incidence of type 1 diabetes in Finnish 
children: a cohort study. Lancet 2008;371:1777-
1782
Harrison LC. Risk assessment, prediction and 101. 
prevention of type 1 diabetes. Pediatr Diabetes 
2001;2:71-82
Hawa MI, Bonfanti R, Valeri C, Delli Castelli M, 102. 
Beyan H, Leslie RD. No evidence for genetically 
determined alteration in insulin secretion or 
sensitivity predisposing to type 1 diabetes: a study 
of identical twins. Diabetes Care 2005;28:1415-
1418
 References 81
Hekkala A, Knip M, Veijola R. Ketoacidosis at 103. 
diagnosis of type 1 diabetes in children in northern 
Finland: temporal changes over 20 years. Diabetes 
Care 2007;30:861-866
Hermann R, Bartsocas CS, Soltész G, Vazeou 104. 
A, Paschou P, Bozas E, Malamitsi-Puchner A, 
Simell O, Knip M, Ilonen J. Genetic screening 
for individuals at high risk for type 1 diabetes in 
the general population using HLA Class II alleles 
as disease markers. A comparison between three 
European populations with variable rates of disease 
incidence. Diabetes Metab Res Rev 2004;20:322-
329
Hermann R, Laine AP, Veijola R, Vahlberg T, 105. 
Simell S, Lähde J, Simell O, Knip M, Ilonen J. The 
effect of HLA class II, insulin and CTLA4 gene 
regions on the development of humoral beta cell 
autoimmunity. Diabetologia 2005;48:1766-1775
Hermann R, Lipponen K, Kiviniemi M, Kakko T, 106. 
Veijola R, Simell O, Knip M, Ilonen J. Lymphoid 
tyrosine phosphatase (LYP/PTPN22) Arg620Trp 
variant regulates insulin autoimmunity and 
progression to type 1 diabetes. Diabetologia 
2006;49:1198-1208
Hermann R, Turpeinen H, Laine AP, Veijola R, 107. 
Knip M, Simell O, Sipilä I, Åkerblom HK, Ilonen 
J. HLA DR-DQ-encoded genetic determinants 
of childhood-onset type 1 diabetes in Finland: an 
analysis of 622 nuclear families. Tissue Antigens 
2003;62:162-169
Hettiarachchi KD, Zimmet PZ, Myers MA. 108. 
Dietary toxins, endoplasmic reticulum (ER) stress 
and diabetes. Curr Diabetes Rev 2008;4:146-156
Hjern A, Söderström U. Parental country of birth is 109. 
a major determinant of childhood type 1 diabetes 
in Sweden. Pediatr Diabetes 2008;9:35-39
Holmberg H, Wahlberg J, Vaarala O, Ludvigsson 110. 
J; ABIS Study Group. Short duration of breast-
feeding as a risk-factor for beta-cell autoantibodies 
in 5-year-old children from the general population. 
Br J Nutr 2007;97:111-116
Holmdahl R. Aire-ing self antigen variability and 111. 
tolerance. Eur J Immunol 2007;37:598-601
Honeyman MC, Coulson BS, Stone NL, Gellert 112. 
SA, Goldwater PN, Steele CE, Couper JJ, Tait 
BD, Colman PG, Harrison LC. Association 
between rotavirus infection and pancreatic islet 
autoimmunity in children at risk of developing 
type 1 diabetes. Diabetes 2000;49:1319-1324
Hoppu S, Ronkainen MS, Kimpimäki T, Simell S, 113. 
Korhonen S, Ilonen J, Simell O, Knip M. Insulin 
autoantibody isotypes during the prediabetic 
process in young children with increased genetic 
risk of type 1 diabetes. Pediatr Res 2004a;55:236-
242
Hoppu S, Ronkainen MS, Kulmala P, Åkerblom 114. 
HK, Knip M; Childhood Diabetes in Finland 
Study Group. GAD65 antibody isotypes and 
epitope recognition during the prediabetic process 
in siblings of children with type I diabetes. Clin 
Exp Immunol 2004b;136:120-128
Hummel M, Bonifacio E, Schmid S, Walter M, 115. 
Knopff A, Ziegler A-G: Brief communication: 
early appearance of islet autoantibodies predicts 
childhood type 1 diabetes in offspring of diabetic 
patients. Ann Intern Med 2004a;140:882-886
Hummel M, Ziegler AG, Roth R. Psychological 116. 
impact of childhood islet autoantibody testing in 
families participating in the BABYDIAB study. 
Diabet Med 2004b;21:324-328
Hyppönen E, Virtanen SM, Kenward MG, Knip M, 117. 
Åkerblom HK, the Childhood Diabetes in Finland 
Study Group. Obesity, increased linear growth 
and risk of type 1 diabetes mellitus in children. 
Diabetes Care 2000;23:1755-1760
Hyppönen E. Micronutrients and the risk of type 1 118. 
diabetes: vitamin D, vitamin E, and nicotinamide. 
Nutr Rev 2004;62:340-347
Ilonen J, Reijonen H, Herva E, Sjöroos M, Iitiä 119. 
A, Lövgren T, Veijola R, Knip M, Åkerblom HK. 
Rapid HLA-DQB1 genotyping for four alleles in 
the assessment of risk for IDDM in the Finnish 
population. The Childhood Diabetes in Finland 
(DiMe) Study Group. Diabetes Care 1996;19:795-
800
Ilonen J, Sjöroos M, Knip M, Veijola R, Simell 120. 
O, Åkerblom HK, Paschou P, Bozas E, Havarani 
B, Malamitsi-Puchner A, Thymelli J, Vazeou A, 
Bartsocas CS. Estimation of genetic risk for type 1 
diabetes. Am J Med Genet 2002;115:30-36
Jaeger C, Hatziagelaki E, Stroedter A, Becker F, 121. 
Scherer S, Petzoldt R, Federlin K, Bretzel RG. The 
Giessen-Bad Oeynhausen family study: improved 
prediction of type I diabetes in a low incidence 
population of relatives using combinations of islet 
autoantibodies in a dual step model. Exp Clin 
Endocrinol Diabetes 1999;107:496-505
Jasinski JM, Eisenbarth GS. Insulin as a primary 122. 
autoantigen for type 1A diabetes. Clin Dev 
Immunol 2005;12:181-186
Kahn HS, Morgan TM, Case LD, Dabelea D, 123. 
Mayer-Davis EJ, Lawrence JM, Marcovina SM, 
82 References
Imperatore G. Association of type 1 diabetes with 
month of birth among US youth. The SEARCH 
for Diabetes in Youth Study Group. Diabetes Care 
2009;32:2010-2015
Karjalainen J, Vähäsalo P, Knip M, Tuomilehto-124. 
Wolf E, Virtala E, Åkerblom HK. Islet cell 
autoimmunity and progression to insulin-dependent 
diabetes mellitus in genetically high- and low-
risk siblings of diabetic children. The Childhood 
Diabetes in Finland (DiMe) Study Group. Eur J 
Clin Invest 1996;26:640-649
Karjalainen JK. Islet cell antibodies as predictive 125. 
markers for IDDM in children with high 
background incidence of disease. Diabetes 
1990;39:1144–1150
Karvonen M, Pitkäniemi J, Tuomilehto J. The 126. 
onset age of type 1 diabetes in Finnish children has 
become younger. The Finnish Childhood Diabetes 
Registry Group. Diabetes Care 1999;22:1066-
1067
Katz A, Nambi SS, Mather K, Baron AD, Follmann 127. 
DA, Sullivan G, Quon MJ. Quantitative insulin 
sensitivity check index: a simple, accurate method 
for assessing insulin sensitivity in humans. J Clin 
Endocrinol Metab 2000;85:2402-2410
Kaufman DL, Erlander MG, Clare-Salzler 128. 
M, Atkinson MA, Maclaren NK, Tobin AJ. 
Autoimmunity to two forms of glutamate 
decarboxylase in insulin-dependent diabetes 
mellitus. J Clin Invest 1992;89:283-292.
Kawasaki E, Sera Y, Fujita N, Yamauchi M, 129. 
Ozaki M, Abe T, Yamakawa K, Uotani S, Takino 
H, Yamasaki H, Yamaguchi Y, Uchigata Y, 
Matsuura N, Eguchi K. Association between IA-2 
autoantibody epitope specificities and age of onset 
in Japanese patients with autoimmune diabetes. J 
Autoimmun 2001;17:323-331
Kawasaki E, Yu L, Rewers MJ, Hutton JC, 130. 
Eisenbarth GS. Definition of multiple ICA512/
phogrin autoantibody epitopes and detection of 
intramolecular epitope spreading in relatives 
of patients with type 1 diabetes. Diabetes 
1998;47:733-742
Keskinen P, Korhonen S, Kupila A, Veijola R, 131. 
Erkkilä S, Savolainen H, Arvilommi P, Simell T, 
Ilonen J, Knip M, Simell O. First-phase insulin 
response in young healthy children at genetic 
and immunological risk for Type I diabetes. 
Diabetologia 2002;45:1639-1648
Kim J, Namchuk M, Bugawan T, Fu Q, Jaffe M, 132. 
Shi Y, Aanstoot HJ, Turck CW, Erlich H, Lennon 
V, Baekkeskov S. Higher autoantibody levels 
and recognition of a linear NH2-terminal epitope 
in the autoantigen GAD65, distinguish stiff-
man syndrome from insulin-dependent diabetes 
mellitus. J Exp Med 1994;180:595-606
Kimpimäki T, Erkkola M, Korhonen S, Kupila A, 133. 
Virtanen SM, Ilonen J, Simell O, Knip M. Short-
term exclusive breastfeeding predisposes young 
children with increased genetic risk of Type I 
diabetes to progressive beta-cell autoimmunity. 
Diabetologia 2001b;44:63-69
Kimpimäki T, Kulmala P, Savola K, Kupila A, 134. 
Korhonen S, Simell T, Ilonen J, Simell O, Knip M. 
Natural history of beta-cell autoimmunity in young 
children with increased genetic susceptibility to type 
1 diabetes recruited from the general population. J 
Clin Endocrinol Metab 2002;87:4572-4579
Kimpimäki T, Kupila A, Hämäläinen AM, Kukko 135. 
M, Kulmala P, Savola K, Simell T, Keskinen 
P, Ilonen J, Simell O, Knip M. The first signs 
of beta-cell autoimmunity appear in infancy in 
genetically susceptible children from the general 
population: the Finnish Type 1 Diabetes Prediction 
and Prevention Study. J Clin Endocrinol Metab 
2001a;86:4782-4788
Knekt P, Reunanen A, Marniemi J, Leino A, 136. 
Aromaa A. Low vitamin E status is a potential risk 
factor for insulin-dependent diabetes mellitus. J 
Intern Med 1999;245:99-102
Knip M, Karjalainen J, Åkerblom HK. Islet cell 137. 
antibodies are less predictive of IDDM among 
unaffected children in the general population than 
in sibs of children with diabetes. The Childhood 
Diabetes in Finland Study Group. Diabetes Care 
1998;21:1670–1673
Knip M, Kukko M, Kulmala P, Veijola R, Simell 138. 
O, Åkerblom HK, Ilonen J. Humoral beta-cell 
autoimmunity in relation to HLA-defined disease 
susceptibility in preclinical and clinical type 1 
diabetes. Am J Med Genet 2002;115:48-54
Knip M. Natural course of preclinical type 1 139. 
diabetes. Horm Res 2002;57, Suppl 1:6-11
Koczwara K, Bonifacio E, Ziegler AG.Transmission 140. 
of maternal islet antibodies and risk of autoimmune 
diabetes in offspring of mothers with type 1 
diabetes. Diabetes 2004;53:1-4
Kondrashova A, Viskari H, Kulmala P, Romanov 141. 
A, Ilonen J, Hyöty H, Knip M. Signs of beta-cell 
autoimmunity in nondiabetic schoolchildren: a 
comparison between Russian Karelia with a low 
incidence of type 1 diabetes and Finland with a 
high incidence rate. Diabetes Care 2007;30:95-
100
 References 83
Kordonouri O, Shuga N, Lewy H, Ashkenazi I, 142. 
Laron Z. Seasonality of month of birth of children 
and adolescents with type 1 diabetes mellitus in 
Berlin differs from the general population. Eur J 
Pediatr 2002;161:291-292
Krischer JP, Cuthbertson DD, Yu L, Orban T, 143. 
Maclaren N, Jackson R, Winter WE, Schatz DA, 
Palmer JP, Eisenbarth GS. Screening strategies 
for the identification of multiple antibody-positive 
relatives of individuals with type 1 diabetes. J Clin 
Endocrinol Metab 2003;88:103-108
Kuglin B, Kolb H, Greenbaum C, Maclaren 144. 
NK, Lernmark A, Palmer JP. The Fourth 
International Workshop on the Standardisation 
of Insulin Autoantibody Workshop. Diabetologia 
1990;33:638-639
Kukko M, Kimpimäki T, Korhonen S, Kupila A, 145. 
Simell S, Veijola R, Simell T, Ilonen J, Simell 
O, Knip M. Dynamics of diabetes-associated 
autoantibodies in young children with human 
leukocyte antigen-conferred risk of type 1 diabetes 
recruited from the general population. J Clin 
Endocrinol Metab 2005;90:2712-2717
Kulmala P, Savola K, Petersen JS, Vähäsalo P, 146. 
Karjalainen J, Löppönen T, Dyrberg T, Åkerblom 
HK, Knip M; The Childhood Diabetes in Finland 
Study Group. Prediction of insulin-dependent 
diabetes mellitus in siblings of children with 
diabetes. A population-based study. J Clin Invest 
1998;101:327-36
Kupila A, Keskinen P, Simell T, Erkkilä S, 147. 
Arvilommi P, Korhonen S, Kimpimäki T, Sjöroos 
M, Ronkainen M, Ilonen J, Knip M, Simell O. 
Genetic risk determines the emergence of diabetes-
associated autoantibodies in young children. 
Diabetes 2002;51:646-651
Kupila A, Muona P, Simell T, Arvilommi P, 148. 
Savolainen H, Hämäläinen AM, Korhonen S, 
Kimpimäki T, Sjöroos M, Ilonen J, Knip M, 
Simell O; Juvenile Diabetes Research Foundation 
Centre for the Prevention of Type I Diabetes in 
Finland. Feasibility of genetic and immunological 
prediction of type I diabetes in a population-based 
birth cohort. Diabetologia 2001;44:290-297
LaGasse JM, Brantley MS, Leech NJ, Rowe RE, 149. 
Monks S, Palmer JP, Nepom GT, McCulloch 
DK, Hagopian WA, Washington State Diabetes 
Prediction Study. Successful prospective 
prediction of type 1 diabetes in schoolchildren 
through multiple defined autoantibodies. Diabetes 
Care 2002;25:505-511
Lamberg-Allardt CJ, Viljakainen HT. 150. 
25-Hydroxyvitamin D and functional outcomes in 
adolescents, Am J Clin Nutr 2008;88:534S-536S.
Lan MS, Wasserfall C, Maclaren NK, Notkins 151. 
AL. IA-2, a transmembrane protein of the protein 
tyrosine phosphatase family, is a major autoantigen 
in insulin-dependent diabetes mellitus. Proc Natl 
Acad Sci U S A 1996;93: 6367-6370
Lee JM, Okumura MJ, Davis MM, Herman WH, 152. 
Gurney JG. Prevalence and determinants of insulin 
resistance among U.S. adolescents: a population-
based study. Diabetes Care 2006;29:2427-2432
Lendrum R, Walker G, Gamble DR. Islet-cell 153. 
antibodies in juvenile diabetes mellitus of recent 
onset. Lancet 1975;1:880-882
Lernmark B, Elding-Larsson H, Hansson G, 154. 
Lindberg B, Lynch K, Sjöblad S. Parent responses 
to participation in genetic screening for diabetes 
risk. Pediatr Diabetes 2004;5:174-181
Leslie RD, Atkinson MA, Notkins AL. 155. 
Autoantigens IA-2 and GAD in type I (insulin-
dependent) diabetes. Diabetologia 1999;42:3-14
Lewy H, Hampe CS, Kordonouri O, Haberland H, 156. 
Landin-Olsson M, Törn C, Laron Z. Seasonality 
of month of birth differs between type 1 diabetes 
patients with pronounced beta-cell autoimmunity 
and individuals with lesser or no beta-cell 
autoimmunity. Pediatr Diabetes 2008;9:46-52
Lindholm E, Hallengren B, Agardh CD. Gender 157. 
differences in GAD antibody-positive diabetes 
mellitus in relation to age at onset, C-peptide and 
other endocrine autoimmune diseases. Diabetes 
Metab Res Rev 2004;20:158-164
Lu J, Li Q, Xie H, Borovitskaya AE, Maclaren NK, 158. 
Notkins AL, Lan MS. Identification of a second 
transmembrane protein tyrosine phosphatase, 
IA-2beta, as an autoantigen in insulin-dependent 
diabetes mellitus: precursor of the 37-kDa tryptic 
fragment. Proc Natl Acad Sci U S A 1996;93:2307-
2311
Ludvigsson J, Ludvigsson M, Sepa A. Screening 159. 
for prediabetes in the general child population: 
maternal attitude to participation. Pediatr Diabetes 
2001;2:170-174
MacCuish AC, Irvine WJ, Barnes EW, Duncan 160. 
LJ. Antibodies to pancreatic islet cells in insulin-
dependent diabetics with coexistent autoimmune 
disease. Lancet. 1974;2:1529-1531
Mackay IR, Rowley MJ. Autoimmune epitopes: 161. 
autoepitopes. Autoimmun Rev 2004;3:487-492
84 References
Maclaren N, Lan M, Coutant R, Schatz D, 162. 
Silverstein J, Muir A, Clare-Salzer M, She JX, 
Malone J, Crockett S, Schwartz S, Quattrin T, 
DeSilva M, Vander Vegt P, Notkins A, Krischer J. 
Only multiple autoantibodies to islet cells (ICA), 
insulin, GAD65, IA-2 and IA- 2beta predict 
immune-mediated (type 1) diabetes in relatives. J 
Autoimmun 1999;12:279-287
Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-163. 
Jemelka HI, Spinas GA, Kaiser N, Halban PA, 
Donath MY. Glucose-induced beta cell production 
of IL-1beta contributes to glucotoxicity in human 
pancreatic islets. Clin Invest 2002;110:851-860
Mäkinen A, Härkönen T, Ilonen J, Knip M; Finnish 164. 
Pediatric Diabetes Register. Characterization of 
the humoral immune response to islet antigen 2 in 
children with newly diagnosed type 1 diabetes. Eur 
J Endocrinol 2008;159:19-26
Mandrup-Poulsen T, Reimers JI, Andersen 165. 
HU, Pociot F, Karlsen AE, Bjerre U, Nerup J. 
Nicotinamide treatment in the prevention of 
insulin-dependent diabetes mellitus. Diabetes 
Metab Rev 1993;9:295-309
Manna R, Migliore A, Martin LS, Ferrara E, Ponte 166. 
E, Marietti G, Scuderi F, Cristiano G, Ghirlanda G, 
Gambassi G. Nicotinamide treatment in subjects 
at high risk of developing IDDM improves insulin 
secretion. Br J Clin Pract 1992;46:177-179
Månsson L, Törn C, Landin-Olsson M. Islet 167. 
cell antibodies represent autoimmune response 
against several antigens. Int J Exp Diabetes Res 
2001;2:85-90
Mari A, Tura A, Pacini G, Kautzky-Willer A, 168. 
Ferrannini E. Relationships between insulin 
secretion after intravenous and oral glucose 
administration in subjects with glucose tolerance 
ranging from normal to overt diabetes. Diabet Med 
2008;25:671-677
Marshall MO, Hoyer PE, Petersen JS, Hejnaes KR, 169. 
Genovese S, Dyrberg T, Bottazzo GF. Contribution 
of glutamate decarboxylase antibodies to the 
reactivity of islet cell cytoplasmic antibodies. J 
Autoimmun 1994;7:497-508
Martín-Gallán P, Carrascosa A, Gussinyé M, 170. 
Domínguez C. Oxidative stress in childhood type 1 
diabetes: results from a study covering the first 20 
years of evolution. Free Radic Res 2007;41:919-
928
Mathieu C, van Etten E, Decallonne B, Guilietti A, 171. 
Gysemans C, Bouillon R, Overbergh L. Vitamin 
D and 1,25-dihydroxyvitamin D3 as modulators in 
the immune system. J Steroid Biochem Mol Biol 
2004;89-90:449-452
Mathis D, Vence L, Benoist C. Beta-cell 172. 
death during progression to diabetes. Nature 
2001;414:792-798
Matthews DR, Hosker JP, Rudenski AS, Naylor 173. 
BA, Treacher DF, Turner RC. Homeostasis 
model assessment: insulin resistance and beta-cell 
function from fasting plasma glucose and insulin 
concentrations in man. Diabetologia 1985;28:412-
419
Mayr A, Schlosser M, Grober N, Kenk H, Ziegler 174. 
AG, Bonifacio E, Achenbach P. GAD autoantibody 
affinity and epitope specificity identify distinct 
immunization profiles in children at risk for type 1 
diabetes. Diabetes 2007;56:1527-1533
Metcalfe KA, Hitman GA, Rowe RE, Hawa M, 175. 
Huang X, Stewart T, Leslie RD. Concordance for 
type 1 diabetes in identical twins is affected by 
insulin genotype. Diabetes Care 2001;24:838-842
Miller BJ, Appel MC, O’Neil JJ, Wicker LS. Both 176. 
the Lyt-2+ and L3T4+ T cell subsets are required 
for the transfer of diabetes in nonobese diabetic 
mice. J Immunol 1988;14:52-58
Moltchanova E, Rytkönen M, Kousa A, Taskinen 177. 
O, Tuomilehto J, Karvonen M. Spat Study Group. 
The Finnish Childhood Diabetes Registry Group. 
Zinc and nitrate in the ground water and the 
incidence of Type 1 diabetes in Finland. Diabet 
Med 2004;21:256-261
Moltchanova EV, Schreier N, Lammi N, Karvonen 178. 
M. Seasonal variation of diagnosis of Type 1 
diabetes mellitus in children worldwide. Diabet 
Med 2009;26:673-678
Mooney JA, Helms PJ, Jolliffe IT, Smail P; 179. 
Scottish Study Group for the Care of Diabetes in 
the Young. Seasonality of type 1 diabetes mellitus 
in children and its modification by weekends and 
holidays: retrospective observational study. Arch 
Dis Child 2004;89:970-973
Morgenthaler NG, Seissler J, Achenbach P, Glawe 180. 
D, Payton M, Meinck HM, Christie MR, Scherbaum 
WA. Antibodies to the tyrosine phosphatase-like 
protein IA-2 are highly associated with IDDM, but 
not with autoimmune endocrine diseases or stiff 
man syndrome. Autoimmunity 1997;25:203-211
Mosmann TR, Sad S. The expanding universe 181. 
of T-cell subsets: Th1, Th2 and more. Immunol 
Today 1996;17:138-146
 References 85
Mrena S, Savola K, Kulmala P, Åkerblom HK, 182. 
Knip M. Staging of preclinical type 1 diabetes in 
siblings of affected children. Childhood Diabetes 
in Finland Study Group. Pediatrics 1999;104:925-
930
Mrena S, Savola K, Kulmala P, Reijonen H, Ilonen 183. 
J, Åkerblom HK, Knip M; Childhood Diabetes in 
Finland Study Group. Genetic modification of risk 
assessment based on staging of preclinical type 
1 diabetes in siblings of affected children. J Clin 
Endocrinol Metab 2003;88:2682-2689
Mrena S, Virtanen SM, Laippala P, Kulmala P, 184. 
Hännilä ML, Åkerblom HK, Knip M. Models for 
predicting type 1 diabetes in siblings of affected 
children. Diabetes Care 2006;29:662-667
Murphy K, Travers P, Walport M. Janeway’s 185. 
Immunobiology, Seventh Edition, Garland 
Science, Taylor & Francis Group, NY, NY, USA 
2008, pp. 1-928
Myers MA, Rabin DU, Rowley MJ. Pancreatic 186. 
islet cell cytoplasmic antibody in diabetes is 
represented by antibodies to islet cell antigen 
512 and glutamic acid decarboxylase. Diabetes 
1995;44:1290-1295
Näntö-Salonen K, Kupila A, Simell S, Siljander 187. 
H, Salonsaari T, Hekkala A, Korhonen S, Erkkola 
R, Sipilä JI, Haavisto L, Siltala M, Tuominen J, 
Hakalax J, Hyöty H, Ilonen J, Veijola R, Simell T, 
Knip M, Simell O. Nasal insulin to prevent type 
1 diabetes in children with HLA genotypes and 
autoantibodies conferring increased risk of disease: 
a double-blind, randomised controlled trial. Lancet 
2008;372:1746-1755
Ng YC, Jacobs P, Johnson JA. Productivity losses 188. 
associated with diabetes in the U.S. Diabetes Care 
2001;24:257-261
Norris JM, Barriga K, Klingensmith G, Hoffman 189. 
M, Eisenbarth GS, Erlich HA, Rewers M. Timing 
of initial cereal exposure in infancy and risk of islet 
autoimmunity. JAMA 2003;290:1713-1720
Notkins AL, Zhang B, Matsumoto Y, Lan MS. 190. 
Comparison of IA-2 with IA-2beta and with six 
other members of the protein tyrosine phosphatase 
family: recognition of antigenic determinants by 
IDDM sera. J Autoimmun 1997;10:245-250
O’Connell MA, Donath S, Cameron FJ. Major 191. 
increase in Type 1 diabetes: no support for the 
Accelerator Hypothesis. Diabet Med 2007;24:920-
923
Oikarinen M, Tauriainen S, Honkanen T, Vuori 192. 
K, Karhunen P, Vasama-Nolvi C, Oikarinen S, 
Verbeke C, Blair GE, Rantala I, Ilonen J, Simell O, 
Knip M, Hyöty H. Analysis of pancreas tissue in a 
child positive for islet cell antibodies. Diabetologia 
2008;51:1796-1802
O’Reilly LA, Hutchings PR, Crocker PR, Simpson 193. 
E, Lund T, Kioussis D, Takei F, Baird J, Cooke A. 
Characterization of pancreatic islet cell infiltrates 
in NOD mice: effect of cell transfer and transgene 
expression. Eur J Immunol 1991;21:1171-1180
Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati 194. 
O, Raghu PK, Paquette TL. Insulin antibodies 
in insulin-dependent diabetics before insulin 
treatment. Science 1983;222:1337-1339
Passini N, Larigan JD, Genovese S, Appella E, 195. 
Sinigaglia F, Rogge L. The 37/40-kilodalton 
autoantigen in insulindependent diabetes mellitus 
is the putative tyrosine phosphatase IA-2. Proc 
Natl Acad Sci U S A 1995; 92: 9412-9416
Pastore MR, Bazzigaluppi E, Bonfanti R, Dozio N, 196. 
Sergi A, Balini A, Belloni C, Meschi F, Bonifacio 
E, Bosi E. Two-step islet autoantibody screening 
for risk assessment of type 1 diabetes in relatives. 
Diabetes Care 1998;21:1445–1450
Patterson CC, Dahlquist GG, Gyürüs E, Green A, 197. 
Soltész G. EURODIAB Study Group. Incidence 
trends for childhood type 1 diabetes in Europe 
during 1989-2003 and predicted new cases 2005-
20: a multicentre prospective registration study. 
Lancet 2009;373:2027-2033
Payton MA, Hawkes CJ, Christie MR. Relationship 198. 
of the 37,000- and 40,000-M(r) tryptic fragments 
of islet antigens in insulin-dependent diabetes to 
the protein tyrosine phosphatase-like molecule 
IA-2 (ICA512). J Clin Invest 1995;96:1506-1511
Permutt MA, Chirgwin J, Rotwein P, Giddings 199. 
S. Insulin gene structure and function: a review 
of studies using recombinant DNA methodology. 
Diabetes Care 1984;7:386-394
Piirainen L, Pesola J, Pesola I, Komulainen J, 200. 
Vaarala O. Breastfeeding stimulates total and 
cow’s milk-specific salivary IgA in infants. Pediatr 
Allergy Immunol 2009;20:295-298
Pujol-Borrell R, Todd I, Doshi M, Bottazzo 201. 
GF, Sutton R, Gray D, Adolf GR, Feldmann M. 
HLA class II induction in human islet cells by 
interferon-gamma plus tumour necrosis factor or 
lymphotoxin. Nature 1987;326:304-306
Rabin DU, Pleasic SM, Shapiro JA, Yoo-Warren H, 202. 
Oles J, Hicks JM, Goldstein DE, Rae PM. Islet cell 
antigen 512 is a diabetes-specific islet autoantigen 
86 References
related to protein tyrosine phosphatases. J Immunol 
1994;152:3183-3188
Radziuk J. Insulin sensitivity and its measurement: 203. 
structural commonalities among the methods. J 
Clin Endocrinol Metab 2000;85:4426-4433
Redondo MJ, Yu L, Hawa M, Mackenzie T, Pyke 204. 
DA, Eisenbarth GS, Leslie RD. Heterogeneity of 
type I diabetes: analysis of monozygotic twins in 
Great Britain and the United States. Diabetologia 
2001;44:354-362
Rennie J, Fraser T. The islets of Langerhans in 205. 
relation to diabetes. Biochem J 1907;2:7-19
Reunanen A, Kangas T, Martikainen J, Klaukka T. 206. 
Nationwide survey of comorbidity, use, and costs 
of all medications in Finnish diabetic individuals. 
Diabetes Care 2000;23:1265-1271
Richter W, Shi Y, Baekkeskov S. Autoreactive 207. 
epitopes defined by diabetes-associated human 
monoclonal antibodies are localized in the middle 
and C-terminal domains of the smaller form of 
glutamate decarboxylase. Proc Natl Acad Sci U S 
A 1993;90:2832-2836
Riley WJ, Maclaren NK, Krischer J, Spillar RP, 208. 
Silverstein JH, Schatz DA, Schwartz S, Malone 
J, Shah S, Vadheim C, Rotter JI. A prospective 
study of the development of diabetes in relatives 
of patients with insulindependent diabetes. N Engl 
J Med 1990;323:1167-1172
Roep BO. The role of T-cells in the pathogenesis of 209. 
type 1 diabetes: from cause to cure. Diabetologia 
2003;46:305-321
Roll U, Christie MR, Fuchtenbusch M, Payton MA, 210. 
Hawkes CJ, Ziegler AG. Perinatal autoimmunity 
in offspring of diabetic parents. The German 
Multicenter BABY-DIAB study: detection of 
humoral immune responses to islet antigens in 
early childhood. Diabetes 1996;45:967-973
Roll U, Ziegler AG. Combined antibody 211. 
screening for improved prediction of IDDM - 
modern strategies. Exp Clin Endocrinol Diabetes 
1997;105:1-14
Ronkainen MS, Savola K, Knip M. Antibodies to 212. 
GAD65 epitopes at diagnosis and over the first 10 
years of clinical type 1 diabetes mellitus. Scand J 
Immunol 2004;59:334-430
Rosenbauer J, Herzig P, Giani G. Early infant 213. 
feeding and risk of type 1 diabetes mellitus-a 
nationwide population-based case-control study 
in pre-school children. Diabetes Metab Res Rev 
2008;24:211-222
Roth R. Psychological and ethical aspects of 214. 
prevention trials. J Pediatr Endocrinol Metab 
2001;14, Suppl 1:669-674
Sabbah E, Savola K, Kulmala P, Veijola R, 215. 
Vähäsalo P, Karjalainen J, Åkerblom HK, Knip 
M. Diabetes-associated autoantibodies in relation 
to clinical characteristics and natural course in 
children with newly diagnosed type 1 diabetes. 
The Childhood Diabetes In Finland Study Group. 
J Clin Endocrinol Metab 1999;84:1534-1539
Salminen K, Sadeharju K, Lönnrot M, Vähäsalo 216. 
P, Kupila A, Korhonen S, Ilonen J, Simell O, Knip 
M, Hyöty H. Enterovirus infections are associated 
with the induction of beta-cell autoimmunity 
in a prospective birth cohort study. J Med Virol 
2003;69:91-98
Samuelsson U, Sundkvist G, Borg H, Fernlund P, 217. 
Ludvigsson J. Islet autoantibodies in the prediction 
of diabetes in school children. Diabetes Res Clin 
Pract 2001;51:51-57
Savola K, Bonifacio E, Sabbah E, Kulmala P, 218. 
Vähäsalo P, Karjalainen J, Tuomilehto-Wolf E, 
Meriläinen J, Åkerblom HK, Knip M; Childhood 
Diabetes in Finland Study Group: IA-2 antibodies 
- a sensitive marker of IDDM with clinical onset 
in childhood and adolescence. Diabetologia 
1998a;41:424-429
Savola K, Läärä E, Vähäsalo P, Kulmala P, 219. 
Åkerblom HK, Knip M; Childhood Diabetes in 
Finland Study Group. Dynamic pattern of disease-
associated autoantibodies in siblings of children 
with type 1 diabetes: a population-based study. 
Diabetes 2001;50:2625-2632
Savola K, Sabbah E, Kulmala P, Vähäsalo P, 220. 
Ilonen J, Knip M: Autoantibodies associated with 
type I diabetes mellitus persist after diagnosis in 
children. Diabetologia 1998b;41:1293-1297
Schatz D, Krischer J, Horne G, Riley W, Spillar R, 221. 
Silverstein J, Winter W, Muir A, Derovanesian D, 
Shah S, Malone J, Maclaren N. Islet cell antibodies 
predict insulin-dependent diabetes in United States 
school age children as powerfully as in unaffected 
relatives. J Clin Invest 1994;93:2403-2407
Schatz DA, Bingley PJ. Update on major trials 222. 
for the prevention of type 1 diabetes mellitus: the 
American Diabetes Prevention Trial (DPT-1) and 
the European Nicotinamide Diabetes Intervention 
Trial (ENDIT). J Pediatr Endocrinol Metab 
2001;14, Suppl 1:619-622
Scheen AJ, Castillo M, Lefèbvre PJ. Insulin 223. 
sensitivity in anorexia nervosa: a mirror image of 
obesity? Diabetes Metab Rev 1988;4:681-690
 References 87
Schlosser M, Banga JP, Madec AM, Binder 224. 
KA, Strebelow M, Rjasanowski I, Wassmuth R, 
Gilliam LK, Luo D, Hampe CS. Dynamic changes 
of GAD65 autoantibody epitope specificities in 
individuals at risk of developing type 1 diabetes. 
Diabetologia 2005b;48:922-930
Schlosser M, Koczwara K, Kenk H, Strebelow M, 225. 
Rjasanowski I, Wassmuth R, Achenbach P, Ziegler 
AG, Bonifacio E. In insulin-autoantibody-positive 
children from the general population, antibody 
affinity identifies those at high and low risk. 
Diabetologia 2005a;48:1830-1832
Schlosser M, Strebelow M, Wassmuth R, Arnold 226. 
ML, Breunig I, Rjasanowski I, Ziegler B, Ziegler 
M. The Karlsburg type 1 diabetes risk study of a 
normal schoolchild population: association of beta-
cell autoantibodies and human leukocyte antigen-
DQB1 alleles in antibody-positive individuals. J 
Clin Endocrinol Metab 2002;87:2254-2261
Schmidli RS, Colman PG, Bonifacio E, Bottazzo 227. 
GF, Harrison LC. High level of concordance 
between assays for glutamic acid decarboxylase 
antibodies. The First International Glutamic Acid 
Decarboxylase Antibody Workshop. Diabetes 
1994;43:1005-1009
Schmidli RS, Colman PG, Bonifacio E. Disease 228. 
sensitivity and specificity of 52 assays for glutamic 
acid decarboxylase antibodies. The Second 
International GADAB Workshop. Diabetes 
1995;44:636-640
Schmidt EM, Wang CJ, Ryan GA, Clough LE, 229. 
Qureshi OS, Goodall M, Abbas AK, Sharpe 
AH, Sansom DM, Walker LS. CTLA-4 controls 
regulatory T cell peripheral homeostasis and 
is required for suppression of pancreatic islet 
autoimmunity. J Immunol 2009;182:274-282
Seissler J, Amann J, Mauch L, Haubruck H, 230. 
Wolfahrt S, Bieg S, Richter W, Holl R, Heinze 
E, Northemann W, Scherbaum WA. Prevalence 
of autoantibodies to the 65- and 67-kD isoforms 
of glutamate decarboxylase in insulin-dependent 
diabetes mellitus. J Clin Invest 1993;92:1394-
1399
Sera Y, Kawasaki E, Abiru N, Ozaki M, Abe T, 231. 
Takino H, Kondo H, Yamasaki H, Yamaguchi Y, 
Akazawa S, Nagataki S, Uchigata Y, Matsuura 
N, Eguchi K. Autoantibodies to multiple islet 
autoantigens in patients with abrupt onset type 
1 diabetes and diabetes diagnosed with urinary 
glucose screening. J Autoimmun 1999;13:257-
265
Seyfert-Margolis V, Gisler TD, Asare AL, Wang 232. 
RS, Dosch HM, Brooks-Worrell B, Eisenbarth 
GS, Palmer JP, Greenbaum CJ, Gitelman SE, 
Nepom GT, Bluestone JA, Herold KC. Analysis of 
T-cell assays to measure autoimmune responses in 
subjects with type 1 diabetes: results of a blinded 
controlled study. Diabetes 2006;55:2588-2594
Sia C. Imbalance in Th cell polarization and its 233. 
relevance in type 1 diabetes mellitus. Rev Diabet 
Stud 2005;2:182-186
Simonen P, Korhonen T, Simell T, Keskinen 234. 
P, Kärkkäinen M, Knip M, Ilonen J, Simell O. 
Parental reactions to information about increased 
genetic risk of type 1 diabetes mellitus in infants. 
Arch Pediatr Adolesc Med 2006;160:1131-1136
Sjöroos M, Iitiä A, Ilonen J, Reijonen H, Lövgren 235. 
T: Triple-label hybridization assay for type 1 
diabetes-related HLA alleles. BioTechniques 
1995;18:870-877
Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, 236. 
Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-
Mervis LE, Chase HP, Leschek E. Effects of oral 
insulin in relatives of patients with type 1 diabetes: 
The Diabetes Prevention Trial--Type 1. Diabetes 
Care 2005;28:1068-1076
Skyler JS; Type 1 Diabetes TrialNet Study Group. 237. 
Update on worldwide efforts to prevent type 1 
diabetes. Ann N Y Acad Sci 2008;1150:190-196
Soltesz G, Patterson CC, Dahlquist G; EURODIAB 238. 
Study Group. Worldwide childhood type 1 diabetes 
incidence--what can we learn from epidemiology? 
Pediatr Diabetes 2007;8, Suppl 6:6-14
Sorenson RL, Garry DG, Brelje TC. Structural 239. 
and functional considerations of GABA in islets 
of Langerhans. Beta-cells and nerves. Diabetes. 
1991;40:1365-1374
Sorva R, Perheentupa J, Tolppanen EM. A novel 240. 
format for a growth chart. Acta Paediatr Scand 
1984;73:527-529
Spencer KM, Tarn A, Dean BM, Lister J, 241. 
Bottazzo GF. Fluctuating islet-cell autoimmunity 
in unaffected relatives of patients with insulin-
dependent diabetes. Lancet 1984;1:764-766
Stene LC, Barriga K, Norris JM, Hoffman M, 242. 
Erlich HA, Eisenbarth GS, McDuffie RS Jr, 
Rewers M. Perinatal factors and development of 
islet autoimmunity in early childhood: the diabetes 
autoimmunity study in the young. Am J Epidemiol 
2004;160:3-10
Strebelow M, Schlosser M, Ziegler B, Rjasanowski 243. 
I, Ziegler M. Karlsburg Type I diabetes risk study of 
a general population: frequencies and interactions 
88 References
of the four major Type I diabetes-associated 
autoantibodies studied in 9419 schoolchildren. 
Diabetologia 1999;42:661-670
Teeäär T, Liivak N, Heilman K, Kool P, Sor R, Paal 244. 
M, Einberg U, Tillmann. Increasing incidence of 
childhood-onset type 1 diabetes mellitus among 
Estonian children in 1999-2006. Time trend 
analysis 1983-2006. Pediatr Diabetes 2009, epub.
Tiittanen M, Paronen J, Savilahti E, Virtanen 245. 
SM, Ilonen J, Knip M, Åkerblom HK, Vaarala 
O; Finnish TRIGR Study Group. Dietary insulin 
as an immunogen and tolerogen. Pediatr Allergy 
Immunol 2006;17:538-543
Timsit J, Caillat-Zucman S, Blondel H, Chedin P, 246. 
Bach JF, Boitard C. Islet cell antibody heterogeneity 
among type 1 (insulin-dependent) diabetic patients. 
Diabetologia 1992;35:792-795
Törn C, Landin-Olsson M, Östman J, Scherstén 247. 
B, Arnqvist H, Blohmé G, Björk E, Bolinder J, 
Eriksson J, Littorin B, Nyström L, Sundkvist 
G, Lernmark Å. Glutamic acid decarboxylase 
antibodies (GADA) is the most important factor 
for prediction of insulin therapy within 3 years in 
young adult diabetic patients not classified as Type 
1 diabetes on clinical grounds. Diabetes Metab Res 
Rev 2000;16:442-447
Törn C, Mueller PW, Schlosser M, Bonifacio E, 248. 
Bingley PJ; Participating Laboratories Diabetes 
Antibody Standardization Program: evaluation 
of assays for autoantibodies to glutamic acid 
decarboxylase and islet antigen-2. Diabetologia 
2008;51:846-852
Tree TI, Roep BO, Peakman M. A mini meta-249. 
analysis of studies on CD4+CD25+ T cells in 
human type 1 diabetes: report of the Immunology 
of Diabetes Society T Cell Workshop. Ann N Y 
Acad Sci 2006;1079:9-18
Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, 250. 
Knowles W, Mackay IR. Antibodies to glutamic 
acid decarboxylase reveal latent autoimmune 
diabetes mellitus in adults with a noninsulin- 
dependent onset of disease. Diabetes 1993;42:359-
362.
Tuomilehto J, Lounamaa R, Tuomilehto-Wolf E, 251. 
Reunanen A, Virtala E, Kaprio EA, Åkerblom 
HK. Epidemiology of childhood diabetes mellitus 
in Finland--background of a nationwide study of 
type 1 (insulin-dependent) diabetes mellitus. The 
Childhood Diabetes in Finland (DiMe) Study 
Group. Diabetologia 1992;35:70-76
Turner R, Stratton I, Horton V, Manley S, 252. 
Zimmet P, Mackay IR, Shattock M, Bottazzo GF, 
Holman R. UKPDS 25: autoantibodies to islet-
cell cytoplasm and glutamic acid decarboxylase 
for prediction of insulin requirement in type 2 
diabetes. UK Prospective Diabetes Study Group. 
Lancet 1997;350:1288-1293
Ueda H, Howson JM, Esposito L, Heward J, 253. 
Snook H, Chamberlain G, Rainbow DB, Hunter 
KM, Smith AN, Di Genova G, Herr MH, Dahlman 
I, Payne F, Smyth D, Lowe C, Twells RC, Howlett 
S, Healy B, Nutland S, Rance HE, Everett V, 
Smink LJ, Lam AC, Cordell HJ, Walker NM, 
Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, 
Metzker ML, Rogers J, Gregory S, Allahabadia A, 
Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto 
J, Bingley P, Gillespie KM, Undlien DE, Rønningen 
KS, Guja C, Ionescu-Tîrgoviste C, Savage DA, 
Maxwell AP, Carson DJ, Patterson CC, Franklyn 
JA, Clayton DG, Peterson LB, Wicker LS, Todd 
JA, Gough SC. Association of the T-cell regulatory 
gene CTLA4 with susceptibility to autoimmune 
disease. Nature 2003;423:506-511
Uusitalo L, Nevalainen J, Niinistö S, Alfthan G, 254. 
Sundvall J, Korhonen T, Kenward MG, Oja H, 
Veijola R, Simell O, Ilonen J, Knip M, Virtanen 
SM. Serum alpha- and gamma-tocopherol 
concentrations and risk of advanced beta cell 
autoimmunity in children with HLA-conferred 
susceptibility to type 1 diabetes mellitus. 
Diabetologia 2008;51:773-780
Vaarala O. Gut and the induction of immune 255. 
tolerance in type 1 diabetes. Diabetes Metab Res 
Rev 1999;15:353-361
Vaarala O. Is it dietary insulin? Ann N Y Acad Sci 256. 
2006;1079:350-359
Vähäsalo P, Knip M, Karjalainen J, Tuomilehto-257. 
Wolf E, Lounamaa R, Åkerblom HK. Islet cell-
specific autoantibodies in children with insulin-
dependent diabetes mellitus and their siblings at 
clinical manifestation of the disease. Childhood 
Diabetes in Finland Study Group. Eur J Endocrinol 
1996;135: 689-695
Vang T, Miletic AV, Bottini N, Mustelin T. 258. 
Protein tyrosine phosphatase PTPN22 in human 
autoimmunity. Autoimmunity 2007;40:453-461
Vardi P, ZieglerAG, MathewsJH, Dib S, Keller 259. 
RJ, Ricker AT, Wolfsdorf JI, Herskowitz RD, 
Rabizedah A, Eisenbarth GS. Concentration of 
insulin autoantibodies at onset of type I diabetes. 
Inverse log-linear correlation with age. Diabetes 
Care 1988;11:736-739
Veening MA, van Weissenbruch MM, Delemarre-260. 
van De Waal HA. Glucose tolerance, insulin 
sensitivity, and insulin secretion in children born 
 References 89
small for gestational age. J Clin Endocrinol Metab 
2002;87:4657-4661
Veening MA, van Weissenbruch MM, Heine RJ, 261. 
Delemarre-van de Waal HA. Beta-cell capacity 
and insulin sensitivity in prepubertal children born 
small for gestational age: influence of body size 
during childhood. Diabetes 2003;52:1756-1760
Verge CF, Gianani R, Kawasaki E, Yu L, 262. 
Pietropaolo M, Jackson RA, Chase HP, Eisenbarth 
GS. Prediction of type I diabetes in first-degree 
relatives using a combination of insulin, GAD, 
and ICA512bdc/IA-2 autoantibodies. Diabetes 
1996;45:926-933
Virtanen SM, Knip M. Nutritional risk predictors 263. 
of beta cell autoimmunity and type 1 diabetes at a 
young age. Am J Clin Nutr 2003;78:1053-1067
von Herrath M. Can we learn from viruses how to 264. 
prevent type 1 diabetes?: the role of viral infections 
in the pathogenesis of type 1 diabetes and the 
development of novel combination therapies. 
Diabetes 2009;58:2-11
Wabl M, Cascalho M, Steinberg C. Hypermutation 265. 
in antibody affinity maturation. Curr Opin Immunol 
1999;11:186-189
Wahlberg J, Vaarala O, Ludvigsson J; ABIS-study 266. 
group. Dietary risk factors for the emergence of 
type 1 diabetes-related autoantibodies in 21/2 year-
old Swedish children. Br J Nutr 2006;95:603-608
Walter M, Albert E, Conrad M, Keller E, Hummel 267. 
M, Ferber K, Barratt BJ, Todd JA, Ziegler AG, 
Bonifacio E. IDDM2/insulin VNTR modifies 
risk conferred by IDDM1/HLA for development 
of Type 1 diabetes and associated autoimmunity. 
Diabetologia 2003;46:712-720
Wasmeier C, Hutton JC. Molecular cloning of 268. 
phogrin, a protein-tyrosine phosphatase homologue 
localized to insulin secretory granule membranes. 
J Biol Chem 1996;271:18161-18170
Wasserman LI, Trifonova EA. Diabetes mellitus 269. 
as a model of psychosomatic and somatopsychic 
interrelationships. Span J Psychol 2006;9:75-85
Weets I, Kaufman L, Van der Auwera B, Crenier 270. 
L, Rooman RP, De Block C, Casteels K, Weber E, 
Coeckelberghs M, Laron Z, Pipeleers DG, Gorus 
FK. The Belgian Diabetes Registry. Seasonality 
in clinical onset of type 1 diabetes in Belgian 
patients above the age of 10 is restricted to HLA-
DQ2/DQ8-negative males, which explains the 
male to female excess in incidence. Diabetologia 
2004;47:614-621
Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, 271. 
Gottlieb P, Rewers M, Eisenbarth GS, Jensen 
J, Davidson HW, Hutton JC. The cation efflux 
transporter ZnT8 (Slc30A8) is a major autoantigen 
in human type 1 diabetes. Proc Natl Acad Sci U S 
A 2007;104:17040-17045
Westerlund A, Ankelo M, Ilonen J, Knip M, 272. 
Simell O, Hinkkanen AE. Absence of avidity 
maturation of autoantibodies to the protein tyrosine 
phosphatase-like IA-2 molecule and glutamic acid 
decarboxylase (GAD65) during progression to 
type 1 diabetes. J Autoimmun 2005;24:153-167
Wild S, Roglic G, Green A, Sicree R, King H. 273. 
Global prevalence of diabetes: estimates for the 
year 2000 and projections for 2030. Diabetes Care 
2004;27:1047-1053
Wilkin T, Mirza I, Armitage M, Casey C, Scott-274. 
Morgan L. Insulin autoantibody polymorphisms 
with greater discrimination for diabetes in humans. 
Diabetologia 1988;31:670-674
Wilkin TJ, Nicholson S. Autoantibodies 275. 
against human insulin. Br Med J (Clin Res Ed) 
1984;288:349-352
Wilkin TJ. The accelerator hypothesis: weight 276. 
gain as the missing link between Type I and Type 
II diabetes. Diabetologia 2001;44:914-922
Williams AJ, Bingley PJ, Chance RE, Gale 277. 
EA. Insulin autoantibodies: more specific than 
proinsulin autoantibodies for prediction of type 1 
diabetes. J Autoimmun 1999;13:357-363
Williams AJ, Bingley PJ, Moore WP, Gale EA. 278. 
Islet autoantibodies, nationality and gender: a 
multinational screening study in first-degree 
relatives of patients with type I diabetes. 
Diabetologia 2002;45:217-223
Williams AJK, Bingley PJ, Bonifacio E, Palmer 279. 
JP, Gale EAM: A novel micro-assay for insulin 
autoantibodies. J Autoimmun 1997;10:473-478
Wong FS, Wen L. B cells in autoimmune diabetes. 280. 
Rev Diabet Stud 2005;2:121-135
Wong FS. Insulin −a primary autoantigen in type 1 281. 
diabetes? Trends Mol Med 2005;11:445-448
World Health Organization (WHO)/ Department 282. 
of Noncommunicable Disease Surveillance. 
Definition, diagnosis and classification of diabetes 
mellitus and its complications. Part 1: Diagnosis 
and Classification of Diabetes Mellitus. Geneva, 
Switzerland 1999, pp. 1-49
90 References
Xie H, Zhang B, Matsumoto Y, Li Q, Notkins AL, 283. 
Lan MS. Autoantibodies to IA-2 and IA-2 beta 
in insulin-dependent diabetes mellitus recognize 
conformational epitopes: location of the 37- 
and 40-kDa fragments determined. J Immunol 
1997;159:3662-3667
Xu P, Cuthbertson D, Greenbaum C, Palmer 284. 
JP, Krischer JP; Diabetes Prevention Trial-Type 
1 Study Group. Role of insulin resistance in 
predicting progression to type 1 diabetes. Diabetes 
Care 2007;30:2314-2320
Yalow RS, Berson SA. Immunoassay of 285. 
endogenous plasma insulin in man. J Clin Invest 
1960;39:1157-1175
Yamamoto AM, Deschamps I, Garchon HJ, 286. 
Roussely H, Moreau N, Beaurain G, Robert JJ, 
Bach JF. Young age and HLA markers enhance the 
risk of progression to type 1 diabetes in antibody-
positive siblings of diabetic children. J Autoimmun 
1998;11:643-650
Yang Z, Long X, Shen J, Liu D, Dorman JS, Laporte 287. 
RE, Chang YF. Epidemics of type 1 diabetes in 
China. Pediatr Diabetes 2005;6:122-128
Yoon JW, Jun HS. Cellular and molecular 288. 
pathogenic mechanisms of insulin-dependent 
diabetes mellitus. Ann N Y Acad Sci 2001;928:200-
211
Yoon JW, Ray UR. Perspectives on the role of 289. 
viruses in insulin-dependent diabetes. Diabetes 
Care 1985;8, Suppl 1:39-44
Yu J, Yu L, Bugawan TL, Erlich HA, Barriga K, 290. 
Hoffman M, Rewers M, Eisenbarth G. Transient 
antiislet autoantibodies: infrequent occurrence and 
lack of association with ”genetic” risk factors. J 
Clin Endocrinol Metab 2000a;85:2421-2428
Yu L, Robles DT, Abiru N, Kaur P, Rewers M, 291. 
Kelemen K, Eisenbarth GS. Early expression 
of antiinsulin autoantibodies of humans and the 
NOD mouse: evidence for early determination of 
subsequent diabetes. Proc Natl Acad Sci U S A 
2000b;97:1701-1706
Zhang B, Lan MS, Notkins AL. Autoantibodies 292. 
to IA-2 in IDDM: location of major antigenic 
determinants. Diabetes 1997;46:40-43
Ziegler AG, Schmid S, Huber D, Hummel 293. 
M, Bonifacio E. Early infant feeding and 
risk of developing type 1 diabetes-associated 
autoantibodies. JAMA 2003;290:1721-1728
Ziegler AG, Ziegler R, Vardi P, Jackson RA, 294. 
Soeldner JS, Eisenbarth GS. Life-table analysis 
of progression to diabetes of anti-insulin 
autoantibody-positive relatives of individuals with 
type I diabetes. Diabetes 1989;38:1320-1325
Zorina TD, Subbotin VM, Bertera S, Alexander 295. 
AM, Haluszczak C, Gambrell B, Bottino R, Styche 
AJ, Trucco M. Recovery of the endogenous beta 
cell function in the NOD model of autoimmune 
diabetes. Stem Cells 2003;21:377-388
